gemcitabine has been researched along with Local Neoplasm Recurrence in 689 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (1.31) | 18.2507 |
| 2000's | 222 (32.22) | 29.6817 |
| 2010's | 350 (50.80) | 24.3611 |
| 2020's | 108 (15.67) | 2.80 |
| Authors | Studies |
|---|---|
| Fukushima, K; Hayashi, H; Hosoda, K; Kobayashi, R; Kubota, K; Motoyama, H; Notake, T; Shimizu, A; Soejima, Y; Sugenoya, S; Yasukawa, K | 1 |
| Cai, J; Cai, Q; Fang, Y; Huang, H; Li, Z; Liu, P; Ma, S; Su, N; Tian, X; Wang, J; Xia, Y; Zhang, Y | 1 |
| Grobet-Jeandin, E; Pinar, U; Rouprêt, M | 1 |
| Chen, X; Fang, D; Guan, J; He, X; Shi, ZW; Wang, H; Wang, X | 1 |
| Du, C; Hu, C; Jiang, J; Kong, F; Lv, Y; Ni, M; Ying, H; Zhai, R | 1 |
| Aggen, D; Al-Ahmadie, H; Apollo, A; Bajorin, DF; Balar, AV; Bochner, BH; Boswell, A; Cha, EK; Donahue, TF; Donat, SM; Durdin, TD; Folefac, E; Francese, K; Funt, SA; Goh, AC; Herr, HW; Hettich, G; Huang, WC; Iyer, G; Jihad, M; Kamradt, J; Khalil, M; Lash, B; Lattanzi, M; Lee, CH; McCoy, AS; McHugh, D; Mortazavi, A; Ostrovnaya, I; Pietzak, E; Quinlan, C; Ratna, N; Regazzi, A; Rosenberg, JE; Teo, MY; Truong, H; Whiting, K; Yang, Y; Zimmerman, D | 1 |
| Imada, K; Kaneko, H; Mizutani, C; Nagata, O; Naka, R; Tada, K; Tashima, M | 1 |
| Abduljabbar, A; Alashwah, A; Alhomoud, S; Aljubran, A; Almanea, H; Alsanea, N; Alsuhaibani, A; Alzahrani, A; Ashari, L; Badran, A; Bazarbashi, S; Elhassan, T; Elshenawy, MA; Ghebeh, H; Mohiuddin, M; Neimatallah, M | 1 |
| Chang, WC; Chiu, CF; Hsieh, CY; Hua, CH; Lien, MY; Lin, CC; Lin, CY; Lo, WJ | 1 |
| Ambo, Y; Ando, M; Benabdelghani, M; Bertaut, A; Ebata, T; Edeline, J; Hammel, P; Hirano, S; Joly, JP; Kaneoka, Y; Konishi, M; Louvet, C; Malka, D; Monard, L; Nagino, M; Ohtsuka, M; Phelip, JM; Uesaka, K; Watelet, J; Yamamoto, M | 1 |
| Cao, Y; Jiang, L; Jin, G; Ju, X; Liu, W; Ye, Y; Zhang, H; Zhao, X; Zhu, X | 1 |
| Baker, K; Buhtoiarov, IN; Bush, R; Cole, PD; Kelly, KM; Mba, NI; McCarten, KM; Metzger, ML; Pei, Q; Santos, CDL | 1 |
| Niu, X; Wang, T; Zhong, B | 1 |
| Cutillas, PR; de Luxán-Delgado, B; Dormann, C; Drake, RJG; Géraud, C; Gómez-Escudero, J; Hodivala-Dilke, K; Maiques, O; Meng, YM; Newport, E; Rajeeve, V; Reynolds, LE; Richards, FM; Roy-Luzarraga, M; Sanz-Moreno, V; Saur, D; Vermeulen, PB; Weller, C; Wisniewski, L; Wong, PP | 1 |
| Ishii, M; Itano, O; Itano, S; Morinaga, J; Shirakawa, H | 1 |
| Cai, MB; Li, ZM; Nie, YH; Tan, YR; Yang, Q; Zhu, HB | 1 |
| Feng, M; Gu, Z; He, Y; Kong, X; Mao, H; Wu, L | 1 |
| Kumar, S; Pareek, T; Parmar, K; Sharma, AP | 1 |
| Ansari Djafari, A; Faraji, S; Garoosi, M; Hojjati, SA; Javanmard, B; Rahavian, A; Razzaghi, M; Razzaghi, Z | 1 |
| Hu, X; Li, Y; Tong, S | 1 |
| Gellhaus, PT; Martin, AC; McElree, IM; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Richards, J; Steinberg, RL | 1 |
| Chan, H; Chiu, M; Elinder-Camburn, A; Hague, S; Merriman, E | 1 |
| Arslan, O; Gokgoz, Z; Gokmen, A; Ilhan, O; Okcu, MK; Ozan, U; Ozcan, M; Sahin, U; Soydan, E | 1 |
| Chen, MY; Ding, X; Duan, CY; Gu, CM; Hua, YJ; Huang, PY; Liu, YL; Liu, YP; Ouyang, YF; Wang, X; Wang, ZQ; Xu, HS; You, R; Zhang, MX; Zhang, WJ; Zou, X | 1 |
| Artru, P; Assenat, E; Bauguion, L; Ben Abdelghani, M; Biagi, JJ; Bouché, O; Castan, F; Conroy, T; Evesque, L; Hammel, P; Lambert, A; Lecomte, T; Lopez, A; Mitry, E; Monard, L; Turpin, A; Wei, AC; Ychou, M | 1 |
| Kavoussi, M; Nasrallah, AA; Williams, SB | 1 |
| Andou, M; Furuse, J; Kitamura, H; Nagashima, F; Nakazawa, J | 1 |
| Hong, J; Hong, JY; Jeong, BC; Kim, CK; Kim, H; Kwon, GY; Park, SH; Park, W; Pyo, H; Song, W; Sung, HH | 1 |
| Fujishita, T; Ito, K; Kinoshita, F; Okamoto, T; Oku, Y; Shoji, F; Takamori, S; Toyozawa, R | 1 |
| Chevuru, PT; McElree, IM; Mott, SL; O'Donnell, MA; Packiam, VT; Steinberg, RL | 1 |
| Araki, M; Kawada, T; Pradere, B; Shariat, SF; Yanagisawa, T | 1 |
| Bin, W; Jing, L; Meimei, Z; Wenjian, C; Xuejin, Z; Yanfei, C | 1 |
| Higashi, M; Momose, S; Morozumi, M; Sugiyama, H; Tamaru, JI; Yamashita, T | 1 |
| Ambrosio, AJ; Birrer, MJ; Bradley, C; Konstantinopoulos, PA; Krasner, CN; Matulonis, UA; Penson, RT; Whalen, CA | 1 |
| Albers, D; Kasper, S; Kostbade, K; Laue, K; Liffers, ST; Markus, M; Markus, P; Maßmann, M; Mende, B; Pogorzelski, M; Reissig, TM; Roehrle, J; Rosery, V; Schildhaus, HU; Schmid, K; Schuler, M; Schumacher, B; Siveke, JT; Ting, S; Treckmann, JW; Virchow, I; Wendling, J; Wiesweg, M; Zaun, G | 1 |
| Funakoshi, S; Harada, H; Hayashi, T; Hirose, S; Hoshino, M; Odaira, M; Ogura, N | 1 |
| Bachy, E; Cartron, G; Chaubard, S; Chauchet, A; Clavert, A; Couronné, L; Damaj, G; Fornecker, LM; Gaulard, P; Ghesquières, H; Gressin, R; Hermine, O; Jaccard, A; Lavergne, D; Le Gouill, S; Lemonnier, F; Marouf, A; Michot, JM; Obéric, L; Rossignol, J; Salles, G; Sibon, D; Tournilhac, O; Vargaftig, J; Waultier-Rascalou, A | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shinohara, Y; Shirakawa, T; Taguchi, H; Ueda, Y; Ueno, S; Ureshino, N | 1 |
| Hosseinifard, H; Hua, Z; Ijaz, I; Imani, S; Kahloon, LE; Liu, S; Sefidan, MO; Shahzad, MN; Zhang, YQ | 1 |
| Araki, M; Babjuk, M; Bekku, K; Chlosta, M; Kawada, T; Laukhtina, E; Pradere, B; Shariat, SF; Teoh, JY; von Deimling, M; Yanagisawa, T | 1 |
| Chen, Q; Fu, D; Huang, S; Li, H; Li, Z; Luo, Q; Wang, L; Wang, Z; Xue, L; Zhang, P | 1 |
| Bae, JH; Kim, J; Koh, EK; Lee, HR; Park, GY; Park, YS; Son, WC | 1 |
| Abbey, L; Abdelghany, TM; Abdellatif, MH; Abdelmohsen, UR; Abduljaleel Alzawar, NS; Abid, MF; Abu Kasim, AFB; Abu Saad, H; Adolpho, LF; Agostini, F; Agrizii, AP; Ahmed, S; Akce, M; Åkesson, D; Al-Awaadh, AM; Al-Mutar, DMK; Al-Odayni, AB; Al-Rajhi, AMH; Alaaeldin, R; Alam, M; Alam, MM; Alanazi, MA; Alattar, H; Alawlaqi, MM; Aldebis, HK; Algehainy, NA; Almeida, AA; Aloisi, F; Alrahlah, A; Alsenani, F; Alshabib, A; Altemani, FH; Althagafi, A; Amari, A; Andronesi, AG; Antonyuk, M; Arantes, TD; Araújo, R; Arrotti, S; Asakura, T; Asib, N; Atlaskin, AA; Aung, MS; Axiaq, A; Azekawa, S; Bacon, S; Bagalagel, A; Balbinot, GS; Barnet, LS; Baroyi, SAHM; Barreto, F; Barth, Y; Barysheva, AV; Bassa, E; Basu, R; Basu, S; Bates, C; Bautista, LS; Beitl, K; Beloti, MM; Benatti, G; Benavent-Celma, C; Bentaher, A; Bergsland, N; Bernardino, AF; Bernhardt, A; Bhandari, RK; Bhaskaran, K; Bhate, K; Bhattacharjee, A; Bian, X; Bien, EM; Birch, M; Bishara, K; Biswas, JP; Bleha, R; Bocale, R; Bona, S; Boriani, G; Bouyssi, A; Bradley, D; Bravo-Sánchez, MG; Bressan, GC; Brik, A; Brizuela, A; Brockbank, KGM; Buchner, F; Bunc, M; Buscombe, JR; Butler, AJ; Buzaleh, AM; Buzin, MI; Cabrera-Capetillo, CA; Calvo, AM; Camerota, A; Campagna, G; Campisi, M; Cano, K; Cao, HST; Cardellini, S; Carvalho, AP; Carvalho, BCR; Castillo-Baltazar, OS; Cataldo, P; Chai, P; Chakraborty, S; Chalo, DM; Chan, MY; Chander, S; Changbunjong, T; Chappuis, CJF; Chee, RCH; Chen, C; Chen, CJ; Chen, E; Chen, M; Chen, X; Chen, Y; Cheng, HT; Cheng, MC; Cheow, HK; Chi, Y; Chirikova, NK; Chiu, SH; Cho, G; Cho, HR; Cho, S; Cho, SJ; Choe, A; Choe, YH; Chun, BS; Chun, Z; Cinque, A; Ciopec, M; Cladas, Y; Cleary, SP; Clermont, O; Cléroux, M; Cockburn, J; Collares, FM; Colombini-Ishikiriama, BL; Conn, BN; Cortina, JL; Cox, DRA; Crini, G; Croker, R; Cursaru, DL; Curtis, HJ; da Silva, KJG; Dalla Costa, T; Davy, S; de Araújo, BV; de Cassia Ribeiro Gonçalves, R; de Gaetano, F; de Gregorio, C; de Oliveira, MG; De Vera, MAT; de Vos, M; de-la-Fuente, I; Dell'Oca, I; Delles, M; Déméautis, T; Dempster, M; Deng, YH; Denisenko, Y; Descombes, C; Desideri, G; Devarbhavi, H; Devouassoux, G; Di Bella, G; Di Marco, F; Diao, Y; Dias, BB; Dilgin, Y; Dimopoulou, I; Dionísio, TJ; Dobrovic, A; Dokin, ES; Dolby, T; Dong, X; Dong, Y; Dou, SX; Douglas, IJ; Dousset, S; Du, Z; Duan, M; Duan, SB; Duke-Williams, O; Duteanu, N; Dutertre, S; Dutta, S; Dwyer, MG; Ebenbauer, J; Eggo, RM; El-Mordy, FMA; Elbhnsawi, NA; Elrehany, MA; Elshewemi, SS; Elwakil, BH; Emadzadeh, D; Eraso, E; Ermolenko, E; Erten, K; Ettorre, E; Evans, D; Evans, SJ; Faheem, M; Fallanza, M; Faramarzi, M; Faria, FAC; Faro, DC; Fatma, YS; Fazil, S; Feng, Y; Ferguson, J; Fernandes, MH; Fernández-Domínguez, M; Ferrari, LAL; Ferraz, EP; Ferreira, LC; Ferri, C; Fikry, M; Floris, M; Forbes, H; Fotouh, B; Franke, K; Freitas, AC; Freitas, GP; Frieboes, HB; Fu, B; Fu, Y; Fukina, DG; Fukuda, DH; Fukunaga, K; Fulham, GJ; Furlan, L; Furtado Mesa, M; Furtunescu, FL; Gabbieri, D; Ganash, M; Gebers, JC; Gehman, V; Ghaedi, A; Ghazali, NSM; Ghebrekristos, Y; Gil, J; Gilbert, NM; Gimenes, R; Giordano, L; Glehen, O; Godeau, C; Goh, SK; Goldacre, B; Gomes, AM; Gomes, MPO; Gomes, PS; Gomes, RMODS; Gómez-Coma, L; Grenho, L; Gu, Q; Gu, T; Gu, YC; Guiducci, V; Guillemin, JP; Guo, W; Guo, YW; Gur, E; Guridi, A; Guzmán-López, A; Gvozdenko, T; H Elmaidomy, A; Hagar, M; Haider, S; Han, JM; Hanratty, J; Hans, R; Haque, N; Harharah, HN; Harharah, RH; Harper, S; Hasegawa, N; Hassanin, AH; Hastuti, YP; Hatem, AE; He, R; He, Y; Heinemann, C; Heinmaa, I; Heinzl, F; Helfer, VE; Hester, F; Hickman, G; Hill, MA; Hill, WG; Hintze, V; Ho, JSY; Ho, LY; Hoang, T; Holzer, I; Houbraken, J; Hsu, CN; Hu, J; Hu, X; Hu, Y; Hua, T; Huang, Z; Hulme, WJ; Hunter, A; Ianăşi, C; Ibañez, R; Iezzi, R; Iliuță, L; Im, YM; Imran, M; Inglesby, P; Inguimbert, N; Iqbal, A; Izawa, N; Jahaj, E; Jain, S; Jakimovski, D; Jalal, MM; Jaroszuk-Ściseł, J; Jasim, DJ; Jauregizar, N; Javle, MM; Jędryczka, M; Ji, H; Jiang, Y; Jin, J; Johnson, NT; Joshi, S; Jullok, N; Kachapulula, PW; Kaczmarek, J; Kaczmarek-Szczepańska, B; Kadota, K; Kaji, M; Kakeji, Y; Kakizoe, S; Kakudidi, E; Kalitukha, L; Kamata, H; Kang, YJ; Kapinos, AA; Karakaya, S; Kashchenko, NI; Kasyanov, S; Kataky, R; Katati, B; Kato, G; Katsina, AU; Kaya, A; Kaya, H; Kazarina, OV; Ke, Y; Keenan, C; Keilson, JM; Keshavan, A; Keskinidou, C; Khalifa, MA; Khan, R; Khan, S; Kim, D; Kim, K; Kim, MS; Kim, SM; Kim, WH; Kim, Y; Kim, YJ; Kishimura, H; Kitagawa, RR; Klemenkova, ZS; Kloss, F; Kobayashi, N; Kohlhoff, M; Kong, WKF; Konsek, H; Kornaros, M; Kotanidou, A; Kovacs, S; Kraska, J; Kruppke, B; Kumagai, Y; Kumar, S; Kumari, R; Kuruva, V; Kuster, RM; Kusumoto, T; Kutyła, M; Kwon, JH; Kwon, SH; Kwong, KY; Kyser, AJ; Lackner, M; Lass-Flörl, C; Lauri, C; Lavandera, JV; Lee, BH; Lee, ECY; Lee, HJ; Lee, J; Lee, PS; Lee, S; Lee, SE; Lee, SY; Lefort, F; Leite, JPV; Leo, G; Leonard, R; Leow, AST; Lepori, N; Leyden, K; Leys, L; Ležaić, L; Li, D; Li, H; Li, J; Li, S; Li, TYW; Li, X; Li, XH; Li, Y; Li, Z; Li, ZH; Liao, S; Liaqat, K; Lim, H; Lin, BS; Lin, MY; Lin, NH; Lin, X; Lin, Y; Liu, C; Liu, H; Liu, HK; Liu, HX; Liu, P; Liu, R; Liu, T; Liu, X; Liu, Y; Lock, GA; Lokaj, G; Lopes, HB; Losi, V; Lotsios, NS; Low, KE; Lu, Z; Luhana, S; Luo, X; Luo, XQ; Lutz, MB; Lysova, AA; Lyssenko, KA; Macit, M; MacIver, B; MacKenna, B; Magalhães, GAP; Magnavacchi, P; Mahadevan, J; Mahboubi, A; Maher, SA; Mahipal, A; Mahmoud, MY; Maithel, SK; Makhtar, MMZ; Makurat-Kasprolewicz, B; Malysheva, YB; Mansourizadeh, A; Marek, EJ; Maresca-Fichter, H; Martin, JT; Maslov, AA; Mastora, Z; Mastroiacovo, D; Mastropetros, SG; Matei, D; Mathur, R; Matos, AO; Matsuda, Y; Maurya, SK; Mayor, Á; Mayrhofer, D; Mazzuco, AC; McCaffrey, J; McClure, T; McDonald, HI; Mchunu, NP; McLaggan, D; Mehrkar, A; Meilik, B; Melito, VA; Mellem, J; Mengozzi, A; Menotti, J; Mesquita, V; Miao, Z; Mihai, S; Miller, S; Minassian, C; Mirabile, A; Mitra, S; Mladin, G; Mo, Z; Moawad, H; Mohamed, EM; Mohammed, TJ; Mohanlall, V; Mohyeldin, RH; Moldovan, H; Monneret, G; Monopoli, DE; Monte, IP; Monteiro, JRB; Morgante, V; Mori, M; Morin-Crini, N; Morita, A; Morton, CE; Mrak, M; Muhammed, AP; Mulick, A; Muralidharan, V; Murthy, P; Muselli, M; Mustafa, S; Mysore Visweswariah, A; Nagao, G; Naicker, S; Nakagawara, K; Namgoong, B; Namkoong, H; Namukobe, J; Nasir, AA; Nasreen, SA; Natarajan, P; Nchiozem-Ngnitedem, VA; Necozione, S; Negrea, A; Negrea, P; Ngubane, S; Nguyen, TT; Nicke, A; Nightingale, E; Nistor, CL; Nitsch, D; Njapau, H; Noman, M; Novgorodtseva, T; Nowak, A; O'Connor, SR; Ofoe, R; Oh, K; Oh, TH; Oki, E; Olama, ZA; Olennikov, DN; Oliveira, GM; Omar, D; Ong, SJ; Orfanos, SE; Origa-Oryem, H; Orita, H; Ortiz, I; Ota, M; Ott, J; Otvagina, KV; Pacheco, N; Pacheco, RR; Padmanabhan, D; Pagan, JD; Pagnotta, PA; Palangi, V; Palanisamy, G; Palanisamy, K; Palanisamy, S; Pan, SG; Panaitescu, E; Pang, X; Panoutsakopoulos, V; Parera, VE; Park, JI; Park, JS; Park, SW; Park, Y; Park, YS; Parkash, O; Parry, J; Parry, JP; Paul, SK; Pavšič, N; Pałubicka, A; Persat, F; Petriz-Prieto, MA; Petukhov, AN; Pham, T; Pillay, S; Poh, KK; Ponomarev, II; Pontons-Melo, JC; Posa, A; Powell, E; Priya, AK; Punekar, R; Puppin Rontani, RM; Purushottam, M; Pusphanathan, K; Qi, JY; Qin, J; Qin, Z; Qiu, B; Qiu, X; Quattrini, G; Quindós, G; Qureshi, F; Rabbany, MA; Rac-Albu, M; Rac-Albu, ME; Rădulescu, BC; Rafatullah, M; Rajab, TK; Rajna, S; Ramanathan, M; Rao, D; Raviglione, D; Razorenov, DY; Redd, MJ; Rehman, W; Reig, M; Rentsch, CT; Ribeiro, LMS; Robles, D; Rocchi, S; Rocha, FG; Rodrigues, C; Rodrigues, LA; Rodrigues, RP; Roh, GH; Ronowska, A; Root, A; Rosa, AL; Rossi, R; Roy, S; Roy, VC; Rupji, M; Saber, EA; Sadarat, F; Saed, Y; Saeed, WS; Saeki, H; Saha, B; Saiwichai, T; Sakowicz-Burkiewicz, M; Sampedro, T; Sands, K; Santos, CF; Sari, M; Sathi, FA; Sauro, S; Sazanova, TS; Scafa-Udriște, A; Schoustra, SE; Schultze, A; Seo, DJ; Sevillano, E; Sezmis, G; Sgura, FA; Shah, NNAK; Shani, N; Shankarappa, B; Sharkey, LM; Sharma, VK; Sharp, C; Shehata, N; Shelton, N; Shieh, PB; Shimokawa, M; Shin, J; Shin, SH; Shin, YN; Shin, YR; Shipilova, A; Shoparwe, NF; Shukor, H; Sia, CH; Siddiqui, MH; Siddiqui, MR; Siena, V; Signore, A; Silwane, B; Siqueira-Sandrin, VS; Siregar, A; Sirignano, P; Sit, NW; Skidmore, S; Skupov, KM; Smeeth, L; Smoczer, C; Smolyanskiy, E; Sohn, H; Solodeev, I; Solovyev, A; Şomoghi, R; Song, F; Song, H; Song, Z; Souf, YM; Sousa, SC; Souza, MT; Steinbach-Rankins, JM; Stockton, J; Stout, JR; Su, K; Su, MZ; Suarez-Lopez, YA; Sukkurd, R; Sultanov, R; Sun, Y; Sun, Z; Supernak, M; Supriyono, E; Suroshe, SS; Suvorov, SS; Svera M Ianăşi, P; Switchenko, JM; Syarif, NY; Synytsya, A; Taherzadeh, MJ; Tain, YL; Tamburino, C; Tammam, OY; Tan, BYQ; Tan, H; Tan, S; Tanaka, H; Tang, R; Tang, X; Tang, Z; Taurino, M; Tazare, J; Teresi, L; Testro, A; Thanasoponkul, W; Thangarasu, S; Thavaselvam, D; Theodoro, RC; Theron, G; Thomas, RH; Thomson, JJ; Tian, X; Tian, Y; Tomaszewski, CA; Tomlinson, LA; Torres, CMME; Tóth, M; Trecourt, A; Trevisani, F; Trimarchi, G; Tristán, C; Truong, VK; Tsigkou, K; Tsutsumi, S; Ubukata, Y; Uehara, H; Uwamino, Y; Vahedi-Shahandashti, R; Valberg, SJ; Valderrama, C; Valdovinos-García, EM; Valsecchi, D; van Diepeningen, AD; van West, P; Vargas-Osuna, E; Vassall, M; Vassilaki, N; Vassiliou, AG; Vecino, X; Velez-Irizarry, D; Venkatesh, YN; Vignali, L; Virdis, A; Viswanath, B; Voisin, AS; Volkova, YA; Vorotyntsev, AV; Vorotyntsev, IV; Vtyurina, ES; Vu, DH; Waldridge, B; Walker, AJ; Wallon, M; Wang, B; Wang, G; Wang, H; Wang, J; Wang, LJ; Wang, S; Wang, T; Wang, X; Wang, Z; Warren, RM; Warren-Gash, C; Wei, SH; Weinstock-Guttman, B; Wekwejt, M; Wessjohann, LA; Wiesmann, HP; Williams, ZJ; Williamson, EJ; Wilson, M; Wing, K; Wong, AY; Wong, BKL; Woodward, S; Wozniak, KL; Wu, C; Wu, K; Wu, S; Wu, Y; Xiang, D; Xie, H; Xiong, X; Xu, C; Xu, H; Xu, J; Xu, WH; Xu, Y; Xun, T; Yamaguchi, S; Yan, P; Yan, W; Yan, Z; Yang, B; Yang, F; Yang, L; Yao, XB; Yasui, H; Yenesew, A; Yeo, LLL; Yeo, TC; Yi, S; Yin, F; Yip, JWL; Yoon, SH; Yoon, SJ; Yoshida, M; Yoshizumi, T; Young, LA; Yu, C; Yu, DD; Yu, F; Yu, H; Yu, JD; Yu, NJ; Yu, X; Yuan, Y; Yurenko, A; Yusof, YA; Zahedipoor, A; Zahran, EM; Zainuddin, NI; Zanatta, AC; Zanotto, ED; Zanozin, ID; Zavascki, AP; Zenke, M; Zhang, F; Zhang, G; Zhang, H; Zhang, J; Zhang, L; Zhang, MX; Zhang, NY; Zhang, Q; Zhang, W; Zhang, X; Zhang, XM; Zhao, F; Zhao, Q; Zhao, R; Zhao, Y; Zheng, J; Zheng, S; Zhou, L; Zhou, X; Zhu, H; Zivadinov, R; Žižek, D; Zuccoli, JR; Zwaan, BJ | 1 |
| Barwad, A; Bhatnagar, S; Bhoriwal, S; Dhamija, E; Kumar, A; Mridha, AR; Rastogi, S; Shamim, SA; Tansir, G | 1 |
| Dumke, C; Eberle, F; Engenhart-Cabillic, R; Exeli, L; Hauswald, H; Lautenschlaeger, S | 1 |
| Bayram, E; Guzel, AB; Khatib, G; Kuçukgoz-Gulec, U; Paydas, S; Vardar, MA | 1 |
| Carvalho, FLF; Clinton, TN; Feldman, A; Hirsch, M; Kibel, AS; Melnick, K; Mossanen, M; Mott, SL; Mouw, KW; O'Donnell, MA; Preston, MA; Rizzo, N; Salari, K; Steele, GS; Wszolek, M; Wu, CL; Yim, K; Zafar, A | 1 |
| Ashrafizadeh, M; Luo, K; Reza Aref, A; Zhang, W; Zhang, X | 1 |
| Chen, C; Cheng, H; Ding, H; Lu, L; Tian, J; Wang, H; Wang, Z | 1 |
| Chen, D; Chen, QY; Chen, X; Chen, Y; Feng, H; He, X; Hsieh, CY; Hu, C; Jiang, Y; Jin, F; Jing, S; Keegan, P; Li, J; Li, P; Li, Q; Liao, W; Lim, WT; Lin, X; Liu, YC; Lu, Y; Luo, X; Mai, HQ; Pan, J; Qu, S; Samol, J; Shi, Y; Tang, X; Wang, HM; Wang, S; Wang, X; Wen, J; Xu, R; Xu, RH; Yang, K; Yang, MH; Yao, S; Yen, CJ; Yuan, X | 1 |
| Biglietto, M; Calabrese, F; Caterino, M; Ciardiello, F; Conzo, G; De Vita, F; Laterza, MM; Molino, C; Orditura, M; Pappalardo, A; Petrillo, A; Pompella, L; Tirino, G; Ventriglia, A | 1 |
| Anthoney, A; Borg, D; Büchler, MW; Campbell, F; Crosby, T; Cummins, S; Cunningham, D; Darby, S; Falk, S; Faluyi, O; Ghaneh, P; Gillmore, R; Glimelius, B; Hackert, T; Halloran, CM; Hammel, P; Izbicki, JR; Jackson, R; Jones, RP; Lerch, MM; Lind, P; Mayerle, J; McDonald, A; Meyer, T; Middleton, GW; Neoptolemos, JP; O'Reilly, DA; Palmer, DH; Patel, K; Psarelli, EE; Ross, PJ; Sherriff, D; Soomal, R; Sothi, S; Strobel, O; Ting, Y; Tjaden, C; Valle, JW; Wadsley, J; Wasan, H | 1 |
| Ando, K; Iwata, T; Mishima, H | 1 |
| Chen, M; Fu, G; Guan, Y; Guo, Z; Jiang, H; Jiang, X; Liang, J; Lu, T; Niu, X; Sun, R; Sun, S; Sun, X; Tang, J; Wang, H; Wang, X; Wu, K; Wu, X; Yang, C; Zheng, S; Zhong, B | 1 |
| Gou, H; Huang, J; Li, Q; Liao, W; Wang, X; Wen, F; Wu, Q; Zhang, P; Zhou, J; Zhou, K; Zhu, G | 1 |
| Berg, T; Nøttrup, TJ; Roed, H | 1 |
| Arcieri, M; Ergasti, R; Fagotti, A; Marchetti, C; Palluzzi, E; Pietragalla, A; Rosati, A; Scaletta, G; Scambia, G | 1 |
| Diao, WL; Guo, HQ; Wang, TW; Yang, R; Yuan, H; Zhao, XZ | 1 |
| Chikhladze, S; Fichtner-Feigl, S; Kousoulas, L; Lederer, AK; Reinmuth, M; Sick, O; Wittel, UA | 1 |
| Lassaletta, A; Madero, L; Moreno-Tejero, ML; Pelaez, I; Perez-Somarriba, M; Rozas, MI | 1 |
| Kaur, H; Lee, YS; Ong, SY; Phipps, C; Tan, L | 1 |
| Bell, R; Bell-McGuinn, K; Buderath, P; Campbell, R; Farrington, DL; Fiorica, J; Golden, L; Hamilton, A; Heitz, F; Lee, CM; Moore, KN; Pitou, C; Powell, M; Sehouli, J; Teneriello, M; Vergote, I; Wenham, RM; Zhang, W | 1 |
| Alvarez Secord, A; Armstrong, DK; Azab, M; Banerjee, S; Basu, B; Birrer, MJ; Blagden, SP; Braly, P; Fleming, GF; Ghamande, S; Hall, GD; Hao, Y; Hirte, HW; Jueliger, S; Keer, H; Kristeleit, R; Markham, MJ; Matei, D; Matulonis, UA; McGuire, WP; Naim, S; Nemunaitis, J; Nephew, KP; Oganesian, A; Oza, AM; Provencher, DM; Roman, LD; Schwartz, B | 1 |
| Huang, KW; Kim, MD; Li, SP; Li, XY; Liang, PC; Pua, U; Yang, PC | 1 |
| Biasoni, D; Bisogno, G; Boldrini, R; Conte, M; Crocoli, A; D'Angelo, P; Dall'Igna, P; De Pasquale, MD; Inserra, A; Miele, E; Siracusa, F; Spreafico, F; Terenziani, M | 1 |
| Chang, J; Chen, T; He, M; Hong, W; Li, F; Li, H; Li, J; Liu, L; Luo, D; Ran, L; Shan, L; Song, Y; Wang, B; Wang, H | 1 |
| Chen, T; Jin, Y; Xiao, Z; Zhuang, B | 1 |
| Bi, J; Chen, S; Diao, C; Dong, Y; Fan, H; Fan, W; Feng, Q; Geng, D; Han, X; Huang, G; Li, F; Li, G; Li, P; Li, Q; Li, T; Li, W; Li, Y; Liu, B; Meng, M; Meng, Q; Ni, Y; Ren, H; Sheng, L; Sun, D; Sun, L; Sun, W; Sun, Y; Tian, H; Wang, C; Wang, J; Wei, Z; Xu, X; Xu, Y; Xue, G; Yang, X; Ye, X; Yu, G; Zhang, B; Zhang, K; Zhang, L; Zheng, A; Zou, Z | 1 |
| Altuntaş, F; Bakırtaş, M; Başçı, S; Batgi, H; Dal, MS; Darçın, T; İskender, D; Kızıl Çakar, M; Merdin, A; Şahin, D; Tetik, A; Uncu Ulu, B; Yiğenoğlu, TN; Yıldız, J | 1 |
| Akkermans-Vogelaar, JM; Besselink, MG; Bonsing, BA; Buijsen, J; Busch, OR; Creemers, GM; de Groot, JWB; de Hingh, IH; de Vos-Geelen, J; Eskens, FALM; Festen, S; Groot Koerkamp, B; Groothuis, K; Homs, MYV; Kerver, ED; Luelmo, SAC; Neelis, KJ; Nuyttens, J; Paardekooper, GMRM; Patijn, GA; Punt, CJ; Suker, M; van Dam, RM; van der Sangen, MJC; van Eijck, CH; van Hooft, JE; van Tienhoven, G; Versteijne, E; Wilmink, JW; Zwinderman, AH | 1 |
| Abate-Shen, CT; Anderson, CB; DeCastro, GJ; Drake, CG; Holder, D; James, B; Kates, MM; Lee, SM; McKiernan, JM; Pak, JS; Sui, W; Virk, RK | 1 |
| Bun, S; Kato, MK; Kato, T; Miyasaka, N; Shimoi, T; Tamura, K; Yonemori, K; Yunokawa, M | 1 |
| Egawa, C; Haruna, K; Hata, T; Kagawa, Y; Katsura, Y; Kawai, K; Masuzawa, T; Murakami, K; Murata, K; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A; Yanagawa, T; Yanai, A | 1 |
| Hada, T; Ishibashi, H; Iwahashi, H; Kakimoto, S; Matsuura, H; Miyamoto, M; Sakamoto, T; Soyama, H; Suminokura, J; Takano, M | 1 |
| Cheng, X; Hu, X; Jia, Z; Liang, X; Yang, J; Zhai, Y | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Peard, L; Saltzman, AF; Stark, T; Ziada, A | 1 |
| Heneghan, M; Kitagawa, M; Prachalias, A; Srinivasan, P; Suzuki, K; Zen, Y | 1 |
| Jin, Y; Li, S; Li, Y; Ma, Z; Sun, R; Yan, H; Zhao, K; Zhao, W | 1 |
| Donnell, R; Hong, T; Hu, Y; Pattarawat, P; Tsai, CL; Wallace, S; Wang, HR; Wang, J; Wang, TH | 1 |
| Gontero, P; Soria, F | 1 |
| Cho, DH; Kim, KM; Lee, DH; Lee, NR; Yim, CY | 1 |
| Arima, K; Kanda, H; Kato, M; Kitano, G; Masui, S; Nishikawa, K; Nishikawa, T; Owa, S; Sasaki, T; Sugimura, Y; Sugino, Y; Uchida, K; Yoshio, Y | 1 |
| Asukai, K; Hara, H; Haraguchi, N; Hasegawa, S; Ishikawa, O; Miyata, H; Nishimura, J; Ohue, M; Omori, T; Sakon, M; Shinno, N; Sugimura, K; Takahashi, H; Ushigome, H; Wada, H; Yamada, D; Yamamoto, K; Yano, M; Yasui, M | 1 |
| Du, B; Lai, J; Lin, M; Wang, Y; Wen, X | 1 |
| Berjon, A; Brenes, J; Casado, G; Castelo, B; Espinosa, E; Feliu, J; Gallego, A; Hardisson, D; Hernandez, A; Mendiola, M; Ramon-Patino, J; Redondo, A | 1 |
| Huang, G; Huang, J; Liu, Y; Xue, C; Zhang, Z | 1 |
| Chan, GHJ; Chong, SM; Chong, WQ; Goh, BC; Goh, RM; Ho, FCH; Huang, Y; Jeyasekharan, AD; Kong, LR; Kumarakulasinghe, NB; Lau, JA; Lee, SC; Lim, CM; Lim, YC; Loh, KS; Loh, WS; Sinha, AK; Soo, RA; Soon, YY; Sundar, R; Tai, BC; Tan, CS; Tay, JK; Wang, L; Wong, AL; Yadav, K | 1 |
| Byun, Y; Chie, EK; Choi, YJ; Han, Y; Jang, JY; Kang, JS; Kim, H; Kim, HS; Kim, YT; Kwon, W; Lee, K; Lee, SH; Oh, DY; Paik, WH; Ryu, JK | 1 |
| Bahra, M; Bechstein, W; Bischoff, S; Bitzer, M; Denzlinger, C; Gellert, K; Ghadimi, M; Hinke, A; Hofheinz, R; Lammert, F; Liersch, T; Lindig, U; Maschmeyer, G; Oettle, H; Pelzer, U; Riess, H; Sinn, M; Striefler, JK; Stübs, P; Waldschmidt, D | 1 |
| Abubakar, M; Jan, MRU; Saeed, H; Wali, RM | 1 |
| Atari, M; Imai, K; Matsuo, T; Minamiya, Y; Motoyama, S; Nakayama, K; Nomura, K; Sato, Y; Shibata, H; Takashima, S | 1 |
| Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS | 1 |
| Fujiwara, H; Koyanagi, T; Machida, S; Saga, Y; Takahashi, S; Takahashi, Y; Takei, Y; Tamura, K; Taneichi, A; Yoshiba, T | 1 |
| Altuntaş, F; Bakırtaş, M; Başcı, S; Batgi, H; Baysal, NA; Dal, MS; Darçın, T; İskender, D; Kılınç, A; Kızıl Çakar, M; Merdin, A; Özcan, N; Şahin, D; Uncu Ulu, B; Yiğenoğlu, TN; Yıldız, J | 1 |
| Chen, Y; Huang, C; Kong, X; Liu, C; Meng, Q; Meng, YM; Qiu, X; Su, L; Wang, M; Wong, PP; Wu, S; Zhao, X | 1 |
| Ando, M; Ando, Y; Ebata, T; Inada-Inoue, M; Maeda, O; Matsuoka, A; Mitsuma, A; Miyai, Y; Mizuno, T; Morita, S; Nagino, M; Shimokata, T; Sugishita, M; Takano, Y; Urakawa, H | 1 |
| Kim, JS; Kim, SJ; Kim, T; Kim, WS; Koh, Y; Moon, JH; Park, GS; Park, J; Shin, HJ; Yang, DH; Yhim, HY | 1 |
| Aoyama, T; Kamiya, M; Kobayashi, S; Masuda, M; Morimoto, M; Morinaga, S; Murakawa, M; Numata, M; Oshima, T; Rino, Y; Sawazaki, S; Shiozawa, M; Tamagawa, H; Ueno, M; Yamamoto, N; Yoshikawa, T; Yukawa, N | 1 |
| Slater, H | 1 |
| Akaike, H; Amemiya, H; Furuya, S; Higuchi, Y; Hosomura, N; Ichikawa, D; Kawaguchi, Y; Kawaida, H; Kono, H; Nakata, Y; Nakayama, T; Saito, R; Shoda, K; Sudo, M; Tsukahara, I | 1 |
| Funakoshi, S; Hirose, S; Kouno, T; Machino, C; Oikawa, H; Sato, T | 1 |
| Alcindor, T; Elkrief, A; Kazandjian, S | 1 |
| Bai, H; Bi, X; Cao, C; Chen, Y; Feng, X; Guan, K; Guan, Y; Hu, L; Hu, Z; Jiang, W; Li, C; Li, Y; Liu, Y; Ma, J; Shi, H; Shou, J; Tian, J; Wang, D; Xiao, Z; Zhang, J; Zhang, W; Zheng, S; Zhou, A | 1 |
| Brandi, G; Rizzo, A | 1 |
| Baba, H; Goel, A; Nishiwada, S; Okada, Y; Sho, M; Takayama, T; Yamamura, K | 1 |
| Goto, M; Hori, K; Ito, K; Nakagawa, M; Ono, H; Onoue, M; Shimoji, K; Shiomi, M; Suzuki, J; Tashima, L; Uragami, K; Yamashita, M; Yoshioka, E | 1 |
| Andoh, A; Fukutomi, A; Fushiki, K; Hamauchi, S; Inoue, H; Kawakami, T; Machida, N; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
| Alva, A; Bandini, M; Curran, C; Diamantopoulos, LN; Gallina, A; Grivas, P; Grunewald, CM; Gupta, S; Jain, RK; Lee, JL; McGregor, BA; Mossanen, M; Necchi, A; Niegisch, G; Olson, KM; Pond, GR; Ravi, P; Singh, P; Skelton, WP; Sonpavde, GP; Su, C; Tward, JD | 1 |
| Fukuda, K; Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, Y | 1 |
| Bahra, M; Bischoff, S; Kruger, S; Kurreck, A; Modest, DP; Oettle, H; Pelzer, U; Riess, H; Sinn, M; Striefler, JK; Weckwerth, J | 1 |
| Archibald, CJ; Hunt, JT; Pattarawat, P; Poloway, J; Wang, HR | 1 |
| Cass, I; Kamrava, M; Karlan, B; Kim, S; Li, A; Rimel, BJ; Rogatko, A; Walsh, CS | 1 |
| Bivalacqua, TJ; Brooks, N; Crump, T; DeWolf, WC; Hyndman, ME; Kamat, AM; Kates, M; Lamm, DL; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Steinberg, RL; Thomas, LJ; Vitale, A; Wang, J | 1 |
| Cleves, A; Dahm, P; Han, MA; Hwang, EC; Hwang, JE; Jung, JH; Maisch, P; Narayan, V | 1 |
| Hayami, S; Hirono, S; Kawai, M; Kitahata, Y; Kobayashi, R; Miyazawa, M; Okada, KI; Ueno, M; Yamaue, H | 1 |
| Burns, G; Greystoke, A; Iqbal, MS; Robinson, M; Rodriguez, CN | 1 |
| Chen, D; Chen, QY; Chen, X; Chen, Y; Feng, H; He, X; Hsieh, CY; Hu, C; Jiang, Y; Jin, F; Jing, S; Keegan, P; Li, J; Li, P; Li, Q; Liao, W; Lim, WT; Lin, X; Liu, YC; Liu, Z; Lu, Y; Mai, HQ; Pan, J; Qu, S; Samol, J; Shi, YR; Wang, HM; Wen, J; Xu, R; Xu, RH; Yang, K; Yang, MH; Yao, S; Yen, CJ; Yuan, X | 1 |
| Chen, X; Dong, T; Ji, J; Kuang, P; Li, J; Liu, J; Liu, T; Liu, Z; Shen, K; Zhang, C; Zhang, L | 1 |
| Janssen, S; Manig, L; Rades, D; Schild, SE | 1 |
| Ariyoshi, K; Matsushita, S; Okadome, M; Saito, T; Shimada, T; Shimamoto, K; Shimokawa, M; Yamaguchi, S | 1 |
| Chen, CS; Cheng, CL; Chiu, KY; Ho, HC; Hung, SC; Li, JR; Ou, YC; Wang, SS; Yang, CK | 1 |
| Hijikata, Y; Hosokawa, Y; Kasuya, K; Katsumata, K; Nagakawa, Y; Nakajima, T; Nakayama, H; Sahara, Y; Takishita, C; Tokuuye, K; Tsuchida, A | 1 |
| Chiba, N; Imai, H; Ishioka, C; Komine, K; Mori, T; Ohori, H; Okada, Y; Saijo, K; Shimodaira, H; Shirota, H; Takahashi, M; Takahashi, S | 1 |
| Baechmann, S; Boeck, S; Haas, M; Heinemann, V; Jung, A; Kirchner, T; Kruger, S; Modest, DP; Ormanns, S; Remold, A; Werner, J | 1 |
| Bonnetain, F; de la Motte Rouge, T; Kalbacher, E; Lesoin, A; Pautier, P | 1 |
| Hazama, S; Iida, M; Kanekiyo, S; Matsui, H; Matsukuma, S; Nagano, H; Nakashima, M; Oka, M; Sakamoto, K; Shindo, Y; Suzuki, N; Takeda, S; Tokuhisa, Y; Ueno, T; Yoshimura, K; Yoshino, S | 1 |
| Ding, L; Dong, X; Geng, L; Li, N; Li, Y; Liu, Y; Luo, Q; Ma, C; Wei, F; Zhang, L; Zhang, Y; Zhou, T | 1 |
| Embry-Schubert, J; Lentz, SE; Littell, RD; Neugebauer, R; Palen, TE; Raine-Bennett, T; Tucker, LY; Zaritsky, E | 1 |
| Assaf, C; Nicolay, JP | 1 |
| Arenare, L; Bergamini, A; Bologna, A; Breda, E; Bryce, J; Cecere, SC; Cinieri, S; Cormio, G; Daniele, G; Di Napoli, M; Ferrandina, G; Gallo, C; Lorusso, D; Mangili, G; Murgia, V; Natale, D; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Sacco, C; Salutari, V; Scambia, G; Signoriello, S; Sorio, R; Vergote, IB; Wagner, U | 1 |
| He, X; Hu, C; Ou, D; Wu, M | 1 |
| Jun, E; Kim, SC; Lee, CM; Lee, S; Oh, J; Shim, IK | 1 |
| Bonetti, A; Giuliani, J | 1 |
| Buckstein, M; Ghiassi-Nejad, Z; Moshier, E; Ru, M; Schwartz, M; Tabrizian, P; Tarchi, P | 1 |
| Anthoney, A; Büchler, MW; Campbell, F; Carter, R; Cox, TF; Deakin, M; Dervenis, C; Ghaneh, P; Glimelius, B; Goldstein, D; Halloran, CM; Izbicki, JR; Jackson, R; Jones, O; Kleeff, J; Lerch, MM; Mayerle, J; McDonald, AC; Melling, J; Neoptolemos, JP; O'Reilly, DA; Oláh, A; Padbury, R; Palmer, DH; Raraty, M; Rawcliffe, CL; Scarfe, AG; Shannon, J; Smith, CJ; Strobel, O; Tebbutt, NC; Valle, JW | 1 |
| Armbrecht, N; Bernhardt, G; Brooks, J; Calvisi, DF; Ceyhan, GO; Demir, IE; Fleischmann-Mundt, B; Gürlevik, E; Kubicka, S; Kühnel, F; Manns, MP; Niemann, J; Peters, K; Ribback, S; Smyth, MJ; Wirth, TC; Woller, N | 1 |
| Abdallah, A; Baumann, BC; Christodouleas, JP; Hwang, WT; Khaled, HM; Smith, A; William, H; Zaghloul, MS | 1 |
| Bartscht, T; Hakim, SG; Idel, C; Rades, D | 1 |
| Chen, L; Chen, Z; Guo, Y; Huang, X; Kang, Y; Liu, Q; Liu, Z; Sun, C; Zhou, D; Zhu, H | 1 |
| Alseidi, A; Badiozamani, K; Biehl, TR; Edwards, AM; Helton, WS; Kanji, ZS; Kozarek, RA; Lin, BS; Mandelson, MT; Picozzi, VJ; Rocha, FG; Sahar, N; Song, G | 1 |
| Capurso, G; Delle Fave, G; Panzeri, V; Passacantilli, I; Sette, C; Terracciano, F | 1 |
| Patel, JA; Piper, JB; Wang, BG | 1 |
| Cao, Y; Dong, P; Fan, W; Guo, S; Han, H; Jiang, L; Li, X; Li, Y; Liu, Z; Qin, Z; Shi, Y; Yao, K; Ye, Y; Zhou, F | 1 |
| Ebara, S; Edamura, K; Hanamoto, M; Hayashi, N; Hirata, T; Ogura, K; Saika, T; Takamura, K | 1 |
| Kawamata, O; Murata, T; Uda, M | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kawamoto, K; Kobayashi, S; Mori, M; Noda, T; Yamada, D | 1 |
| Brand, TC; Culkin, DJ; Evans, CP; Hafez, KS; Holzbeierlein, JM; Karsh, LI; Koppie, TM; Lerner, SP; Mack, PC; Messing, EM; Plets, M; Sahasrabudhe, DM; Svatek, RS; Tangen, CM; Thompson, IM; Vogelzang, NJ; Wilson, SS; Wood, DP; Wu, G | 1 |
| Stone, L | 1 |
| Bo, JJ; Duan, XH; Huang, YR; Liu, Q; Wang, ZL; Yang, GL; Zhang, LH | 1 |
| Chen, GP; Chen, YQ; Hu, JL; Liu, NF; Sun, HY; Yang, Y; Yu, H; Zhu, JQ; Zhu, T | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kawamoto, K; Kobayashi, S; Mori, M; Noda, T; Okumura, Y; Sakamoto, T; Takeda, Y; Tanemura, M; Umeshita, K; Wada, H; Yamada, D | 1 |
| Bowers, M; Cozens, K; Cross, N; Hennig, IM; Huddart, R; McKenzie, HS; Mead, G; Rustin, GJS; Wheater, MJ; White, JD | 1 |
| Akita, H; Asukai, K; Ishikawa, O; Matsunaga, T; Miyata, H; Nakanishi, M; Nishimura, J; Ohue, M; Omori, T; Sakon, M; Shirayanagi, M; Sugimura, K; Takahashi, H; Takahashi, Y; Tomokuni, A; Wada, H; Yamamoto, K; Yamamoto, T; Yamasaki, T; Yanagimoto, Y; Yano, M; Yasui, M | 1 |
| Berkowitz, RS; Bonventre, JV; Crum, CP; D'Andrea, AD; Decker, B; Do, KT; Feltmate, CM; Hill, SJ; Horowitz, NS; Kochupurakkal, BS; Konstantinopoulos, PA; Liu, JF; Matulonis, UA; Morizane, R; Muto, MG; Nguyen, H; Nucci, MR; Roberts, EA; Shapiro, GI; Swisher, EM; Worley, MJ; Yang, C | 1 |
| Franch-Sarto, M; López, L; Moreno, M; Ribera, JM; Sancho, JM; Sorigue, M | 1 |
| Chang, HM; Hwang, I; Ip, HNN; Jeong, JH; Kang, J; Kim, KP; Ryoo, BY; Yoo, C | 1 |
| Babjuk, M | 1 |
| Brunner, TB; Willich, C | 1 |
| Arima, K; Baba, H; Chikamoto, A; Fukuzawa, K; Hashimoto, D; Hirata, T; Hirota, M; Inomata, M; Maehara, Y; Nakagawa, S; Negoro, Y; Ohga, T; Oki, E; Saeki, H; Yamashita, YI | 1 |
| Beltran, BE; Conlon, K; Cook, L; Dwyer, K; Feldman, T; Fields, PA; Gonsky, J; Hermine, O; Horwitz, SM; Humphrey, J; Kurman, M; Leoni, M; Moriya, J; Pereira, J; Phillips, AA; Ramos, JC; Sawas, A; Taylor, GP; Wandroo, F | 1 |
| Cao, F; Cao, Y; Fang, F; Jia, Z; Ju, X; Qing, S; Shen, Y; Zhang, H; Zhu, X | 1 |
| Fushida, S; Kinoshita, J; Makino, I; Miyashita, T; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohbatake, Y; Ohta, T; Okamoto, K; Okazaki, M; Sakai, S; Tajima, H; Takamura, H; Terai, S | 1 |
| Hakamada, K; Ishido, K; Kimura, N; Kudo, D; Sakuraba, S; Yachi, T | 1 |
| Egawa, C; Inatome, J; Kagawa, Y; Katsura, Y; Kawai, K; Masuzawa, T; Mori, R; Murakami, K; Murata, K; Naito, A; Nose, Y; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A | 1 |
| Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Kouroussis, C; Polyzos, A; Syrios, J; Vardakis, N | 1 |
| Chang, SS | 1 |
| Akiyama, T; Fukada, T; Kametaka, H; Makino, H; Miyazaki, M; Okura, R; Oya, M; Saitou, M; Seike, K; Tabe, S; Yoshitomi, H | 1 |
| Choi, HJ; Hong, JH; Jang, JS; Kang, JH; Kim, MJ; Kim, S; Kim, ST; Lee, HW; Lee, J; Lee, MA; Lim, HY; Oh, SY; Park, JO; Park, YS; Sohn, BS; Yoon, SY | 1 |
| Are, C; Grem, JL; Hahn, SM; Lazenby, A; Li, S; Lin, C; Ly, QP; Meza, JL; Sasson, A; Schwarz, JK; Verma, V; Wang, S | 1 |
| Gutierrez, A | 1 |
| Higashi, T; Matsumoto, H; Nagatsu, K; Oe, Y; Sugyo, A; Tsuji, AB; Yoshii, Y; Yoshimoto, M; Zhang, MR | 1 |
| Hata, T; Imamoto, H; Kawada, J; Kim, Y; Miwa, H; Murakami, M; Okano, M; Okuyama, M; Shimizu, J; Tanizaki, K; Tsujinaka, T; Yamasaki, M | 1 |
| Burges, A; Colomban, O; Du Bois, A; Freyer, G; Hardy-Bessard, AC; Kurzeder, C; Leary, A; Lortholary, A; Péron, J; Pfisterer, J; Ray-Coquard, I; Tod, M; You, B | 1 |
| André, F; Cortés, J; Dent, R; Deurloo, R; Easton, V; Gonçalves, A; Kümmel, S; Martín, M; Pollex, E; Schmid, P; Schuetz, F; Swain, SM | 1 |
| Choi, HY; Jeon, HG; Jeon, SS; Jeong, JY; Lee, HM; Seo, SI; Song, W; Sung, HH | 1 |
| Awasthi, A; Bill, KLJ; Brock, GN; Bupathi, M; Chen, JL; Demoret, B; Duggan, MC; Hays, JL; Millis, SZ; Pollock, RE; Seligson, ND; Shakya, R; Stets, CW; Timmers, CD; Wakely, PE | 1 |
| Franses, JW; Hong, TS; Zhu, AX | 1 |
| Ishigaki, A; Kainuma, O; Kato, M; Kuwayama, N; Maruyama, T; Matsumoto, Y; Miyazaki, A; Mizumoto, H; Natsume, T; Note, H; Oshima, S; Sato, Y; Shimizu, S; Suzuki, K; Tanaka, H; Yoshioka, T | 1 |
| Chen, X; Jiang, J; Liang, W; Wan, N; Yang, Y; Zhang, L; Zhang, T | 1 |
| Barangi, M; Bouvet, M; Chawla, SP; Endo, I; Higuchi, T; Hiroshima, Y; Hoffman, RM; Homma, Y; Katsuya, Y; Li, Y; Matsuyama, R; Miyake, K; Murakami, T; Nelson, SD; Oshiro, H; Park, JH; Razmjooei, S; Singh, SR; Sugisawa, N; Zhang, Z | 1 |
| Burge, M; Cohen, J; Cooray, P; Gibbs, P; Goldstein, D; Harris, M; Haydon, A; Javed, AA; Kinzler, KW; Lawrence, B; Lee, B; Lennon, AM; Li, L; Lipton, L; Nagrial, A; Nikfarjam, M; Papadopoulos, N; Simons, K; Tai, DWM; Tebbutt, NC; Thomson, B; Tie, J; Tomasetti, C; Vogelstein, B; Wolfgang, CL | 1 |
| Ahmad, M; Akhlaq, M; Danish, Z; Saeed, H; Saleem, Z; Sattar, S | 1 |
| Bie, Z; Li, B; Li, L; Li, X; Li, Y; Wang, D | 1 |
| Aerts, J; Biesma, B; Dingemans, AC; Groen, HJM; Hoekstra, O; Klinkenberg, TJ; Kloosterziel, C; Pieterman, R; Schramel, FMNH; Smit, EF; Smit, HJM; van den Borne, B; van der Heijden, EHFM; van der Noort, V; van Tinteren, H; Verhagen, A | 1 |
| Anai, S; Fujii, T; Fujimoto, K; Gotoh, D; Hori, S; Itami, Y; Miyake, M; Morizawa, Y; Nakai, Y; Ohnishi, S; Owari, T; Shimizu, T; Tanaka, N; Torimoto, K; Toritsuka, M | 1 |
| du Bois, A; Harter, P; Heitz, F; Kurzeder, C; Lubbe, D; Pfisterer, J; Plante, M; Vergote, I | 1 |
| Dohrmann, T; Izbicki, JR; Jaenicke, F; Kutup, A; Mahner, S; Müller, V; Vashist, YK | 1 |
| Fang, J; Li, S; Lv, C; Ma, Y; Sun, Y; Wu, N; Yan, S; Yang, Y; Zheng, Q | 1 |
| Cheng, J; Gao, J; Liu, X; Wang, J; Wang, L; Xiong, L | 1 |
| Chun, F; Gontero, P; Gurioli, A; Kluth, LA; Lucca, I; Marson, F; Martorana, G; Mehnert, A; Oderda, M; Pappagallo, G; Rink, M; Sanguedolce, F; Schiavina, R; Schmid, M; Shariat, SF; Sogni, F | 1 |
| Ikeda, Y; Kikuchi, Y; Kita, T; Kudoh, K; Sasaki, N; Takano, M | 1 |
| Bauer, D; Biassoni, V; Casanova, M; Catania, S; De Pava, MV; Gandola, L; Indini, A; Massimino, M; Modena, P; Pecori, E; Podda, M; Polastri, D; Rampini, P; Schiavello, E | 1 |
| Benson, M; Goldman, B; Lee, CT; Lenz, HJ; Lerner, SP; Petrylak, DP; Sakr, WA; Skinner, EC; Tangen, CM; Thompson, IM; Wilson, SS | 1 |
| Abe, H; Azuma, H; Inamoto, T; Kiyama, S; Komura, K; Kotake, Y; Kouno, J; Minami, K; Narumi, Y; Nomi, H; Takagi, S; Takahara, K; Uehara, H; Yamamoto, K | 1 |
| Beijnen, JH; Huitema, AD; Leijen, S; Schellens, JH; van Werkhoven, E; Veltkamp, SA | 1 |
| Han, H; Li, YH; Liu, JY; Liu, ZW; Qin, ZK; Yao, K; Ye, YL; Zhang, ZL; Zhou, FJ | 1 |
| Lv, X; Pan, ZH; Su, A; Zhang, J; Zhou, QM | 1 |
| Ciombor, KK; Goff, LW | 1 |
| Armbrecht, N; Fleischmann-Mundt, B; Gürlevik, E; Hoffmann, D; Kloos, A; Kubicka, S; Kühnel, F; Longerich, T; Manns, MP; Schambach, A; Wirth, TC; Woller, N; Zender, L | 1 |
| Hiraoka, N; Ikeda, M; Kondo, S; Kosuge, T; Morizane, C; Nara, S; Okusaka, T; Otsuka, T; Shimada, K; Ueno, H | 1 |
| Abu-Rustum, NR; Andikyan, V; Barakat, RR; Chi, DS; Khoury-Collado, F; Konner, JA; O'Cearbhaill, RE; Sandadi, S; Sonoda, Y; Tew, WP | 1 |
| Adam, J; Pinilla-Dominguez, P; Richardson, J; Robertson, J | 1 |
| Amano, R; Hirakawa, K; Kimura, K; Murata, A; Nakata, B; Yamada, N; Yashiro, M | 1 |
| Khunnarong, J; Manusirivithaya, S; Pataradool, K; Pitakkarnkul, S; Prutthiphongsit, W; Srijaipracharoen, S; Tangjitgamol, S; Thavaramara, T | 1 |
| Ahmad, S; Khattak, J; Naqi, N; Shah, I | 1 |
| Hatano, E; Ishii, T; Kanai, M; Machimoto, T; Nagata, H; Narita, M; Tanaka, S; Taura, K; Uemoto, S; Yamamoto, K; Yamanaka, K | 1 |
| Blackford, AL; Cameron, JL; Choti, MA; De Jesus-Acosta, A; Donehower, RC; Edil, BH; Ellsworth, S; Fan, KY; Hacker-Prietz, A; Herman, JM; Hidalgo, M; Hruban, RH; Laheru, DA; Le, DT; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD; Zheng, L | 1 |
| Fujikawa, T; Maekawa, H; Shimoike, N; Tanaka, A | 1 |
| Akagi, Y; Ishikawa, H; Kinugasa, T; Mizobe, T; Ohshima, K; Oka, Y; Setojima, K; Shiratsuchi, I; Shirouzu, K | 1 |
| Ishihara, Y; Itoh, K; Komatsu, N; Matsueda, S; Mine, T; Noguchi, M; Sasada, T; Yamada, A; Yonemoto, K; Yoshitomi, M; Yutani, S | 1 |
| Ball, D; Collins, M; Francis, H; Franco, M; Kofoed, S; Mileshkin, L; Paramanathan, A; Solomon, B | 1 |
| Alongi, F; Clerici, E; Comito, T; Cozzi, L; Fogliata, A; Iftode, C; Mancosu, P; Navarria, P; Reggiori, G; Rimassa, L; Scorsetti, M; Tomatis, S; Tozzi, A; Zerbi, A | 1 |
| Akada, M; Egawa, S; Fujishima, F; Ishida, K; Katayose, Y; Motoi, F; Nakagawa, K; Oikawa, M; Okada, T; Ono, F; Ottomo, S; Shimamura, H; Takemura, S; Unno, M | 1 |
| Butthongkomvong, K; Jhankumpha, S; Kumdang, S; Sirachainan, E; Sukhontharot, OU | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, V; Can, A; Demir, L; Dirican, A; Erten, C; Kucukzeybek, Y; Somali, I; Tarhan, MO | 1 |
| Ariyoshi, K; Eto, T; Okadome, M; Saito, T; Shimamoto, K; Tomita, Y | 1 |
| Abood, GJ; Bahary, N; Bartlett, DL; Krasinskas, AM; Lembersky, BC; Moser, AJ; Potter, DM; Ramanathan, RK; Shuai, Y; Smith, RP; Van Buren, G; Zeh, HJ; Zureikat, AH | 1 |
| Arena, MG; Barba, M; Corrado, G; Di Lauro, L; Giannarelli, D; Mariani, L; Maugeri-Saccà, M; Paoletti, G; Pizzuti, L; Sergi, D; Tomao, F; Tomao, S; Vici, P; Vincenzoni, C; Vizza, E | 1 |
| Abe, H; Azuma, H; Hirano, H; Ibuki, N; Inamoto, T; Kiyama, S; Komura, K; Kotake, Y; Kouno, J; Minami, K; Narumi, Y; Nomi, H; Takagi, S; Takahara, K; Uehara, H; Yamamoto, K | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Celano, P; Eisenhauer, E; Fader, AN; Frasure, H; Gehrig, PA; Giuntoli, RL; Havrilesky, LJ; Krill, L; Levinson, K; Lopez, MA; Ricci, S; Secord, AA; Tanner, EJ | 1 |
| Aiba, K; Fujiwara, Y; Furukawa, K; Futagawa, Y; Kitamura, H; Misawa, T; Shiba, H; Tsutsui, N; Uwagawa, T; Yanaga, K | 1 |
| Bellmunt, J; Blais, N; Castellano, D; Cerbone, L; Le-Guennec, S; Machiels, JP; Peters, F; Risse, ML; Skoneczna, IA; Sternberg, CN; Theodore, C; Voog, E | 1 |
| Arning, MB; Fahlke, J; Gellert, K; Hartmann, JT; Hinke, A; Hochhaus, A; Neuhaus, P; Niedergethmann, M; Oettle, H; Ridwelski, K; Riess, H; Sinn, M; Zülke, C | 1 |
| Azad, A; Bolton, D; Davis, ID; Eapen, R; Liew, MS; Sengupta, S; Tafreshi, A | 1 |
| Biasoni, D; Catanzaro, M; Farè, E; Giannatempo, P; Gianni, AM; Lo Vullo, S; Mariani, L; Milani, A; Necchi, A; Nicolai, N; Piva, L; Raggi, D; Salvioni, R; Stagni, S; Torelli, T | 1 |
| Clark, JI; Kucuk, O; Malhotra, B; Moon, J; Urba, SG; Wolf, GT; Worden, FP | 1 |
| Asna, N; Grisaru, D; Inbar, M; Matcejevsky, D; Safra, T; Shpigel, S; Veizman, A | 1 |
| Momeni, M; Veras, L; Zakashansky, K | 1 |
| Jiang, Y; Yang, L; Yuan, Z; Zhang, Y; Zhao, Q | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY | 1 |
| Ahn, KO; Jeong, KC; Jung, NR; Lee, KH; Lee, SJ; Park, WS; Seo, HK; Shin, JS | 1 |
| Aghajanian, C; Blank, S; Goff, B; Husain, A; Nycum, LR; Wang, Y | 1 |
| Hussain, R; Iqbal, H; Jamshed, A | 1 |
| Burcoveanu, D; Chevreau, C; Culine, S; Delva, R; Eymard, JC; Fizazi, K; Flechon, A; Geoffrois, L; Gravis, G; Houede, N; Laguerre, B; Laplanche, A; Rolland, F | 1 |
| Hiraoka, M; Itasaka, S; Kawaguchi, Y; Matsuo, Y; Mizowaki, T; Nakamura, A; Shibuya, K; Takaori, K; Uemoto, S; Yoshimura, M | 1 |
| Ichioka, D; Kawai, K; Kimura, T; Miyazaki, J; Nishiyama, H; Suetomi, T; Takaoka, E; Uchida, M | 1 |
| Chang, H; Chen, X; Dai, Y; Dong, T; He, C; Ji, J; Li, J; Liu, T; Liu, W; Xiang, B | 1 |
| Azuma, H; Hirano, H; Ibuki, N; Inamoto, T; Kiyama, S; Komura, K; Minami, K; Narumi, Y; Nomi, H; Saito, K; Takahara, K; Takai, T; Tanda, N; Uchimoto, T; Uehara, H; Yamamoto, K | 1 |
| Alberts, SR; Borad, MJ; Costello, BA; Erlichman, C; Kim, GP; Northfelt, DW; Qi, Y | 1 |
| Chen, L; Huang, MJ; Lu, Y; Song, LL; Wang, YS; Xiong, WJ; Xue, JX; Zhang, XX | 1 |
| Callahan, MJ; Cobb, B; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; O'Malley, DM; Salani, R; Sutton, G; Zanagnolo, V | 1 |
| Chang, Y; Chen, C; Fu, X; Li, L; Li, X; Li, Z; Lu, L; Ma, W; Qin, B; Sun, Z; Wang, X; Wen, J; Wu, J; Yan, J; Zhang, L; Zhang, M; Zhang, X; Zhou, Z | 1 |
| Baker, AF; Bolejack, V; Burris, H; Crowley, J; Dayyani, F; Dragovich, T; Hidalgo, M; Laheru, D; Raghunand, N; Ritch, P; Rosen, P; Seng, J; Smith, L; Von Hoff, DD | 1 |
| Aghajanian, C; DeLair, D; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Sala, E; Zhou, Q | 1 |
| Eskander, RN; Tewari, KS | 1 |
| Bachet, JB; Blanc, JF; Carbonnel, F; Coriat, R; Cueff, A; De La Fouchardière, C; Francois, E; Gauthier, M; Lécaille, C; Malka, D; Manfredi, S; Marthey, L; Sa-Cunha, A; Solub, D; Taieb, J; Terrebonne, E; Thirot Bidault, A; Trouilloud, I | 1 |
| Chanpanitkitchot, S; Khunnarong, J; Pataradool, K; Srijaipracharoen, S; Tangjitgamol, S; Thavaramara, T | 1 |
| Ahn, JB; Chon, HJ; Chung, HC; Hong, MH; Jeung, HC; Kang, B; Lim, S; Nam, CM; Park, JS; Rha, SY; Yang, WI | 1 |
| Ak, G; Akcay, M; Bayman, E; Etiz, D | 1 |
| Bechstein, WO; Brunner, TB; Bruns, C; Fietkau, R; Golcher, H; Grabenbauer, GG; Hohenberger, W; Jungnickel, H; Marti, L; Merkel, S; Meyer, T; Schreiber, S; Witzigmann, H | 1 |
| Guo, H; Liu, Y; Yang, S; Yao, S; Yao, Z; Zhao, Y | 1 |
| Carlson, RW; Charpentier, E; Danso, MA; Finn, RS; Garcia-Ribas, I; Hellerstedt, B; Miller, KD; Neubauer, M; O'Shaughnessy, J; Richards, P; Robert, N; Rugo, HS; Saleh, M; Schwartzberg, L; Specht, JM; Winer, EP; Yardley, DA | 1 |
| Liu, LH; Liu, YH; Xu, L; Yang, H | 1 |
| Grąt, M; Kornasiewicz, O; Krasnodębski, M; Krawczyk, M; Patkowski, W; Stankiewicz, R | 1 |
| Wang, W; Wang, Z; Xiao, X | 1 |
| Asami, K; Atagi, S; Isa, S; Kawaguchi, T; Kitaichi, M; Kubo, A; Matsumura, A; Okishio, K; Shimizu, S; Takada, M; Tamiya, A | 1 |
| Abe, K; Aiba, K; Futagawa, Y; Hata, D; Okui, N; Sakamoto, T; Shiba, H; Uwagawa, T; Yanaga, K | 1 |
| Akita, H; Fujiwara, Y; Gotoh, K; Ishikawa, O; Kishi, K; Kobayashi, S; Marubashi, S; Miyoshi, N; Motoori, M; Noura, S; Ohigashi, H; Ohue, M; Sakon, M; Sugimura, K; Takahashi, H; Yano, M | 1 |
| Byun, JH; Hong, SH; Jung, KH; Kim, HG; Kim, HY; Kim, KH; Lee, HJ; Lee, NR; Lee, S; Lee, SC; Park, KH; Rha, SY; Woo, IS; Yun, J | 1 |
| Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T | 1 |
| Addeo, G; Allendorf, J; Chabot, J; Chu, K; Fine, RL; Hecht, E; Jin, B; Leung, D; Postolov, I; Remotti, H; Schrope, BA; Sherman, WH; Tsai, W | 1 |
| Hanada, K; Hasebe, O; Isayama, H; Ito, Y; Kamada, H; Koike, K; Maetani, I; Maguchi, H; Matsubara, S; Mukai, T; Nakai, Y; Okabe, Y; Sasaki, T; Toda, N; Yagioka, H; Yasuda, I | 1 |
| Beuzeboc, P; Chevreau, C; Culine, S; Dupuy, L; Filleron, T; Fléchon, A; Gravis, G; Houédé, N; Laguerre, B; Théodore, C | 1 |
| Fang, H; Lin, RY; Sun, MX; Tian, Y; Wang, Q; Wang, XY; Yu, JL; Zhao, YL | 1 |
| Barton, S; Edwards, SJ; Thurgar, E; Trevor, N | 1 |
| Cho, JW; Choi, DR; Ha, HI; Han, B; Jeon, JY; Jung, JY; Kim, HS; Kim, HY; Kim, JH; Kim, MJ; Kwon, JH; Oh, HS; Park, CK; Song, H; Zang, DY | 1 |
| André, T; Aparicio, T; Bachet, JB; Berger, A; Bonnetain, F; Cojean Zeleck, D; Colussi, O; Coriat, R; Dousset, B; Hammel, P; Locher, C; Malka, D; Nordlinger, B; Paye, F; Pozet, A; Rougier, P; Sauvanet, A; Taieb, J; Tchinou, L; Vaillant, JC; Voron, T | 1 |
| Cockerill, PA; Frank, I; Karnes, RJ; Knoedler, JJ; Tarrell, R | 1 |
| Mahdi, H; Rizzo, A; Rose, PG | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Christein, JD; Dulaney, CR; Heslin, MJ; Jacob, R; Keene, KS; López-Araujo, J; McDonald, AM; Posey, JA; Wood, TE | 1 |
| Duconseil, P; Dusetti, N; Garcia, S; Gasmi, M; Gayet, O; Gilabert, M; Iovanna, J; Loncle, C; Lopez-Millan, MB; Molejon, MI; Moutardier, V; Ouaissi, M; Poizat, F; Tellechea, JI; Turrini, O | 1 |
| Ding, T; Liu, XH; Lv, QY; Song, J; Wang, SH; Wang, Y; Wei, MH; Wu, MD; Yang, QH; Zhou, J; Zhou, YF | 1 |
| Li, Y; Shang, YM; Yang, Y; Zheng, H | 1 |
| Frischknecht, L; Meerang, M; Moch, H; Opitz, I; Seifert, B; Soltermann, A; Stahel, R; Weder, W | 1 |
| Buchbinder, N; Jaffray, M; Lutun, A; Piquenot, JM; Schneider, P; Vannier, JP | 1 |
| Bergmann, F; Brecht, IC; Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Jäger, D; Rieken, S; Springfeld, C; Werner, J | 1 |
| Aishima, S; Baba, H; Harimoto, N; Hualin, W; Itoh, S; Maehara, Y; Shirabe, K; Takeishi, K; Uchihara, T; Yamashita, Y; Yoshizumi, T | 1 |
| Huang, CB; Huang, LL; Lin, SJ; Pan, JJ; Qiu, SF; Xu, YJ; Zheng, W; Zong, JF | 1 |
| Chang, YF; Chen, SY; Hsiao, CH; Hsieh, JC; Hsieh, RK; Hsu, CL; Lee, KD; Lu, CH; Ng, SH; Shiau, CY; Wang, CH; Wang, HM; Yeh, KH | 1 |
| Belfiore, G; Belfiore, MP; De Lucia, G; Di Gennaro, TL; Gallo, C; Ianniello, GP; Marsicano, C; Romano, F; Ronza, FM | 1 |
| Berlin, S; Campos, S; Horowitz, N; Krasner, C; Lee, H; Liu, J; Matulonis, U; Obermayer, E; Penson, R; Whalen, C | 1 |
| Bevis, KS; Blansit, K; Chan, JK; ElNaggar, A; Fuh, KC; Huh, W; Kapp, DS; Previs, R; Secord, AA; Tillmanns, T | 1 |
| Bassett, R; Champlin, R; Gulbis, AM; Holmberg, L; Jones, RB; Kingham, A; Ledesma, C; Margolin, K; Nieto, Y; Pagliaro, L; Tannir, N; Tu, SM | 1 |
| Aghajanian, C; Blank, SV; Goff, B; Husain, A; Nycum, LR; Wang, YV | 1 |
| Adams, PT; Baez-Diaz, L; Bear, HD; Brufsky, AM; Costantino, JP; Fehrenbacher, L; Gaur, R; Geyer, CE; Gross, HM; Liu, Q; Mamounas, EP; Margolese, RG; Mehta, RS; Paik, S; Rastogi, P; Robidoux, A; Senecal, FM; Swain, SM; Tang, G; Wolmark, N; Young, JA | 1 |
| Hoegdall, E; Nielsen, D; Ole Larsen, F; Taksony Solyom Hoegdall, D | 1 |
| Bradley, WH; Eng, KH; Hanlon, BM; Szender, JB | 1 |
| Bokemeyer, C; Oechsle, K; Oing, C; Rink, M; Seidel, C; von Amsberg, G | 1 |
| Chang, KP; Chang, YS; Fan, HC; Hsieh, CH; Hsu, CL; Huang, Y; Huang, YC; Kuo, YC; Lee, LY; Li, HP; Lin, AC; Lin, TL; Lui, KW; Wang, HM | 1 |
| Bae, K; Han, SS; Hong, EK; Jung, MK; Kim, TH; Koh, YH; Lee, WJ; Park, SJ; Park, WS; Woo, SM; Yoon, KA | 1 |
| Crowder, C; Hamner, JB; Singh, G; White, M | 1 |
| Dobelbower, MC; Dreicer, R; George, A; Heney, NM; Kaufman, DS; Mitin, T; Sandler, HM; Shipley, WU; Souhami, L; Uzzo, RG; Wallace, HJ; Zietman, AL | 1 |
| Benasso, M; Merlano, MC; Peeters, M; Specenier, P; Szturz, P; Van den Weyngaert, D; Van Gestel, D; Van Laer, C; Vanderveken, OM; Vermorken, J; Wouters, K | 1 |
| Hwang, HK; Kang, CM; Kim, H; Kim, MJ; Lee, SH; Lee, WJ; Seong, J; Song, SY | 1 |
| Fujiwara, K; Hanaoka, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T | 1 |
| Gehrig, PA; Kim, KH; Milam, B; Palisoul, M; Raker, C; Robison, K; Roque, DR; Taylor, KN; Wysham, WZ | 1 |
| Haddock, MG; Hallemeier, CL; Harmsen, WS; Kendrick, ML; Merrell, KW; Miller, RC; Quevedo, JF | 1 |
| Dong, M; Gui, L; He, XH; Li, YX; Liu, P; Shi, YK; Wang, JJ; Wang, WH; Yang, JL; Yang, S; Zhang, CG; Zhou, SY | 1 |
| Hanvoravongchai, P; Havanond, P; Khempech, N; Luealon, P; Vasuratna, A | 1 |
| Ben Shem, E; Ben Zvi, M; Levy, T; Menczer, J; Peled, O; Schreiber, L; Vaknine, H | 1 |
| Brody, JR; Daum, GS; DuHadaway, JB; Dunton, CJ; Furuuchi, N; Huang, YH; Jimbo, M; Leiby, BE; Peng, W; Pirritano, A; Sawicki, JA | 1 |
| Culine, S; Kránitz, N; Kullmann, T; Pintér, T; Szepesvári, Z | 1 |
| Besselink, MG; Boerma, D; Bonsing, BA; Busch, OR; de Hingh, IH; de Vos-Geelen, J; Dohmen, MA; Erdmann, JI; Festen, S; Groothuis, KB; Klaase, JM; Molenaar, IQ; Patijn, GA; Punt, CJ; Rasch, CR; Suker, M; Ten Tije, AJ; van der Harst, E; van der Kolk, MB; van Eijck, CH; van Tienhoven, G; Versteijne, E; Zwinderman, AH | 1 |
| Bae, SH; Baek, JH; Choi, Y; Jo, JC; Joo, YD; Kim, DY; Kim, H; Lee, JH; Lee, JL; Lee, KH; Lee, WS; Ryoo, HM | 1 |
| Dearnaley, D; Hafeez, S; Hansen, VN; Harris, V; Horwich, A; Huddart, R; Jones, K; Khan, A; Kumar, P; Lalondrelle, S; McDonald, F; McNair, HA; Mohammed, K; Tan, M; Thomas, K; Thompson, A; Warren-Oseni, K | 1 |
| Frank, H; Kitzwögerer, M; Moser, M; Wiedemann, D | 1 |
| Chang, Y; Cui, Y; Fu, X; Li, L; Li, W; Li, X; Ma, W; Nan, F; Su, L; Sun, Z; Wang, J; Wang, X; Wu, J; Xue, H; Zhang, L; Zhang, M; Zhang, X | 1 |
| Argnani, L; Chiappella, A; Corradini, P; Degl'Innocenti, D; Dodero, A; Monaco, F; Pellegrini, C; Salvi, F; Vitolo, U; Zinzani, PL | 1 |
| Andorsky, D; Beck, JT; Belada, D; Dakhil, S; Daly, R; Dean, JP; Failloux, N; Georgiev, P; Hübel, K; Inhorn, LF; Pavlyuk, M; Pettengell, R; Quick, D | 1 |
| Asaftei, S; Cesari, M; Coccoli, L; Fagioli, F; Ferrari, S; Grignani, G; Jones, RL; Longhi, A; Marchesi, E; Meazza, C; Paioli, A; Palmerini, E; Picci, P; Pollack, SM; Tamburini, A | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC; Wei, W | 1 |
| Armbrecht, N; Brooks, J; Calvisi, DF; Ceyhan, GO; Demir, IE; Dombrowski, F; Esposito, I; Fleischmann-Mundt, B; Gürlevik, E; Kleine, M; Kloos, A; Kubicka, S; Kühnel, F; Manns, MP; Oettle, H; Ostroumov, D; Ribback, S; Saborowski, M; Steiger, K; Wirth, TC; Woller, N; Yevsa, T | 1 |
| Almorsy, W; Elshebeiny, M | 1 |
| Fujibayashi, S; Fujiya, M; Goto, T; Kawamoto, T; Kohgo, Y; Koizumi, K; Moriichi, K; Sasajima, J; Sugiyama, Y; Yamada, M | 1 |
| Furukawa, D; Hirabayashi, K; Izumi, H; Mashiko, T; Nakagohri, T; Ozawa, S; Sadahiro, S; Tomioku, M; Yasuda, S; Yazawa, N | 1 |
| Guo, J; Han, X; Hu, GF; Liu, LY; Tang, N; Wang, X; Wang, Y; Wang, ZH; Zhang, QQ | 1 |
| Dawson, DW; Fernandez-Zapico, ME | 1 |
| Akita, H; Fijiwara, Y; Ishikawa, O; Kobayashi, S; Ohigashi, H; Sakon, M; Takahashi, H; Tomokuni, A; Yano, M | 1 |
| Dan, G; Deng, D; Jiang, J; Li, W; Zheng, X; Zheng, Y | 1 |
| Alunni-Fabbroni, M; Andergassen, U; Fasching, P; Fehm, T; Friedl, TW; Hecker, N; Hepp, P; Jäger, B; Janni, W; Lorenz, R; Rack, B; Schneeweiss, A; Trapp, E | 1 |
| Esumi, H; Fujioka, R; Hasegawa, H; Hashimoto, Y; Ikeda, M; Kishino, S; Mitsunaga, S; Miyoshi, C; Mochizuki, N; Nomura, S; Ohno, I; Sato, A; Takahashi, H; Takahashi, R; Toyosaki, K; Tsuchihara, K; Yomoda, S | 1 |
| Cho, MH; Chung, J; Joung, JY; Kim, SH; Lee, KH; Park, WS; Seo, HK | 1 |
| Fujiwara, Y; Goto, K; Horinouchi, H; Hozumi, H; Kanda, S; Kitazono, S; Kubo, E; Mizugaki, H; Nokihara, H; Shiraishi, H; Sunami, K; Tamura, T; Tanaka, A; Utsumi, H; Yamamoto, N | 1 |
| Cui, H; Jiang, R; Li, X; Lin, X; Liu, C; Tao, R; Tian, S; Zhuang, H; Zhuo, C | 1 |
| Belau, AK; Bover-Barcelo, I; Canzler, U; Chekerov, R; Gonzalez-Martin, A; Hanker, LC; Harter, P; Hilpert, F; Keil, E; Klare, P; Kurzeder, C; Mahner, S; Meier, W; Petru, E; Reinthaller, A; Richter, R; Sehouli, J; Wimberger, P; Woopen, H; Zeimet, A | 1 |
| Grande, C; Groman, A; Iancu, DM; Iyer, RV; Ma, WW; Malhotra, U; Pokuri, VK; Saab, TB | 1 |
| Dong, M; Gui, L; He, X; Li, Y; Liu, P; Qi, F; Shi, Y; Wang, W; Yang, J; Yang, S; Zhang, C; Zhou, S | 1 |
| Lian, B; Mo, Q; Qin, Q; Tan, Q; Wei, C; Yang, W | 1 |
| Juszczak, M; Paschke, L; Slupski, M | 1 |
| Fujiwara, H; Machida, S; Matsubara, S; Morisawa, H; Nagashima, T; Saga, Y; Takahashi, S; Takahashi, Y; Takei, Y; Taneichi, A | 1 |
| Hong, S; Zhang, L | 1 |
| Jiang, W; Luo, S; Pan, H; Shi, M; Wang, J; Xu, M; Zang, J; Zhao, L; Zhou, Y | 1 |
| Arenare, L; Bergamini, A; Cecere, SC; Della Pepa, C; Di Napoli, M; Facchini, G; Gargiulo, P; Mangili, G; Pignata, S; Pisano, C; Rossetti, S; Tambaro, R | 1 |
| Bhosale, P; Dalton, HJ; Fleming, ND; Gershenson, DM; Schmeler, KM; Sun, CC | 1 |
| Fields, RC; Hawkins, WG; Linehan, DC; Liu, J; Ohman, KA; Strasberg, SM; Tan, BR; Tan, MC | 1 |
| Guru Murthy, GS; Hamadani, M; Jethava, Y | 1 |
| Hayasaka, T; Honda, T; Imai, N; Kagabu, S; Kin, S; Matsui, T; Nishigori, H; Oishi, T; Otsuki, T; Sato, H; Sato, K; Shimokawa, H; Shoji, T; Sugiyama, T; Takahashi, F; Tando, T; Tokunaga, H; Wagatsuma, S; Watanabe, T; Watanabe, Y; Yaegashi, N; Yamada, H; Yamamoto, H; Yokoyama, Y; Yoshida, Y; Yoshinaga, K | 1 |
| Anandadas, C; Choudhury, A; Elliott, T; Joseph, N; Logue, J; Lyons, J; Sanderson, B; Thompson, C; Wylie, J | 1 |
| Goff, BA; Holmberg, LA; Kurland, BF; Veljovich, D | 1 |
| Ceballos, J; García-Foncillas, J; Pérez-Gracia, JL; Santisteban, M; Vivas, I | 1 |
| Lebret, T | 1 |
| Camara, O; Keil, E; Klare, P; Lichtenegger, W; Oskay-Oezcelik, G; Paulenz, A; Sehouli, J; Sommer, H; Stauch, M; Stengel, D; Zeimet, AG | 1 |
| Goodman, A; Ko, E; Lee, S | 1 |
| Eisenkop, SM; McAlpine, JN; Spirtos, NM | 1 |
| Chen, X; Chen, ZS; Li, J; Ouyang, XN; Xie, FW; Yu, ZY | 1 |
| Butts, C; Ciardiello, F; Feld, R; Gallo, C; Gridelli, C; Perrone, F | 1 |
| Dabanaka, K; Hanazaki, K; Kobayashi, M; Kohsaki, T; Maeda, H; Nishimori, I; Nishioka, A; Ogawa, Y; Okabayashi, T; Onishi, S; Sugimoto, T; Yamashita, K | 1 |
| Etoh, T; Hoshiai, H; Koike, E; Nakai, H; Watanabe, Y | 1 |
| Kato, A; Kimura, F; Miyazaki, M; Nomura, F; Ohtsuka, M; Shida, T; Shimizu, H; Takano, S; Togawa, A; Tomonaga, T; Yoshidome, H; Yoshitomi, H | 1 |
| Borghaei, H; Cohen, RB; Huang, CH; Langer, CJ; Millenson, MM; Mintzer, DM; Ruth, KJ; Seldomridge, J; Sherman, EJ; Staddon, AP; Treat, OJ; Tuttle, H | 1 |
| Aono, T; Hatakeyama, K; Kawachi, Y; Kurosaki, I; Nihei, K; Shimizu, T; Tsuchiya, Y; Yokoyama, N | 1 |
| Awada, A; Bernier, J; Bogaerts, J; Buter, J; de Mulder, P; Lacombe, D; Licitra, L; Locati, LD; Thomas, J; van Herpen, CM; Vermorken, JB | 1 |
| Antonia, S; Bepler, G; Cantor, A; Chiappori, A; Haura, E; Li, X; Obasaju, C; Robinson, LA; Sharma, A; Simon, G; Sommers, KE; Tanvetyanon, T; Williams, C | 1 |
| Backes, FJ; Cohn, DE; Copeland, LJ; Fowler, JM; O'Malley, DM; Richardson, DL; Seamon, LG; Zanagnolo, V | 1 |
| Blitzer, J; Evans, S; Flam, M; Hager, S; Link, J; Lyons, W; Nagourney, RA; Sommers, BL | 1 |
| Flynn, PJ; Garbo, LE; Kolibaba, KS; MacRae, MA; Rauch, MA; Wang, Y | 1 |
| El-Baradie, M; Ismail, HM; Khorshid, O; Moneer, M; Touny, A | 1 |
| Aklilu, M; Kindler, HL; Nattam, S; Vokes, EE | 1 |
| Agelaki, S; Agelidou, A; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Gerogianni, A; Pallis, AG; Papakotoulas, P; Pavlakou, G; Rapti, A; Varthalitis, I | 1 |
| Kim, DH; Nakamura, Y; Ogawa, K; Otani, T; Shiozawa, S; Tsunoda, T; Usui, T; Yoshimatsu, K | 1 |
| Kitade, H; Kwon, AH; Matsui, Y; Mergental, H; Satoi, S; Takahashi, K; Takai, S; Tanigawa, N; Toyokawa, H; Yanagimoto, H | 1 |
| Fukui, T; Hatooka, S; Ishiguro, F; Kobayashi, R; Mitsudomi, T; Mori, S; Ogawa, S; Okuda, K; Shinoda, M | 1 |
| Alberola Candel, V; Esteban González, E; Gasent Blesa, JM; Martín Algarra, S; Provencio Pulla, M | 1 |
| Foo, KF; Wang, ML | 1 |
| Chen, L; Cole, PD; de Alarcon, PA; Drachtman, RA; Schwartz, CL; Trippett, TM | 1 |
| Cho, GJ; Chung, JS; Joo, YD; Kim, KH; Kim, YS; Lee, WS; Shin, HJ; Shin, SH; Sohn, CH | 1 |
| Han, H; Li, YH; Liu, ZW; Qin, ZK; Wu, PH; Xiong, YH; Yu, SL; Zhou, FJ | 1 |
| Bekaii-Saab, TS; Fortune, BE; Kosuri, KV; Li, X; Thomas, JP; Weatherby, LM | 1 |
| Cass, CE; Demetter, P; Devière, J; Lai, R; Mackey, JR; Maréchal, R; Peeters, M; Polus, M; Salmon, I; Van Laethem, JL; Young, J | 1 |
| Chekerov, R; Fotopoulou, C; Karavas, A; Lichtenegger, W; Sehouli, J; Trappe, R | 1 |
| Ece, F; Hanta, I; Hasturk, S; Hatabay, N; Karatasli, M | 1 |
| Chang, PM; Chang, SY; Chen, PM; Chu, PY; Huang, JL; Tai, SK; Tsai, TL; Tzeng, CH; Wang, HM; Wang, YF; Yang, MH | 1 |
| Chovanec, J; Dorr, A; Habetinek, V; Helpianska, L; Horvathova, D; Jancokova, I; Koza, I; Kroslakova, D; Lalabova, R; Laluha, A; Magdin, D; Malec, V; Minarik, T; Packan, T; Rakicka, G; Sevcik, L; Spacek, J; Stresko, M; Sufliarsky, J; Svetlovska, D; Tkacova, V | 1 |
| Cheng, AL; Kuo, SH; Lin, ZZ; Yang, SH | 1 |
| Abe, T; Ikeda, K; Koeda, K; Minakawa, Y; Nitta, H; Obuchi, T; Otsuka, K; Sasaki, A; Shimooki, O; Wakabayashi, G | 1 |
| Akita, H; Bepler, G; Doki, Y; Dono, K; Kim, C; Kittaka, N; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Nagano, H; Nakamori, S; Takeda, Y; Takemasa, I; Zheng, Z | 1 |
| Delpero, JR; Giovannini, M; Guiramand, J; Lelong, B; Moureau-Zabotto, L; Moutardier, V; Turrini, O; Viret, F | 1 |
| Endo, S; Hashimoto, K; Iguchi, C; Itakura, M; Koike, M; Nio, Y; Nishi, T; Omori, H; Sato, Y; Takamura, M; Takeda, H | 1 |
| Belderbos, JS; Burgers, SA; Kappers, I; Klomp, HM; van Sandick, JW; van Zandwijk, N | 1 |
| Benda, J; Boardman, CH; Cella, D; Cohn, DE; McMeekin, DS; Monk, BJ; Ramondetta, LM; Sill, MW | 1 |
| Hagihara, A; Hashimoto, K; Ikeda, M; Kojima, Y; Kondo, S; Morizane, C; Okusaka, T; Ueno, H | 1 |
| Aogi, K; Fujiwara, Y; Iwata, H; Nambu, Y; Saeki, T; Saji, S; Sasaki, Y; Suri, A; Suzuki, Y; Takashima, S; Tokuda, Y | 1 |
| Abbruzzese, A; Addeo, R; Bellini, S; Caraglia, M; Cennamo, G; Del Prete, S; Faiola, V; Guarrasi, R; Lanna, M; Miragliuolo, A; Montella, L; Vincenzi, B | 1 |
| Autorino, R; Bruni, G; Cantiello, F; Damiano, R; De Sio, M; Di Lorenzo, G; Federico, P; Gallo, L; Masala, D; Perdonà, S; Pizzuti, M; Quattrone, C | 1 |
| Amour, E; Beckendorf, V; Bossard, N; Douillard, JY; Girard, N; Grunenwald, D; Milleron, B; Mornex, F; Quoix, E | 1 |
| Auner, V; Horvat, R; Oskay-Oezcelik, G; Sehouli, J; Speiser, P; Zeillinger, R | 1 |
| Ansari, RH; Belani, CP; Chen, R; Edelman, MJ; Monberg, MJ; Obasaju, CK; Socinski, MA; Treat, J | 1 |
| Archer, V; Gorbounova, V; Hirsh, V; Leighl, N; Manegold, C; Mezger, J; Moore, N; Ramlau, R; Reck, M; von Pawel, J; Zatloukal, P | 1 |
| Arai, S; Blume, KG; Horning, SJ; Johnston, LJ; Laport, GG; Lavori, PW; Letsinger, R; Lowsky, R; Miklos, DB; Negrin, RS; Shizuru, JA; Weng, WK; Wong, RM | 1 |
| Busakhala, N; Gregory, KM; Jakait, B; Loehrer, PJ; Pastakia, SD; Rosmarin, AG; Schellhase, EM; Strother, RM; Tenge, C; Were, P | 1 |
| Cho, JS; Cho, KS; Chung, BH; Doo, SH; Hong, SJ; Kim, CI; Kim, SJ; Song, KH; Song, YS; Yang, WJ | 1 |
| Elias, AD; Gralow, J; Muscato, J; Neubauer, M; O'Shaughnessy, JA; Orlando, M; Pippen, J; Shonukan, O; Stokoe, C; Vaughn, LG; Wang, Y | 1 |
| Abulafia, O; Blessing, JA; Miller, BE; Richards, WE; Secord, AA; Shahin, MS; Stehman, FB; Van Le, L; Warshal, DP; Yamada, SD | 1 |
| Alpaugh, RK; Astsaturov, IA; Burtness, BA; Cheng, JD; Cohen, SJ; McLaughlin, S; Meropol, NJ; Rogatko, A; Watson, JC; Weiner, LM; Xu, Z | 1 |
| Eastwood, A; Manca, A; Misso, K; Palmer, S; Paton, F; Paulden, M; Saramago, P | 1 |
| Sun, WZ; Zhang, QY; Zhao, S | 1 |
| Bepler, G; Cognetti, F; Conti, F; Di Lauro, L; Fabi, A; Giannarelli, D; Lopez, M; Metro, G; Sergi, D; Tomao, F; Vici, P | 1 |
| Cho, SY; Han, SS; Kim, SH; Kim, TH; Kim, YK; Lee, KW; Lee, WJ; Park, SJ; Woo, SM | 1 |
| Daniels, JT; Garrison, MA; Gjerset, GF; Gooley, TA; Gopal, AK; Lonergan, M; Murphy, AE; Pagel, JM; Petersdorf, SH; Press, OW; Shustov, AR; Smith, JC | 1 |
| Arcuri, C; Arisi, E; Caffo, O; Caldara, A; Ferro, A; Galligioni, E; Griso, C; Murgia, V; Scalone, S; Sorio, R | 1 |
| Baker, LH; Chenevert, T; Chugh, R; Karantza, V; Mehnert, J; Moss, RA; Poplin, EA; Saraiya, B; Savkina, N; Stein, MN | 1 |
| Asada, M; Chiba, T; Fukushima, M; Hamada, A; Hatano, E; Ikai, I; Inoue, N; Kanai, M; Matsumoto, S; Mori, Y; Niimi, M; Nishimura, T; Nitta, T; Osaki, Y; Suzuki, C; Tada, S; Taura, K; Tsumura, T; Uemoto, S; Yanagihara, K; Yasuchika, K; Yazumi, S; Yoshimura, K | 1 |
| Benda, J; Boardman, CH; Cella, D; Cohn, D; Huang, HQ; McMeekin, DS; Monk, BJ; Ramondetta, L; Wenzel, L | 1 |
| Elit, L; Hirte, HW; Macalpine, K; Oza, AM; Schilder, RJ; Wang, L; Welch, SA; Wright, JJ | 1 |
| Grendys, EC; Holloway, RW; Lefebvre, P; McMeekin, S; Vekeman, F | 1 |
| Aerts, I; Boos, J; Cesare, C; Chisholm, J; Couanet, D; Devos, A; Dias, N; Frappaz, D; Gentet, JC; Geoerger, B; Hain, S; Jaspan, T; Le Deley, MC; Leblond, P; Mc Hugh, K; Riccardi, R; Vassal, G; Zwaan, CM | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakashima, A; Ohge, H; Sakabe, R; Sudo, T; Sueda, T; Uemura, K | 1 |
| Leighl, NB; Manegold, C; Mezger, J; Moore, N; Ramlau, R; Reck, M; Zatloukal, P | 1 |
| Baba, H; Beppu, T; Hirota, M; Ikeda, O; Kanemitsu, K; Oya, N; Takamori, H; Tanaka, H; Yamashita, Y | 1 |
| Liu, F; Liu, H; Ning, K; Wang, F; Wang, Y; Yu, J; Yuan, S; Zhang, J | 1 |
| Eguchi, K; Ichinose, Y; Kishi, K; Minato, K; Nishikawa, M; Nogami, N; Okamoto, H; Seki, N; Seto, T; Shinkai, T; Takiguchi, Y; Watanabe, K | 1 |
| Guan, Z; Jiang, Z; Shen, Z; Xu, B; Zhang, X | 1 |
| Blessing, JA; Hoffman, JS; Lachance, JA; Miller, DS; Moore, KN; Rotmensch, J; Spirtos, NM; Tait, DL | 1 |
| Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK | 1 |
| Chu, P; DU, XL; Li, DP; Liu, NF; Lu, CH; Sheng, XG; Zhou, CX | 1 |
| Chang, QY; Li, M; Li, XG; Li, YF; Liu, J; Song, PP; Tian, HM; Wang, XB; Wu, LY; Zhang, W; Zhao, D | 1 |
| Bepler, G; Chen, DT; Chiappori, A; Dilling, TJ; Greenberg, H; Haura, E; Hazelton, T; Simon, G; Stevens, C; Tanvetyanon, T; Wagner, H; Walsh, F; Williams, C | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, TY; Lee, KH; Lim, KH; Oh, DY | 1 |
| Bharadwaj, RR; Chen, EX; Jarvi, A; Kamel-Reid, S; Le Tourneau, C; Mann, V; Perez-Ordonez, B; Siu, LL; Wang, L; You, B | 1 |
| Coban, I; El-Rayes, BF; Kauh, JS; Kneuertz, PJ; Kooby, DA; Maithel, SK; Sarmiento, J; Staley, CA; Volkan Adsay, N | 1 |
| Hasegawa, S; Hayashi, T; Hirayama, K; Ikematsu, Y; Kageyama, S; Kanai, T; Mori, H; Nakata, Y; Nishiwaki, Y; Okawada, T; Ozawa, T; Sugimura, H; Tamura, H | 1 |
| Beniwal, P; Blair, EA; Cohen, EEW; Dekker, AJ; Gomez-Abuin, G; Haraf, D; Kocherginsky, M; Langerman, A; Portugal, L; Salama, JK; Seiwert, T; Stenson, KM; Villaflor, VM; Vokes, EE; Williams, RD; Witt, ME | 1 |
| Berros, JP; Blay, P; Crespo, G; Esteban, E; Fernández, Y; Fonseca, PJ; Fra, J; Lacave, AJ; Losa, R; Luque, M; Muriel, C; Sanmamed, M; Sierra, M; Villanueva, N | 1 |
| Al-Barrak, J; Gilks, CB; Hoskins, P; Lau, H; Santos, JL; Swenerton, KD; Tinker, A | 1 |
| Abrams, R; Benson, AB; Hoffman, JP; Konski, A; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, KA | 1 |
| Anne, PR; Berger, AC; Chervoneva, I; Kennedy, EP; Mitchell, EP; Rosato, EL; Showalter, TN; Yeo, CJ; Zhan, T | 1 |
| Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Umeshita, K; Wada, H | 1 |
| Grigull, L; Hartmann, C; Linderkamp, C; Reinhardt, D; Sander, A; Schmid, H; Weinel, P; Welte, K | 1 |
| Chang, GC; Chang, JW; Chua, DT; Hsia, TC; Manegold, C; Mok, TS; Moore, N; Sirisinha, T; Sriuranpong, V; Thitiya, S; Thongprasert, S; Tsai, CM; Tsang, K | 1 |
| Choi, DW; Choi, SH; Heo, JS; Jang, KT; Kang, WK; Kim, ST; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, DH; Lim, HY; Park, HC; Park, JO; Park, SH; Park, YS | 1 |
| Bennouna, J; Favrel, S; Lemarie, E; Pinel, MC; Pouget, JC; Senellart, H; Tourani, JM; Tournoux-Facon, C | 1 |
| Conversano, A; D'Abbicco, D; Epifania, BR; Indellicato, R; Margari, A | 1 |
| Andrieu, JM; Bats, AS; Eme, D; Hofmann, H; Huchon, C; Le Frere-Belda, MA; Lecuru, F; Levy, E; Medioni, J; Oudard, S | 1 |
| Blasco, A; Cabrera, A; Camps, C; Carrato, A; Gil, M; Gómez-Aldaraví, L; González-Larriba, JL; Guijarro, R; Iranzo, V; Jantus, E; Massuti, B; Provencio, M; Rossell, R; Sanmartín, E; Sirera, R; Velasco, A | 1 |
| Chan, S; Davidson, SE; Harden, S; McMahon, T; Paul, J; Rai, D; Reed, NS; Symonds, RP | 1 |
| Beck, T; Bromund, J; Brufsky, A; Frontiera, M; Hainsworth, J; Hoelzer, K; Keaton, M; Krill-Jackson, E; Kroener, J; Marciniak, MD; Middleman, E; Nadella, P; Obasaju, C; Orlando, M; Panella, T; Paul, D; Tai, F; Whorf, R; Zhao, L | 1 |
| Kanetake, H; Matsuo, T; Miyata, Y; Ohba, K; Sagara, Y; Sakai, H; Takahashi, H | 1 |
| Armstrong, DK; Bristow, RE; Diaz-Montes, TP; Giuntoli, RL | 1 |
| Hanna, N; Langer, C; Monberg, M; Ortuzar, W; Peng, G; Pennella, E; Scagliotti, G | 1 |
| Jensen, JB; Jensen, KM; Ulhøi, BP | 1 |
| Boccardo, F; Cognetti, F; Felici, A; Gallucci, M; Giannarelli, D; Massidda, B; Muto, G; Pollera, CF; Rubagotti, A; Ruggeri, EM | 1 |
| Cao, M; Chen, HG; Ma, CK; Ma, J; Xue, W | 1 |
| Christenson, R; Edelman, MJ; Hodgson, L; Jewell, S; Kratzke, R; Vokes, E; Wang, X | 1 |
| Bryant, A; Gaitskell, K; Haldar, K; Kehoe, S; Morrison, J; Nicum, S | 1 |
| Bahleda, R; Bosq, J; Hartl, DM; Hollebecque, A; Massard, C; Soria, JC | 1 |
| Abbruzzese, J; Abdalla, EK; Balachandran, A; Bhosale, P; Charnsangavej, C; Chopin-Laly, X; Crane, CH; Fleming, JB; Katz, MH; Lee, JE; Pisters, PW; Varadhachary, G; Vauthey, JN; Wang, H; Wang, X; Wolff, R | 1 |
| Kotek, A; Parlak, C; Pehlivan, B; Topkan, E; Yapar, AF | 1 |
| Doki, Y; Eguchi, H; Gotoh, K; Ishikawa, O; Nagata, S; Ohigashi, H; Takahashi, H; Tomita, Y; Yamada, T; Yano, M | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Tsutsui, T; Ueda, Y; Yoshino, K | 1 |
| Abelson, JA; Chang, DT; Chung, M; Fisher, GA; Ford, JM; Koong, AC; Kunz, P; Minn, AY; Murphy, JD; Norton, JA; Poultsides, GA; Visser, BC | 1 |
| Cormier, Y; Gitlitz, B; Gleave, ME; Hao, D; Laskin, JJ; Lee, C; Murray, N; Nemunaitis, J; Nicholas, G; Nugent, F; Pressnail, B; Sanborn, R; Stephenson, J; Ung, Y; Vincent, M | 1 |
| Hashimoto, Y; Hatakeyama, S; Imanishi, K; Kamimura, N; Koie, T; Ohyama, C; Okamoto, A; Okamoto, T; Tokui, N; Yoneyama, T | 1 |
| Ben-Ami, T; Gosiengfiao, Y; Reichek, J; Walterhouse, D; Woodman, J | 1 |
| Aprile, G; Balzano, G; Cereda, S; Di Carlo, V; Di Muzio, N; Fugazza, C; Magli, A; Milandri, C; Passoni, P; Reni, M; Rognone, A; Saletti, P; Tronconi, MC; Villa, E; Zerbi, A | 1 |
| Ajiki, T; Fujiwara, Y; Hatano, E; Ioka, T; Kanai, M; Kobayashi, S; Kodama, Y; Nagano, H; Sakai, D | 1 |
| Cleves, A; Jones, G; Kynaston, HG; Mason, M; Shelley, M; Wilt, TJ | 1 |
| Hashimoto, Y; Kobayashi, H; Kondo, N; Murakami, Y; Nakagawa, N; Nakashima, A; Sakabe, R; Sudo, T; Sueda, T; Uemura, K | 1 |
| Chen, Y; Shi, Y; Wang, C; Yang, Y | 1 |
| Thigpen, T | 1 |
| Benjamin, RS; Chawla, S; Chugh, R; Fox, E; Harmon, D; Helman, LJ; Patel, S; Reinke, D; Schuetze, S; Wathen, JK | 1 |
| Cook, L; Hughes, G; Kanfer, EJ; Karadimitris, A; Macdonald, DH; Marks, AJ; Matthey, F; Naresh, KN; Sivam, V; Szydlo, RM; Yarranton, H | 1 |
| Abdullah, M; Al Khodary, A; Barsoum, M; El Nowieam, S; El Zawahry, H; Gaafar, R; Gouda, Y; Halim, IA; Hamada, E; Hamid, TA; Kohail, H; Mansour, O; Meshref, M; Shehata, S; Taleb, FA; Wareth, AA | 1 |
| He, AN; Lin, F; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Arbea, L; Aristu, J; Gil-Bazo, I; Moreno-Jimenez, M; Perez-Gracia, JL; Rodríguez-Ruiz, ME; San Miguel, I | 1 |
| Facio, G; Garcia, AA; Muderspach, L; Pham, H; Roman, L; Yessaian, A | 1 |
| Egawa, S; Katayose, Y; Kitamura, Y; Masuda, K; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Onogawa, T; Rikiyama, T; Unno, M; Yamamoto, K; Yoshida, H | 1 |
| Iyoda, A; Jiang, SX; Kageyama, T; Masuda, N; Matsumoto, T; Nagashio, R; Ryuge, S; Saegusa, M; Sato, Y; Satoh, Y | 1 |
| Cheewakriangkrai, C; Manopunya, M; Suprasert, P | 1 |
| Cariello, A; Casanova, C; Cruciani, G; Dazzi, C; Freier, E; Gamboni, A; Leoni, M; Mazza, V; Milandri, C; Montanari, M; Papi, M; Papiani, G; Verlicchi, A; Vertogen, B | 1 |
| Arsenijevic, L; Atanackovic, J; Jeftovic, M; Jeremic, K; Stefanovic, A; Stojnic, J; Zecevic, N | 1 |
| Adaniel, C; Aghajanian, C; Grisham, RN; Hyman, DM; Iasonos, A; Konner, J; Ma, W | 1 |
| Basile, S; Bellati, F; Benedetti-Panici, P; Di Donato, V; Donfrancesco, C; Graziano, M; Marchetti, C; Palaia, I; Pernice, M; Perniola, G; Tomao, F | 1 |
| Araujo, JC; Jonasch, E; Lim, ZD; Lin, E; Ng, CS; Pagliaro, LC; Richey, SL; Sharma, P; Tamboli, P; Tannir, NM | 1 |
| An, X; Chen, C; Chen, YC; Li, YH; Luo, HY; Wang, FH; Wang, ZQ; Xu, RH; Zhang, L | 1 |
| Bertetto, O; Ceccarelli, M; Chiappino, I; Ciccone, G; Ciuffreda, L; Giacobino, A; Napoletano, R; Novarino, AM; Satolli, MA; Schena, M | 1 |
| Hagihara, A; Kido, H; Kondo, S; Morizane, C; Okusaka, T; Tamura, T; Ueno, H | 1 |
| Chen, Q; Huang, JZ; Liang, JG; Shi, CM; Zhong, DT | 1 |
| Hirakata, A; Makino, H; Maruyama, H; Matsushita, A; Matsutani, T; Sasajima, K; Suzuki, S; Uchida, E; Yokoyama, T; Yoshida, H | 1 |
| Chen, XQ; Li, YJ; Wang, KF; Wang, L; Wang, ZH; Xia, YF; Xia, ZJ | 1 |
| Berk, V; Buyukberber, S; Ciltas, A; Colak, D; Dane, F; Gumus, M; Inal, A; Isikdogan, A; Kos, FT; Ozdemir, NY; Ozkan, M; Unek, IT; Yildiz, R | 1 |
| Blay, JY; Bompas, E; Cioffi, A; Collin, F; Cupissol, D; Delcambre, C; Duffaud, F; Floquet, A; Isambert, N; Jimenez, M; Pautier, P; Penel, N; Piperno-Neumann, S; Rey, A | 1 |
| Burnside, N; MacGowan, SW | 1 |
| Enomoto, T; Fujita, M; Hiramatsu, K; Kimura, T; Kiyohara, Y; Kobayashi, E; Tsutsui, T; Ueda, Y; Yoshino, K | 1 |
| Arrowsmith, E; Beck, T; Borson, R; Bromund, J; Hager, S; Harker, G; Harrer, G; Horvath, W; Jones, M; Kornberg, LJ; Kudrik, FJ; Malamud, SC; Obasaju, C; Orlando, M; Reeves, J; Tai, DF; Tillinghast, G; Yardley, DA; Zeigler, H | 1 |
| Biesma, B; Heideman, D; Smit, EF; Thunnissen, E; van Riel, S | 1 |
| Gu, J; Li, YM; Wang, HX; Wang, M; Wang, YJ; Wu, MH | 1 |
| Ahn, HK; Hwang, DW; Kim, SJ; Kim, WS; Ko, YH; Lim, ST; Tang, T | 1 |
| Carboni, GL; Fahrner, R; Ochsenbein, A; Schmid, RA | 1 |
| Cai, J; Daneshmand, S; Dorff, T; Dorin, R; Fairey, AS; Lieskovsky, G; Miranda, G; Quinn, D; Schuckman, A; Skinner, EC | 1 |
| Alam, Y; Bianco, R; Butts, C; Ciardiello, F; Cinieri, S; Di Maio, M; Fasano, M; Favaretto, A; Feld, R; Felletti, R; Fregoni, V; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, NB; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Ravaioli, A; Riccardi, F; Rossi, A; Siena, S; Signoriello, S; Spatafora, M; Tsao, MS; Wierzbicki, R | 1 |
| Katsumata, N; Maejima, A | 1 |
| Kitao, A; Matsumoto, K | 1 |
| Ito, R; Kitamura, H; Miyake, R; Nojiri, T; Okui, N; Saito, R; Son, K; Toyama, Y; Usuba, T; Yanaga, K; Yoshida, S | 1 |
| Araujo, DM; Baker, LH; George, S; Hensley, ML; Maki, RG; Priebat, DA; Soslow, RA; Sutton, G; Wathen, JK | 1 |
| Bergmann, F; Brecht, IC; Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Rieken, S; Schirmacher, P; Welzel, T; Werner, J | 1 |
| Cognetti, F; Felici, A; Gelibter, A; Nardoni, C; Serrone, L | 1 |
| Crawford, ED | 1 |
| Alesiani, F; Corvatta, L; Leoni, P; Malerba, L; Marconi, M; Mele, A; Offidani, M; Olivieri, A; Rupoli, S | 1 |
| Alvarez Castelo, L; Blanco Díez, A; Fernández Rosado, E; González Martín, M; Rodríguez Gómez, I; Sánchez Rodríguez Losada, J; Suárez Pascual, G | 1 |
| Au, SK; Chan, TM; Cheung, FY; Chiu, CY; Foo, W; Kwok, CH; Lau, WH; Law, CK; Ngan, RK; Tse, KC; Yau, S; Yiu, HH | 1 |
| Blohmer, J; Camara, O; Elling, D; Heinrich, G; Hindenburg, HJ; Klare, P; Ledwon, P; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D | 1 |
| Edmonds, MR; Ma, BB; Pond, GR; Siu, LL; Tannock, IF | 1 |
| Budd, GT; Bukowski, RM; Elson, P; Hutson, TE; Mekhail, T; Olencki, T; Peereboom, D; Pelley, R; Srkalovic, G | 1 |
| Dühmke, E; Heinemann, V; Rau, HG; Stoffregen, C; Thoma, M; Wagner, A; Wilkowski, R | 1 |
| Büchler, MW; Dunn, JA; Friess, H; Ghaneh, P; Hickey, H; Neoptolemos, JP; Raraty, MG; Stocken, DD | 1 |
| Blanke, C; Declerck, L; DeVore, R; Johnson, D; Masters, GA; Miller, K; Sandler, A | 1 |
| Bilgin, T; Ozalp, S; Ozerkan, K; Vardar, MA; Yalçin, OT; Zorlu, G | 1 |
| Alonso, L; Arrivi, A; Carles, J; Font, A; Garrido, P; Juan, O; Mellado, B; Nogué-Aliguer, M; Sáenz, A | 1 |
| Balzer, JO; Berger, D; Eichler, K; Heller, M; Mack, MG; Schwarz, W; Vogl, TJ; Zangos, S | 1 |
| Oettle, H | 1 |
| Goff, BA; Greer, BE; Jacobs, A; Storer, B; Thompson, T | 1 |
| Heimans, JJ; Hoekman, K; Postma, TJ; Verstappen, CC | 1 |
| Blohmer, J; Kaubitzsch, S; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D | 2 |
| Economopoulos, T; Fountzilas, G; Raptis, S; Rontogianni, D; Valsami, S; Xiros, N | 1 |
| Bloss, JD; Mutch, DG | 1 |
| Fowler, WC; Van Le, L | 1 |
| Hanibuchi, M; Hirano, H; Ito, M; Maeda, H; Nakagawa, M; Okumura, Y; Sawabata, Y; Takeda, S; Uematsu, K | 1 |
| Beatty, P; Hoang, T; Jaslowski, A; Kim, K; Koch, P; McGovern, J; Quisumbing, M; Schiller, JH; Shapiro, G; Witte, R | 1 |
| Breda, E; D'Agostino, G; Ferrandina, G; Gbaguidi, N; Lorusso, D; Ludovisi, M; Mancuso, S; Scambia, G; Testa, A | 1 |
| Black, PC; Lange, PH; Takayama, TK | 1 |
| Abbruzzese, JL; Benedetti, JK; Chansky, K; Macdonald, JS; Pluenneke, RE; Urba, SG; VanVeldhuizen, PJ | 1 |
| Bickels, J; Inbar, M; Kollender, Y; Meller, I; Merimsky, O | 1 |
| Akar, S; Akkoc, N; Birlik, M; Kirkali, Z; Manisali, M; Onen, F; Ozer, E; Tuzel, E | 1 |
| Dono, K; Maruhashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takahashi, Y; Tujie, M; Umeshita, K | 1 |
| Blessing, JA; Look, KY; Lucci, JA; Rose, PG; Sandler, A | 1 |
| Aravantinos, G; Farmakis, D; Gaglia, A; Kostopoulou, V; Koumpou, M; Mylonakis, N; Nikolaou, M; Pectasides, D; Pectasides, M; Skarlos, D | 1 |
| Pfisterer, J | 1 |
| Aghajanian, C; Ben-Porat, L; Chi, DS; Hensley, ML; Hoppe, B; Prasad, M; Sabbatini, P | 1 |
| Aerts, R; Haustermans, K; Topal, B; Van Cutsem, E; Van Steenbergen, W; Verslype, C | 1 |
| Agustí, C; Casas, F; Gascón, P; Gimferrer, JM; Martin-Richard, M; Molina, R; Reguart, N; Sanchez-Reyes, A; Viñolas, N | 1 |
| Chahine, GY; Dagher, JE; Farhat, FS; Ghosn, MG; Kattan, JG; Mokaddem, WT; Nasr, FL; Tueni, EA | 1 |
| Piura, B | 1 |
| Piura, B; Rabinovich, A | 1 |
| Burger, RA; Falkner, CA; Hunter, M; Monk, BJ; Tewari, D | 1 |
| Cesák, T; Kohlová, T; Melichar, B; Nová, M; Urminská, H | 1 |
| Besalduch, J; Galmés, B; Gutierrez, A; Rodriguez, J; Sampol, A | 1 |
| Del Valle, J; Gómez, A; Ruiz, I | 1 |
| Freiha, F; Morgan, K; Srinivas, S | 1 |
| Boutry, N; Brénuchon, C; Devulder, B; Hachulla, E; Hatron, PY; Lambert, M; Launay, D; Maurage, CA; N'Guyen, HD; Queyrel, V | 1 |
| Han, H; Li, YH; Liu, ZW; Qin, ZK; Wang, B; Wang, H; Yu, SL; Zhou, FJ | 1 |
| Driscoll, DL; Lele, S; Marchetti, D; Odunsi, K; Rodabaugh, K; Villella, J | 1 |
| Choi, M; Fogoros, S; Griffith, KA; Hu, YY; Liu, JR; Lucas, PC; Williams, J | 1 |
| Beslija, S; Fitzthum, E; Hayden, A; Kose, MF; Krejcy, K; Melemed, A; Minarik, T; Saip, P; Sufliarsky, J; Tulunay, G | 1 |
| Allegro, R; Galuffo, A; Pavone, C; Pavone-MacAluso, M; Serretta, V | 1 |
| Fujii, Y; Yoneto, T; Yoshikawa, K | 1 |
| Komut, K; Minami, S | 1 |
| Inoue, S; Kitamura, M; Maeshiro, T; Matsuo, S; Miyamoto, S; Ohkubo, T; Ohmura, T; Tanaka, S; Umekita, N | 1 |
| Argiris, A; Haraf, DJ; Kao, J; Milano, MT; Mittal, BB; Salama, JK; Stenson, KM; Vokes, EE; Weichselbaum, RR; Witt, ME | 1 |
| Catovsky, D; Chau, I; Cunningham, D; Hill, M; Horwich, A; Ng, M; Norman, AR; Waters, J; Wotherspoon, A | 1 |
| Hlavatá, Z; Koza, I; Mardiak, J; Mego, M; Obertová, J; Recková, M; Sálek, T; Sycová-Milá, Z | 1 |
| Adamo, V; Breda, E; D'Agostino, G; Ferrandina, G; Lorusso, D; Ludovisi, M; Paris, I; Pezzella, G; Pisconti, S; Scambia, G; Testa, A; Zanghi, M | 1 |
| Amano, R; Hirakawa, K; Inoue, M; Kosaka, K; Nakata, B; Nishino, H; Tendo, M; Yamada, N | 1 |
| Andres, R; Escudero, P; Isla, D; Lambea, J; Lara, R; Lastra, R; Mayordomo, JI; Ortega, E; Polo, E; Saenz-Cusi, A; Tres, A | 1 |
| Endo, S; Hashimoto, K; Higami, T; Itakura, M; Koike, M; Maruyama, R; Nio, Y; Tsuji, M; Yamaguchi, K; Yano, S | 1 |
| Beckman, E; Carringer, M; Gårdmark, T; Malmström, PU | 1 |
| Ozols, RF | 2 |
| Bier, J; Gath, HJ; Oettle, H; Raguse, JD; Riess, H | 1 |
| Chen, MD; Fleming, GF; Horowitz, I; Mitchell, S | 1 |
| Brom, R; Candelaria, M; Cantu, D; Cetina, L; Chanona, J; de la Garza, J; Dolores, R; Duenas-Gonzalez, A; Gonzalez, A; Lopez-Graniel, C; Uribe, J | 1 |
| Blankenburg, T; Bork, I; Juergens, S; Nagel, S; Schaedlich, S; Schuette, W; Wollschlaeger, B | 1 |
| Au, GK; Chua, DT; Sham, JS | 1 |
| Chmura, SJ; Haraf, DJ; Kao, J; Milano, MT; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Forkert, R; Fronhoffs, S; Ko, Y; Koll, C; Neuhaus, T; Stier, S; Tuohimaa, A; Vetter, H | 1 |
| Aurer, I; Bogdanić, V; Labar, B; Mrsić, M; Nemet, D; Radman, I; Sertić, D; Zupancić-Salek, S | 1 |
| An, CH; Bang, SM; Cho, EK; Jeong, SH; Kyung, SY; Lee, JH; Lee, SP; Lim, YH; Park, JW; Park, SH; Shin, DB | 1 |
| Hisaka, T; Horiuchi, H; Ishikawa, H; Kawahara, R; Kinoshita, H; Sakai, T; Shirouzu, K; Uchida, S | 1 |
| Poveda, A | 1 |
| Bruns, C; Dühmke, E; Heinemann, V; Thoma, M; Wilkowski, R | 1 |
| Albers, P; Fechner, G; Kobalz, L; Reimann, M; Siener, R | 1 |
| Angleitner-Boubenizek, L; Deibl, M; Marth, C; Petru, E; Reinthaller, A; Stempfl, A; Volgger, B; Zeimet, AG | 1 |
| Ohkawa, S | 1 |
| Ioka, T; Nakaizumi, A; Nishiyama, K; Tanaka, S; Yamazaki, H | 1 |
| Bartoletti, R; Cai, T; Carini, M; Gacci, M; Ghezzi, P; Nerozzi, S; Nesi, G; Pinzi, N; Repetti, F; Viggiani, F | 1 |
| Kose, MF; Meydanli, MM; Tulunay, G | 1 |
| Hennemann, B | 1 |
| Atkinson, T; Campos, S; Duska, L; Fuller, AF; Goodman, A; Krasner, CN; Matulonis, UA; Penson, RT; Seiden, MV; Verrill, C | 1 |
| Asmar, L; Ilegbodu, D; Khandelwal, P; O'Shaughnessy, JA; Pluenneke, R; Sternberg, J | 1 |
| Blessing, JA; Brewer, CA; Hanjani, P; Morgan, M; Nagourney, RA | 1 |
| Capobianco, G; Corazzelli, G; Della Cioppa, P; Marcacci, G; Pinto, A; Russo, F | 1 |
| Odicino, F; Pasinetti, B; Pecorelli, S; Tisi, G | 1 |
| Ledermann, JA; Pfisterer, J | 1 |
| Economopoulos, T; Pectasides, D; Pectasides, M; Psyrri, A | 1 |
| Castelli, E; Casu, M; Conti, G; Cretarola, E; D'Urso, L; Ferrando, U; Francesca, F; Graziano, ME; Hurle, R; Lancini, V; Lissoni, G; Luporini, AC; Morabito, F; Muto, G; Razionale, P; Rossi, R; Simone, M; Sommariva, M | 1 |
| Boaz, M; Brenner, J; Golan, A; Grisaru, D; Hayat, H; Inbar, M; Levy, T; Menczer, J; Ron, I; Safra, T | 1 |
| Laurie, SA; Licitra, L | 1 |
| Antoniou, D; Chaimala, D; Chondrou, E; Dariotaki, F; Karydis, I; Papageorgiou, C; Pavlakou, G; Stathopoulos, GP; Veslemes, M | 1 |
| Kagaya, T; Kaneko, S; Kato, Y; Sunagozaka, H; Yamashita, T | 1 |
| Case, AS; Estes, JM; Partridge, EE; Rocconi, RP; Straughn, JM | 1 |
| Di Stefano, A; Fanfani, F; Lorusso, D; Scambia, G | 1 |
| Bruns, C; Heinemann, V; Thoma, M; Wagner, A; Wilkowski, R | 1 |
| Endo, I; Fujii, Y; Ichikawa, Y; Kubota, T; Miura, Y; Shimada, H; Tanaka, K; Togo, S; Ueda, M | 1 |
| Ishikawa, N; Mizumoto, K; Murakami, M; Nagai, E; Ogura, Y; Ohuchida, K; Tanaka, M; Yamada, D | 1 |
| Büchler, MW; Friess, H; Kleeff, J; Michalski, C | 1 |
| Blackstock, AW; Case, LD; Descos, L; Kachnic, LA; Levine, EA; Limentani, SA; Melin, SA; Mishra, G; Mornex, F; Partensky, C; Tepper, JE | 1 |
| Bentley, J; du Bois, A; Eisenhauer, E; Emerich, J; Hirte, H; Jackisch, C; Kimmig, R; Kuhn, W; Lacave, AJ; Le, T; Lück, HJ; Olbricht, S; Pfisterer, J; Plante, M; Rochon, J; Stähle, A; Stuart, G; Vergote, I; Wagner, U; Zimmermann, AH | 1 |
| Jackisch, C | 1 |
| Lehoczky, O; Pulay, T | 1 |
| Fangusaro, J; Finlay, J; Rook, J; Rosser, T | 1 |
| Gemba, K; Harita, S; Hiraki, S; Kishino, D; Kiura, K; Kozuki, T; Segawa, Y; Shibayama, T; Tabata, M; Tada, A; Tada, S; Takigawa, N; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Cipolat, M; Colantonio, I; Di Costanzo, G; Fea, E; Garrone, O; Gasco, M; Granetto, C; Merlano, M; Numico, G; Occelli, M; Pelissero, A; Russi, EG; Sorrentino, R; Taglianti, RV; Vitiello, R | 1 |
| Campodonico, F; Canepa, G; Capponi, G; Fontana, V; Maffezzini, M | 1 |
| Calabrò, F; Sternberg, CN | 1 |
| Atkins, JN; Green, MR; Herndon, JE; Lee, ME; Mauer, A; Rocha-Lima, CM; Vokes, E | 1 |
| Bauters, F; Bouabdallah, R; Chouaki, N; Coiffier, B; Depil, S; Dumontet, C; Jourdan, E; Marit, G; Morschhauser, F; Sebban, C; Solal-Céligny, P; Wetterwald, M | 1 |
| Boswell, JS; Flam, MS; Tashjian, DN; Tschang, TP | 1 |
| Kamiyama, Y; Kano, Y; Kodama, T; Kondo, T; Mori, K | 1 |
| Cheng, WW; Cho, WC; Law, SC; Ma, VW; Ngan, RK; Podust, VN; Yip, C; Yip, TT; Yip, V; Yiu, HH | 1 |
| Alcaide, J; Alés, I; Benavides, M; Bretón, JJ; Carabantes, F; Cobo, M; Durán, G; Gil, S; Gutiérrez, V; Martínez, J; Villar, E | 1 |
| Adrover, E; Balil, A; Calvo, L; Carrasco, E; Casado, A; Escudero, MJ; García-Mata, J; García-Saenz, JA; Guillem, V; Jara, C; Mahillo, E; Martín, M; Mel, JR; Morales-Vasquez, F; Muñoz, M; Ribelles, N; Rodríguez, CA; Ruiz, A; Salas, F; Soto, C | 1 |
| Bergsland, EK; Dito, E; Ko, AH; Quivey, JM; Schillinger, B; Tempero, MA; Venook, AP | 1 |
| Ahn, MJ; Kim, HK; Kim, JS; Kim, TY; Lee, J; Lee, MA; Lee, NS; Lim, HY; Park, BJ | 1 |
| Bae, DS; Choi, CH; Huh, SJ; Kim, BG; Kim, TJ; Kim, WY; Lee, JH; Lee, JW; Nam, HR | 1 |
| Adusumilli, S; Ben-Josef, E; Griffith, KA; Lawrence, TS; Murphy, JD; Ray, ME; Zalupski, MM | 1 |
| Bortolotti, L; Breda, C; Favaretto, AG; Loreggian, L; Marulli, G; Rea, F; Sartori, F | 1 |
| Clegg, AJ; Jones, J; Loveman, E; Takeda, AL; Tan, SC | 1 |
| Belhadj, K; Copie-Bergman, C; Diviné, M; Dupuis, J; El Gnaoui, T; Gaillard, I; Haioun, C; Jais, JP; Rahmouni, A; Reyes, F; Tabah-Fisch, I | 1 |
| Arthur, C; Reed, K; Spencer, A | 1 |
| Komiyama, S; Kurahashi, T; Kuwabara, Y; Mikami, M; Murakami, I; Nakamura, M; Tanaka, K | 1 |
| Beerepoot, LV; Beijnen, JH; Enas, N; Mehra, N; Musib, L; Radema, SA; Rademaker-Lakhai, JM; Schellens, JH; van Hal, G; van Maanen, R; Vermaat, JS; Visseren-Grul, CM; Voest, EE; Witteveen, EO | 1 |
| Iwata, H; Yamashita, T | 1 |
| Albanell, J; Bellmunt, J; Berrocal, A; Carles, J; Climent, M; Esteban, E; Fabregat, X; Font, A; Garcia-Ribas, I; Gonzalez-Larriba, JL; Marfa, X | 1 |
| Gu, Y; Guo, Y; Hong, X; Hu, X; Li, J; Tang, W; Wang, B; Wang, J | 1 |
| Havrilesky, LJ; Kulasingam, S; Myers, E; Secord, AA | 1 |
| Faerber, GJ; Weizer, AZ; Wolf, JS | 1 |
| Chang, AY; Fong, FK; Hsin, KW; Lim, R; Lopes, G; Wong, J | 1 |
| Blaszkowsky, LS; Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Kwak, EL; Lawrence, C; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Zhu, AX | 1 |
| Bauer, RW; Böcher, E; Hammerstingl, RM; Heller, M; Jacob, U; Vogl, TJ; Zangos, S | 1 |
| Fujiwara, S; Ino, K; Kajiyama, H; Kato, S; Kikkawa, F; Nakamura, S; Nawa, A; Shibata, K; Suzuki, K | 1 |
| Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K | 1 |
| Fayad, LE; Goy, A; Hagemeister, F; McLaughlin, P; Neelapu, S; Oki, Y; Pro, B; Romaguera, J; Samaniego, F; Younes, A | 1 |
| Borg, M; Carroll, S; Davies, T; Goldstein, D; Graham, P; Harvey, J; Iacopetta, B; Kneebone, A; Macleod, C; Millar, JL; Ngan, SY; Reece, WH; Spry, N; Zissiadis, Y | 1 |
| Berardi, R; Cantore, M; Cascinu, S; Cereda, S; Ferrari, VD; Grisanti, S; Mambrini, A; Mazza, E; Pasetto, L; Reni, M | 1 |
| Behringer, D; Gelos, M; Mann, B; Philippou, S | 1 |
| Breda, E; Del Medico, P; Ferrandina, G; Katsaros, D; Lorusso, D; Ludovisi, M; Pignata, S; Priolo, D; Savarese, A; Scaltriti, L; Scambia, G | 1 |
| Aysan, T; Cok, G; Göksel, T; Soyer, S | 1 |
| Carone, V; Corrado, G; Ferrandina, G; Ludovisi, M; Petrillo, M; Scambia, G | 1 |
| Bastos Oreiro, M; López Rodríguez, M; Monedero Martín, MC; Plasencia Rodríguez, C | 1 |
| Abulafia, O; Blessing, JA; Degeest, K; Hensley, ML; Homesley, HD; Rose, PG | 1 |
| Bartlett, NL; Cass, CE; Cheson, B; Cook, JR; Hsi, ED; Johnson, JL; Jones, D; Jung, SH; Lai, R; Mackey, JR; Said, J; Young, JD | 1 |
| Aydiner, A; Derin, D; Guney, N; Tas, F; Topuz, E | 1 |
| Bauerfeind, P; Clavien, PA; Heinrich, S; Knuth, A; Pestalozzi, BC; Schäfer, M; Weber, A | 1 |
| Kurosaki, I; Nakadaira, K; Ueki, H | 1 |
| Eisenhauer, EA; Mertens, WC; Moore, M; Muldal, A; Stewart, D; Venner, P; Wong, D | 1 |
| Athanassiades, A; Bacoyiannis, C; Briassoulis, E; Fountzilas, G; Kalogera-Fountzila, A; Kosmidis, P; Pavlidis, N; Samantas, E; Skarlos, D | 1 |
| Nori, D; Parikh, S | 1 |
| Steward, WP; Thomas, A | 1 |
| Alvarez Vincent, JJ; Brandariz, A; Castellano, D; Cortés-Funes, H; García-Carbonero, R; Hidalgo, M; Hitt, R; Millán, JM; Peña, M | 1 |
| Piver, MS; Silver, DF | 1 |
| Horning, SJ; Horwitz, SM; Lucas, JB; Sayegh, A | 1 |
| Adjei, AA; Erlichman, C | 1 |
| Brader, KR; Burnett, AF; Garcia, AA; Morrow, CP; Muderspach, LI; Roman, LD | 1 |
| Ariad, S; Fenig, E; Flusser, G; Inbar, M; Issakov, J; Kollender, Y; Meller, I; Merimsky, O; Neuman, G; Sapir, D; Weil-Ben-Arush, M | 1 |
| Camps, C; Herrero, CC; Jaime, AB; Martínez, EN | 1 |
| Belanger, K; Forsyth, P; Fulton, D; Gertler, SZ; Goodyear, M; MacDonald, D; Perry, J; Seymour, L; Steward, W; Stewart, DJ; Wainman, N | 1 |
| Blitzer, JB; Evans, SS; Forsthoff, C; Link, JS; Nagourney, RA | 1 |
| Agostara, B; Gebbia, V; Leonardi, V; Valenza, R | 1 |
| D'Agostino, G; Genovesi, D; Greggi, S; Lorusso, D; Scambia, G; Smaniotto, D | 1 |
| Glisson, BS; Hong, WK; Khuri, FR; Lippman, SM; Shin, DM | 1 |
| Buccheri, G; Ferrigno, D | 1 |
| Cree, IA; Hindley, A; Kurbacher, CM; Lamont, A; Neale, MH | 1 |
| Endo, M; Kadou, T; Kotani, Y; Ohbayashi, K; Satouchi, M; Takada, Y | 1 |
| Belani, CP; Calvo, AR | 1 |
| Blair, S; Carman, L; Colborn, D; George, C; Jones, J; Kuebler, JP; Laufman, LR; Moore, T; Patel, T; Roach, R; Rupert, R; Spiridonidis, CH; Zangmeister, J | 1 |
| Abbruzzese, JL; Breslin, TM; Cleary, KR; Crane, CH; Dackiw, AP; Evans, DB; Harbison, DB; Hess, KR; Janjan, NA; Jean, ME; Lee, JE; Pisters, PW; Vauthey, JN; Wolff, RA | 1 |
| Arends, J; Unger, C | 1 |
| de la Guerra, J; Dueñas-Gonzalez, A; Hinojosa-García, LM; López-Graniel, C; Maldonado, V; Meléndez-Zagla, J | 1 |
| Antonopoulos, M; Kalofonos, HP; Kosmas, C; Kourelis, T; Malamos, N; Panopoulos, C; Stavroyianni, N; Tsavaris, N; Vadiaka, M | 1 |
| Baranov, E; Bouvet, M; Hoffma, RM; Jiang, P; Lee, NC; Moossa, AR; Nardin, S; Rashidi, B; Wang, X; Yang, M | 1 |
| Ensley, JF; Giguere, JK; Gundacker, H; Kuebler, JP; Mills, GM; Samlowski, WE; Schuller, DE | 1 |
| Alonso, V; Antón, A; Artal, A; Herrero, A; Martinez-Trufero, J; Maurel, J; Puertas, MM; Puertolas, T; Zorrilla, M | 1 |
| Kalofonos, HP; Kosmas, C; Koutras, A; Malamos, N; Onyenadum, A; Polyzos, A; Rokana, S; Stavroyianni, N; Tsavaris, N; Vadiaka, M | 1 |
| Calabrò, F; Marini, L; Pizzocaro, G; Schnetzer, S; Sella, A; Sternberg, CN | 1 |
| Bethe, U; Cornely, OA; Pels, H; Ritzkowsky, A; Seibold, M; Soehngen, D; Toepelt, K | 1 |
| Fukuda, M; Kato, K; Kawasaki, Y; Kobayashi, K; Miyata, M; Saito, S; Shimizu, E; Yano, S | 1 |
| Markman, M | 1 |
| Moore, MJ | 1 |
| Breidenbach, M; Kurbacher, CM; Mallmann, P; Rein, DT | 1 |
| Barlogie, B; Crowley, JJ; Hussein, MA; Moore, DF; Weick, JK | 1 |
| Dueñas, R; Fernández, M; Jaén, A; Lozano, A; Martínez, E; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Hensley, ML | 1 |
68 review(s) available for gemcitabine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic | 2022 |
Sequential intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2023 |
Evaluation of the efficacy of systemic therapy for advanced uterine leiomyosarcoma: A systematic review, meta-analysis, and meta-regression analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Neoplasm Recurrence, Local; Proportional Hazards Models; Uterine Neoplasms | 2023 |
The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Network Meta-Analysis; Non-Muscle Invasive Bladder Neoplasms; Urinary Bladder Neoplasms | 2023 |
Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; alpha-Glucosidases; Anemia; Animals; Anthozoa; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Ascites; Asthma; Bacteria; beta-Lactamases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Binding Sites; Biological Availability; Biomass; Borderline Personality Disorder; Brain; Brucella abortus; Brucella melitensis; Brucellosis; Calcium; Carbapenems; Case-Control Studies; Caseins; Cattle; CD8-Positive T-Lymphocytes; Ceftaroline; Cell Line; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cephalosporins; Chemotherapy, Adjuvant; China; Chitin; Chlorella; Chlorophyll; Chlorophyll A; Chlorophyta; Cholangiocarcinoma; Cisplatin; Conotoxins; Contrast Media; Conus Snail; Cross-Sectional Studies; Cytokines; Decapodiformes; Deoxycytidine; Diagnostic and Statistical Manual of Mental Disorders; Dietary Fiber; Diterpenes; DNA Methylation; Dogs; Double-Blind Method; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Epidermis; Escherichia coli; Escherichia coli Infections; Extraintestinal Pathogenic Escherichia coli; Fatty Acids; Fatty Acids, Unsaturated; Fatty Acids, Volatile; Feasibility Studies; Feces; Female; Ferritins; Fluorodeoxyglucose F18; Gastrectomy; Gastrointestinal Microbiome; Gemcitabine; Glomerular Filtration Rate; Glucose; Glycerol; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunoassay; Immunoglobulin G; India; Infant, Newborn; Infertility; Inflammation; Intensive Care Units; Iron; Iron Deficiencies; Kidney; Lacticaseibacillus rhamnosus; Laurencia; Leukocytes; Lipids; Liver Cirrhosis; Long Interspersed Nucleotide Elements; Longitudinal Studies; Male; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; Mice; Microalgae; Microbial Sensitivity Tests; Microscopy; Middle Aged; Minerals; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephropidae; Nicotinic Antagonists; Nitrogen; Obesity; Oxaliplatin; Paclitaxel; Panax; Pancreatic Neoplasms; Pancreatitis; Personality; Personality Disorders; Personality Inventory; Photobioreactors; Plant Extracts; Plasmalogens; Plasmids; Polymorphism, Genetic; Polynesia; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prebiotics; Predictive Value of Tests; Prognosis; Prolyl-Hydroxylase Inhibitors; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Receptors, Nicotinic; Recombinant Proteins; Retrospective Studies; Rifampin; Risk Factors; RNA, Ribosomal, 16S; Salinity; Seaweed; Sensitivity and Specificity; Sepsis; Sesquiterpenes; Severity of Illness Index; Shock, Septic; Silicones; Single Photon Emission Computed Tomography Computed Tomography; Skin; Snails; Solubility; Solvents; Sputum; Staphylococcal Infections; Stomach Neoplasms; Stramenopiles; Structure-Activity Relationship; Technetium Tc 99m Exametazime; Technology; Terpenes; Tuberculosis; Tuberculosis, Multidrug-Resistant; Urinary Catheters; Urinary Tract Infections; Vascular Endothelial Growth Factor A; Virulence Factors; Water; Wound Healing | 2023 |
Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile and drug/nanotherapeutic approaches.
Topics: Carcinogenesis; Cell Transformation, Neoplastic; Gemcitabine; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pharmaceutical Preparations | 2024 |
Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 2023 |
Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Randomized Controlled Trials as Topic | 2019 |
Considering gemcitabine-based combination chemotherapy as a potential treatment for advanced oesophageal cancer: A meta-analysis of randomised trials.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Primary transitional cell carcinoma of the fallopian tube: A case report and literature review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Hysterectomy; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Palliative Care; Salpingo-oophorectomy | 2020 |
Nivolumab plus gemcitabine, dexamethasone, and cisplatin chemotherapy induce durable complete remission in relapsed/refractory primary mediastinal B-cell lymphoma: a case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Nivolumab; Treatment Outcome | 2020 |
Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Review Literature as Topic; Standard of Care | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; BCG Vaccine; Bias; Cause of Death; Confidence Intervals; Deoxycytidine; Disease Progression; Drug Administration Schedule; Gemcitabine; Humans; Mitomycin; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Saline Solution; Urinary Bladder Neoplasms | 2021 |
[Treatment of mycosis fungoides and Sézary syndrome].
Topics: Adrenal Cortex Hormones; Bexarotene; Brentuximab Vedotin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Immunoconjugates; Interferon-alpha; Mycosis Fungoides; Neoplasm Recurrence, Local; Neoplasm Staging; Phototherapy; Polyethylene Glycols; PUVA Therapy; Sezary Syndrome; Skin Neoplasms; World Health Organization | 2017 |
Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mass Screening; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Topotecan; Uterine Cervical Neoplasms | 2014 |
The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Ifosfamide; Methotrexate; Neoplasm Recurrence, Local; Osteosarcoma; Taxoids | 2014 |
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Double-Blind Method; Doxorubicin; Female; Gemcitabine; Health Care Costs; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tetrahydroisoquinolines; Topotecan; Trabectedin; Treatment Outcome; United Kingdom | 2015 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Factors; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Pyrimidines; Salvage Therapy; Sulfonamides; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Gemcitabine; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Radiotherapy, Intensity-Modulated; Squamous Cell Carcinoma of Head and Neck | 2016 |
Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Gemcitabine; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2016 |
Bladder chondrosarcoma plus urothelial carcinoma in recurred transitional cell carcinoma of the upper urinary tract: a case report and literature review.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Chondrosarcoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney; Kidney Neoplasms; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Tomography, X-Ray Computed; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2016 |
Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; BCG Vaccine; Deoxycytidine; Disease Progression; Epirubicin; Female; Gemcitabine; Humans; Isoniazid; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Odds Ratio; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Surgical treatment of recurrent urachal carcinoma with liver metastasis: a case report and literature review.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Hepatectomy; Humans; Hysterectomy; Liver Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Neoplasms; Salvage Therapy; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2016 |
Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment?
Topics: Adult; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunotherapy; Middle Aged; Neoplasm Recurrence, Local; Risk Factors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2017 |
[Nonmuscle-invasive bladder cancer (NMIBC): when to perform cystectomy?].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Cystectomy; Cystoscopy; Deoxycytidine; Disease Progression; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Patient Selection; Prognosis; Risk Factors; Time Factors; Urinary Bladder Neoplasms | 2008 |
Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cost-Benefit Analysis; Cross-Linking Reagents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Quality of Life; Quality-Adjusted Life Years; Radiation-Sensitizing Agents; Topotecan; Treatment Outcome; United Kingdom; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine | 2010 |
Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols | 2010 |
Splenic localization of the peritoneal mesothelioma: case report and literature revue.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Laparoscopy; Male; Mesothelioma; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Radiography; Splenectomy; Splenic Neoplasms; Time Factors; Treatment Failure | 2012 |
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Randomized Controlled Trials as Topic | 2011 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Gemcitabine; Humans; Mitomycin; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 2012 |
A rational approach to the management of recurrent or persistent ovarian carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Chemotherapy, Cancer, Regional Perfusion; Decision Making; Deoxycytidine; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Ovary; Paclitaxel; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic | 2012 |
Pathological vertebral fracture after stereotactic body radiation therapy for lung metastases. Case report and literature review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Carboplatin; Carcinoma, Transitional Cell; Cervical Vertebrae; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fractures, Spontaneous; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Osteoporosis, Postmenopausal; Pemetrexed; Radiosurgery; Radiotherapy, Conformal; Rib Fractures; Ribs; Spinal Fractures; Thoracic Vertebrae; Urinary Bladder Neoplasms | 2012 |
Malignant primary cardiac tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cardiac Surgical Procedures; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Doxorubicin; Fatal Outcome; Female; Gemcitabine; Heart Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Myxoma; Neoplasm Recurrence, Local; Reoperation; Sarcoma; Taxoids; Time Factors; Treatment Outcome | 2012 |
[Adjuvant and additive therapy for cancer of the pancreas].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Controlled Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Folic Acid; Gemcitabine; Hematinics; Humans; Leucovorin; Male; Mitoxantrone; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Quality of Life; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Retrospective Studies; Surveys and Questionnaires; Time Factors | 2003 |
[Adjuvant treatment of pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Intraoperative Care; Metalloendopeptidases; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organic Chemicals; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Phenylbutyrates; Postoperative Care; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Time Factors | 2003 |
Gemcitabine in cervical cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Uterine Cervical Neoplasms | 2003 |
Gemcitabine as a single-agent treatment for ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms | 2003 |
Localized pleural malignant mesothelioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Mesothelioma; Neoplasm Recurrence, Local; Paclitaxel; Pleural Neoplasms; Radiography, Thoracic; Tomography, X-Ray Computed | 2003 |
Palliative treatment for advanced or metastatic osteosarcoma.
Topics: Amputation, Surgical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Neoplasm Recurrence, Local; Osteosarcoma; Palliative Care; Pneumonectomy; Prognosis; Radiotherapy, Adjuvant; Severity of Illness Index; Survival Rate; Treatment Outcome | 2004 |
Systemic treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Duodenal Obstruction; Gemcitabine; Humans; Neoplasm Recurrence, Local; Palliative Care; Pancreatic Neoplasms; Postoperative Care; Treatment Outcome | 2004 |
Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Deoxycytidine; Epithelial Cells; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2004 |
Gemcitabine and carboplatin in second-line ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Survival Rate | 2005 |
Gemcitabine in patients with ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Quality of Life; Remission Induction | 2005 |
[Gemcitabine chemotherapy for patients with advanced or relapsed pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2006 |
[Concurrent chemoradiation therapy with gemcitabine for advanced or relapsed pancreatic tumors].
Topics: Animals; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Radiation-Sensitizing Agents | 2006 |
Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Quality of Life; Survival | 2006 |
[Palliative chemotherapy of head and neck cancer: present status and future development].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; ErbB Receptors; Forecasting; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rats; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Optimizing gemcitabine regimens in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Decision Trees; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2006 |
Management of platinum-sensitive recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2006 |
Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?
Topics: Antineoplastic Agents; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Topotecan | 2006 |
Systemic therapy in the palliative management of advanced salivary gland cancers.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab | 2006 |
Role of gemcitabine in ovarian cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Survival Analysis; Treatment Outcome | 2006 |
Pancreatic cancer: from bench to 5-year survival.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lymph Node Excision; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Pancreaticojejunostomy; Prognosis; Randomized Controlled Trials as Topic; Survival Rate | 2006 |
HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Recurrence, Local; Receptor, ErbB-2; Trastuzumab; Vinblastine; Vinorelbine | 2006 |
State-of-the-art management of metastatic disease at initial presentation or recurrence.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Taxoids; Urinary Bladder Neoplasms | 2006 |
The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.
Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Markov Chains; Models, Economic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Factors | 2007 |
[Current situation and features of chemotherapy for breast neoplasms].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Taxoids; Trastuzumab | 2007 |
Pancreatic carcinosarcoma. Case report of multimodal therapy and review of the literature.
Topics: Antimetabolites, Antineoplastic; Carcinosarcoma; Combined Modality Therapy; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis | 2008 |
Future directions in the chemotherapy of ovarian cancer.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Europe; Female; Forecasting; Gemcitabine; Humans; Injections, Intraperitoneal; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Time Factors; Topotecan; Vinblastine; Vinorelbine | 1997 |
Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2000 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Second-line treatment of ovarian cancer with single-agent gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2002 |
Pancreatic cancer: what the oncologist can offer for palliation.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Genes, ras; Humans; Mutation; Neoplasm Recurrence, Local; Organophosphonates; Palliative Care; Pancreatic Neoplasms | 2002 |
Neoadjuvant gemcitabine therapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2002 |
Epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Practice Guidelines as Topic; Tamoxifen; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2002 |
262 trial(s) available for gemcitabine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2022 |
Neoadjuvant concurrent chemoradiotherapy using infusional gemcitabine in locally advanced rectal cancer: A phase II trial.
Topics: Adolescent; Adult; Chemoradiotherapy; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Rectal Neoplasms; Treatment Outcome | 2022 |
Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: a phase I trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Rituximab; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2022 |
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pyridones; Pyrimidinones; Radiosurgery | 2022 |
Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Randomized Controlled Trial.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; BCG Vaccine; Female; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Non-Muscle Invasive Bladder Neoplasms; Urinary Bladder Neoplasms | 2023 |
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Neoplasm Recurrence, Local; Oxaliplatin; Pancreatic Neoplasms | 2022 |
Development and investigation of a novel device with gemcitabine for hyperthermic intravesical chemotherapy.
Topics: Gemcitabine; Humans; Hyperthermia, Induced; Incidence; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pilot Projects; Urinary Bladder Neoplasms | 2023 |
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Recurrence; Treatment Outcome | 2023 |
Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; alpha-Glucosidases; Anemia; Animals; Anthozoa; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Ascites; Asthma; Bacteria; beta-Lactamases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Binding Sites; Biological Availability; Biomass; Borderline Personality Disorder; Brain; Brucella abortus; Brucella melitensis; Brucellosis; Calcium; Carbapenems; Case-Control Studies; Caseins; Cattle; CD8-Positive T-Lymphocytes; Ceftaroline; Cell Line; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cephalosporins; Chemotherapy, Adjuvant; China; Chitin; Chlorella; Chlorophyll; Chlorophyll A; Chlorophyta; Cholangiocarcinoma; Cisplatin; Conotoxins; Contrast Media; Conus Snail; Cross-Sectional Studies; Cytokines; Decapodiformes; Deoxycytidine; Diagnostic and Statistical Manual of Mental Disorders; Dietary Fiber; Diterpenes; DNA Methylation; Dogs; Double-Blind Method; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Epidermis; Escherichia coli; Escherichia coli Infections; Extraintestinal Pathogenic Escherichia coli; Fatty Acids; Fatty Acids, Unsaturated; Fatty Acids, Volatile; Feasibility Studies; Feces; Female; Ferritins; Fluorodeoxyglucose F18; Gastrectomy; Gastrointestinal Microbiome; Gemcitabine; Glomerular Filtration Rate; Glucose; Glycerol; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunoassay; Immunoglobulin G; India; Infant, Newborn; Infertility; Inflammation; Intensive Care Units; Iron; Iron Deficiencies; Kidney; Lacticaseibacillus rhamnosus; Laurencia; Leukocytes; Lipids; Liver Cirrhosis; Long Interspersed Nucleotide Elements; Longitudinal Studies; Male; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; Mice; Microalgae; Microbial Sensitivity Tests; Microscopy; Middle Aged; Minerals; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephropidae; Nicotinic Antagonists; Nitrogen; Obesity; Oxaliplatin; Paclitaxel; Panax; Pancreatic Neoplasms; Pancreatitis; Personality; Personality Disorders; Personality Inventory; Photobioreactors; Plant Extracts; Plasmalogens; Plasmids; Polymorphism, Genetic; Polynesia; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prebiotics; Predictive Value of Tests; Prognosis; Prolyl-Hydroxylase Inhibitors; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Receptors, Nicotinic; Recombinant Proteins; Retrospective Studies; Rifampin; Risk Factors; RNA, Ribosomal, 16S; Salinity; Seaweed; Sensitivity and Specificity; Sepsis; Sesquiterpenes; Severity of Illness Index; Shock, Septic; Silicones; Single Photon Emission Computed Tomography Computed Tomography; Skin; Snails; Solubility; Solvents; Sputum; Staphylococcal Infections; Stomach Neoplasms; Stramenopiles; Structure-Activity Relationship; Technetium Tc 99m Exametazime; Technology; Terpenes; Tuberculosis; Tuberculosis, Multidrug-Resistant; Urinary Catheters; Urinary Tract Infections; Vascular Endothelial Growth Factor A; Virulence Factors; Water; Wound Healing | 2023 |
A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Quality of Life; Sarcoma; Sarcoma, Synovial; Soft Tissue Neoplasms; Treatment Outcome | 2023 |
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cisplatin; Double-Blind Method; Female; Gemcitabine; Humans; Internationality; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; United States | 2023 |
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2019 |
S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Combinations; Gemcitabine; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatic Neoplasms; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tegafur | 2020 |
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Imidazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Progression-Free Survival; Pyridines; Young Adult | 2020 |
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Patient Safety; Polyethylene Glycols; Survival Rate; Topotecan; Treatment Outcome | 2020 |
Pilot study of docetaxel combined with lobaplatin or gemcitabine for recurrent and metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclobutanes; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Pilot Projects; Survival Analysis | 2019 |
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microwaves; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Progression-Free Survival; Prospective Studies; Radiofrequency Ablation; Treatment Outcome; Vinorelbine | 2020 |
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Netherlands; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Time Factors | 2020 |
A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Urinary Bladder Neoplasms | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Relapse and Prognosis of Non-Muscle Invasive Bladder Cancer After Combined HOLRBT with Sunitinib and TGC Perfusion Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Lasers, Solid-State; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Sunitinib; Survival Rate; Urinary Bladder; Urinary Bladder Neoplasms | 2020 |
Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Sunitinib | 2020 |
CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Sorafenib; Time Factors; Treatment Outcome | 2020 |
Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial.
Topics: Deoxycytidine; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Pyrimidines; Quinazolines; Treatment Outcome | 2021 |
Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Sparing Treatments; Prognosis; Prospective Studies; Quality of Life; Remission Induction; Retrospective Studies; Survival Rate; Urinary Bladder Neoplasms | 2021 |
Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; CA-125 Antigen; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Progression-Free Survival; Survival Rate; Treatment Outcome | 2021 |
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Neoplasm Recurrence, Local; Progression-Free Survival | 2021 |
A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Busulfan; Cladribine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2021 |
A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arteries; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Radiotherapy, Intensity-Modulated; Survival Rate; Tegafur; Tomography, X-Ray Computed | 2017 |
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Early Termination of Clinical Trials; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Tetrahydroisoquinolines; Time Factors; Topotecan; Trabectedin; Treatment Outcome | 2017 |
Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Compliance; Progression-Free Survival; Radiotherapy, Intensity-Modulated; Young Adult | 2017 |
The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Margins of Excision; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Analysis | 2019 |
Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Urinary Bladder Neoplasms | 2018 |
Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; Carcinoma, Papillary; Deoxycytidine; Double-Blind Method; Female; Follow-Up Studies; Gemcitabine; Humans; Incidence; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Sodium Chloride; Urinary Bladder Neoplasms; Urothelium | 2018 |
Salvage Chemotherapy With Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin for Relapsed Germ Cell Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Ifosfamide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Salvage Therapy; Survival Rate; Taxoids; Treatment Failure; Young Adult | 2018 |
Subclinical cancer cell dissemination in peritoneal lavage fluid detected by reverse-transcription polymerase chain reaction identifies patients at high risk for peritoneal recurrence and consequent impaired survival in the setting of preoperative chemora
Topics: Aged; Antimetabolites, Antineoplastic; Ascitic Fluid; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Incidence; Japan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Peritoneal Lavage; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment | 2018 |
Mogamulizumab
Topics: Adult; Aged; Aged, 80 and over; Aminopterin; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Deoxycytidine; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; International Agencies; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Oxaliplatin; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2019 |
Highlights of the NCCN Oncology Research Program.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Female; Folate Receptor 1; Gemcitabine; Humans; Immunoconjugates; Male; Maytansine; Neoplasm Recurrence, Local; Neoplasms; Progression-Free Survival; Young Adult | 2019 |
Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Salvage Therapy; Topotecan | 2019 |
Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Oxaliplatin; Progression-Free Survival; Survival Rate | 2019 |
Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Nelfinavir; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Radiosurgery | 2019 |
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Mastectomy; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Placebos; Randomized Controlled Trials as Topic; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nadroparin; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Pneumonectomy; Positron-Emission Tomography | 2019 |
Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Young Adult | 2013 |
The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Quality of Life; Risk Assessment; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2013 |
Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Thrombocytopenia | 2013 |
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate | 2013 |
A multicentre phase-II feasibility study evaluating gemcitabine/vinorelbine / prednisolone combination chemotherapy in relapsed / refractory Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prednisolone; Salvage Therapy; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2013 |
A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Hepatectomy; Humans; Male; Neoplasm Recurrence, Local; Treatment Outcome | 2014 |
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quality of Life; Quinazolines; Radiotherapy, Intensity-Modulated | 2013 |
A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; HLA Antigens; Humans; Immunoglobulins; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Peptide Fragments; Precision Medicine; Prognosis; Survival Rate; Tegafur; Vaccination; Young Adult | 2013 |
Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiotherapy Dosage; Remission Induction; Survival Rate; Tegafur | 2013 |
Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Laparoscopy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Preoperative Care; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate | 2013 |
Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Salvage Therapy | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2013 |
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Survival Analysis | 2013 |
Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes.
Topics: Adult; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Retrospective Studies; Salvage Therapy; Survival; Treatment Outcome | 2014 |
Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2014 |
[ATP-tumor chemosensitivity assay directed chemotherapy in patients with cervical cancer].
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Uterine Cervical Neoplasms; Vincristine | 2013 |
Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer.
Topics: Adult; Advisory Committees; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Radiology; Tomography, X-Ray Computed | 2014 |
Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Prospective Studies; Salvage Therapy; Testicular Neoplasms; Treatment Outcome; Young Adult | 2014 |
Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Everolimus; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Sirolimus | 2014 |
A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2014 |
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Phthalazines; Prognosis; Pyridines; Survival Rate | 2014 |
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Young Adult | 2014 |
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Republic of Korea; Severity of Illness Index; Taxoids; Treatment Outcome | 2014 |
Timing of thoracic radiotherapy in limited stage small cell lung cancer: results of early versus late irradiation from a single institution in Turkey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Time Factors | 2014 |
Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.
Topics: Adult; Age Distribution; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Prevalence; Prospective Studies; Risk Factors; Sex Distribution; Survival Rate; Switzerland; Treatment Outcome | 2015 |
Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome; Triple Negative Breast Neoplasms; United States | 2014 |
Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Prodrugs; Survival Analysis; Tegafur | 2015 |
Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Republic of Korea; Vinblastine; Vinorelbine | 2015 |
Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Taxoids; Treatment Outcome | 2015 |
Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Prospective Studies; Tegafur; Time Factors; Treatment Outcome | 2014 |
Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Penile Neoplasms; Treatment Outcome | 2016 |
Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2015 |
Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial.
Topics: Adult; Aged; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Prospective Studies; Survival Analysis; Taiwan; Treatment Outcome | 2015 |
Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: Our preliminary experience.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Electroporation; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Hydroxamic Acids; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Vorinostat | 2015 |
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Survival Rate | 2015 |
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Topics: Adult; Aged; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids; United States | 2015 |
Gemcitabine, capecitabine and oxaliplatin with or without cetuximab in advanced biliary tract carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cetuximab; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate; Young Adult | 2016 |
Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Consolidation Chemotherapy; Cystectomy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Sparing Treatments; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Remission Induction; Salvage Therapy; Urinary Bladder Neoplasms | 2016 |
Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Clinical Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Netherlands; Pancreatectomy; Pancreatic Neoplasms; Radiation Dose Hypofractionation; Research Design; Time Factors; Treatment Outcome; Tumor Burden | 2016 |
Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Salvage Therapy; Treatment Outcome | 2016 |
DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; China; Cisplatin; Deoxycytidine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Lymphoma, Extranodal NK-T-Cell; Male; Methotrexate; Middle Aged; Natural Killer T-Cells; Neoplasm Recurrence, Local; Polyethylene Glycols; Remission Induction; Young Adult | 2016 |
A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Depsipeptides; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome; Young Adult | 2016 |
Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Research Design; Rituximab | 2016 |
Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer: Impact of Venous and Arterial Involvement Status on Surgical Outcome and Pattern of Recurrence.
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome; Vascular Neoplasms | 2016 |
Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Mucin-1; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Taxoids | 2016 |
Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Deoxycytidine; Drug Monitoring; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Paclitaxel; Pemetrexed; Taxoids | 2016 |
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Austria; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality of Life; Topotecan | 2016 |
A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Quality of Life; Survival Rate | 2018 |
Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate | 2016 |
Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Interferon-alpha; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Missouri; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Tolerability of Concurrent Chemoradiation Therapy With Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy, in Muscle Invasive Bladder Cancer.
Topics: Aged; Antineoplastic Agents; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Tolerance; Female; Follow-Up Studies; Gemcitabine; Humans; Longitudinal Studies; Male; Middle Aged; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Radiation Dose Hypofractionation; Radiation Injuries; Radiation Tolerance; Survival Rate; Treatment Outcome; United Kingdom; Urinary Bladder Neoplasms | 2017 |
Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Fallopian Tube Neoplasms; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Quality of Life; Topotecan | 2008 |
Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Deoxycytidine; Etoposide; Female; Gemcitabine; Germany; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Proportional Hazards Models; Quality of Life; Survival Rate; Topotecan; Treatment Outcome | 2008 |
[Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Survival Rate | 2008 |
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rat
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Research Design | 2008 |
Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Salvage Therapy | 2008 |
Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate; Taxoids | 2008 |
Liver perfusion chemotherapy with 5-Fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Survival Rate | 2009 |
Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Adenoid Cystic; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Patient Compliance; Treatment Outcome | 2008 |
Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pemetrexed; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Survival Rate | 2008 |
Carboplatin plus gemcitabine repeating doublet therapy in recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local | 2008 |
Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gastrectomy; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tissue Array Analysis; Treatment Outcome; Tumor Suppressor Protein p53; Young Adult | 2007 |
Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Pancreatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma | 2009 |
[A phase I study of combination-therapy with gemcitabine and epitope peptides derived from human vascular endothelial growth factor receptor for unresectable or recurrent pancreas cancer].
Topics: Aged; Antineoplastic Agents; Cancer Vaccines; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Epitopes; Female; Gemcitabine; Humans; Immunotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Peptides; Receptors, Vascular Endothelial Growth Factor | 2008 |
Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Glutamates; Guanine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Pemetrexed; Platinum Compounds; Salvage Therapy; Survival Analysis; Treatment Outcome | 2009 |
Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Gemcitabine; Hodgkin Disease; Humans; Neoplasm Recurrence, Local; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2009 |
Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Deoxycytidine; Dexamethasone; Etoposide; Female; Follow-Up Studies; Gemcitabine; Glucocorticoids; Humans; Immunosuppressive Agents; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Stem Cell Transplantation; Treatment Outcome; Young Adult | 2009 |
Intra-arterial chemotherapy with gemcitabine and cisplatin for patients with recurrence of transitional cell carcinoma confined to the pelvis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Pelvic Neoplasms; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2009 |
Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
Venous thromboembolism in recurrent ovarian cancer-patients: A systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Germany; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Venous Thromboembolism | 2009 |
Gemcitabine, vinorelbine, and Cisplatin in the treatment of advanced nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Promising overall survival of patients with recurrent/metastatic squamous cell carcinoma of head and neck receiving gemcitabine plus cisplatin treatment: report of a multi-center phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis | 2010 |
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Quality of Life; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine; Young Adult | 2009 |
Phase II study of gemcitabine monotherapy as a salvage treatment for Japanese metastatic breast cancer patients after anthracycline and taxane treatment.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Taxoids; Treatment Outcome | 2009 |
Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2010 |
Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Urinary Bladder Neoplasms | 2010 |
Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Survival Analysis; Vinblastine; Vinorelbine | 2010 |
Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Placebos; Prognosis; Survival Rate | 2010 |
Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Transplantation Conditioning; Transplantation, Autologous; Vinblastine; Vinorelbine; Young Adult | 2010 |
A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Salvage Therapy; Taxoids; Treatment Outcome | 2010 |
A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Uterine Neoplasms | 2010 |
Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Blood Coagulation Factors; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Peritoneal Neoplasms; Survival Rate; Treatment Outcome | 2011 |
Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Ribonucleoside Diphosphate Reductase; Survival; Time Factors; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2011 |
Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Dexamethasone; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Multicenter phase 2 study of combined gemcitabine and epirubicin as second-line treatment for patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Italy; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Remission Induction; Survival Analysis; Treatment Outcome | 2010 |
Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Docetaxel; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Michigan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; New Jersey; Perfusion Imaging; Piperazines; Pyrimidines; Taxoids; Time Factors; Treatment Outcome | 2012 |
A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2011 |
Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine | 2010 |
Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2010 |
Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infant; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Young Adult | 2011 |
Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging | 2010 |
Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Platinum; Salvage Therapy; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2011 |
A phase II study of gemcitabine plus paclitaxel in patients with metastatic breast cancer and prior anthracycline treatment.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome | 2010 |
A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Endometrioid; Deoxycytidine; Endometrial Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local | 2011 |
[Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Platinum Compounds; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gamma Rays; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Radiography, Thoracic; Radiotherapy Dosage; Standard of Care; Survival Rate; Treatment Outcome | 2011 |
Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Gemcitabine; Health Status Indicators; Humans; Infusions, Intravenous; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Prospective Studies; Radiotherapy; Squamous Cell Carcinoma of Head and Neck | 2011 |
Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Endometrial Neoplasms; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Polyethylene Glycols; Survival Rate; Tissue Distribution; Treatment Outcome | 2011 |
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome | 2011 |
Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging | 2011 |
Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
Phase I and pharmacokinetic study of IV vinflunine in combination with gemcitabine for treatment of advanced non-small cell lung cancer in Chemonaive patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate; Tissue Distribution; Treatment Outcome; Vinblastine | 2011 |
Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2011 |
Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome | 2011 |
SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Quality of Life; Taxoids; Uterine Cervical Neoplasms | 2011 |
A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Survival Rate; Treatment Outcome | 2011 |
Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Recurrence; Urinary Bladder Neoplasms | 2012 |
[Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2011 |
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arachidonate 5-Lipoxygenase; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2011 |
Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Peripheral Nerves; Prognosis; Prospective Studies; Risk Factors | 2012 |
Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligonucleotides, Antisense; Survival Rate; Thionucleotides; Treatment Outcome | 2012 |
Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate; Young Adult | 2012 |
Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2012 |
Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
Topics: Adolescent; Adult; Aged; Bone Neoplasms; Chondrosarcoma; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Osteosarcoma; Sarcoma, Ewing; Taxoids | 2012 |
A phase 2 study of the combination of gemcitabine and cisplatin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines with/without taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy | 2012 |
Phase II study of gemcitabine and docetaxel in recurrent platinum resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Taxoids | 2012 |
Gemcitabine and paclitaxel combination as second-line chemotherapy in patients with small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Neutropenia; Paclitaxel; Small Cell Lung Carcinoma | 2013 |
Intraperitoneal chemotherapy by ultrasound-guided direct puncture in recurrent ovarian cancer: feasibility, compliance, and complications.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Injections, Intraperitoneal; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Patient Compliance; Pilot Projects; Prospective Studies; Ultrasonography, Interventional | 2012 |
Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Infusions, Intravenous; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Prognosis; Survival Rate; Young Adult | 2013 |
Salvage gemcitabine-vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Risk Factors; Salvage Therapy; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bone Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Efficacy and safety of gemcitabine monotherapy for patients with advanced biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2012 |
Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; France; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Leiomyosarcoma; Lenograstim; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Recombinant Proteins; Taxoids; Uterine Neoplasms | 2012 |
Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Female; Gemcitabine; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Survival Rate; Taxoids | 2012 |
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Research Design; Salvage Therapy; Surveys and Questionnaires | 2012 |
Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prospective Studies; Taxoids; Treatment Outcome; Uterine Neoplasms | 2013 |
Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Diseases; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Life Tables; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome | 2002 |
Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Survival Rate; Treatment Outcome | 2002 |
A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Probability; Survival Analysis; Topotecan; Treatment Failure; Treatment Outcome | 2002 |
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcome | 2003 |
Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quality of Life; Survival Rate; Urologic Neoplasms | 2003 |
[Transarterial chemoperfusion of inoperable pancreas carcinoma and local recurrence].
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intra-Arterial; Magnetic Resonance Imaging; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Quality of Life; Survival Rate; Tomography, X-Ray Computed | 2003 |
Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Prospective Studies; Quality of Life; Survival Analysis; Treatment Outcome; Washington | 2003 |
Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Treatment Outcome | 2003 |
Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Liposomes; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Salvage Therapy; Treatment Outcome | 2003 |
Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate | 2004 |
[Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Pancreatic Neoplasms; Tegafur; Uracil | 2004 |
Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Leiomyosarcoma; Middle Aged; Neoplasm Recurrence, Local; Uterine Neoplasms | 2004 |
Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Germinoma; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Gonadal Tissue; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Salvage Therapy; Treatment Outcome | 2004 |
Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure | 2004 |
Integrating concurrent navelbine and cisplatin to hyperfractionated radiotherapy in locally advanced non-small cell lung cancer patients treated with induction and consolidation chemotherapy: feasibility and activity results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Mastectomy; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Risk Assessment; Survival Analysis; Treatment Outcome | 2004 |
A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2005 |
Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prodrugs; Remission Induction; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Paclitaxel; Radiotherapy Dosage | 2005 |
Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lymphoma; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Analysis; Treatment Outcome | 2005 |
Gemcitabine plus cisplatine and paclitaxel (GCP) in second-line treatment of germ cell tumors (GCT): a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Germinoma; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Testicular Neoplasms; Treatment Outcome | 2005 |
Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Salvage Therapy; Survival Rate | 2005 |
[Changes in tumor marker levels as a predictor of gemcitabine effect on patients with unresectable or recurrent pancreatic cancer].
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2005 |
Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2005 |
Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Constipation; Cyclophosphamide; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Fever; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiotherapy; Survival Rate; Tegafur; Thrombocytopenia; Treatment Outcome; Uracil | 2005 |
Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Urinary Bladder Neoplasms | 2005 |
Gemcitabine in the treatment of advanced head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality of Life; Radiotherapy; Salvage Therapy; Survival Rate; Treatment Outcome | 2005 |
A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan | 2006 |
Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Time Factors; Treatment Outcome | 2005 |
Gemcitabine and paclitaxel in metastatic or recurrent squamous cell carcinoma of the head and neck: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel | 2005 |
Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Croatia; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Risk Assessment; Risk Factors; Survival Rate; Treatment Failure; Treatment Outcome | 2005 |
Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Quality of Life | 2006 |
Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Treatment Failure; Urinary Bladder Neoplasms | 2006 |
Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Uterine Cervical Neoplasms | 2006 |
Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms | 2006 |
Multicenter study on the use of gemcitabine to prevent recurrence of multiple-recurring superficial bladder tumors following intravesical antiblastic agents and/or BCG: evaluation of tolerance.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2006 |
Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Recurrence; Survival Rate; Treatment Outcome | 2006 |
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quality of Life; Survival Analysis; Treatment Outcome | 2006 |
A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Pregnancy; Survival Analysis; Taxoids; Treatment Outcome; Vomiting | 2007 |
Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Risk Factors; Urinary Bladder Neoplasms | 2007 |
Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate | 2007 |
Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Treatment Outcome | 2007 |
Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Survival Rate | 2007 |
A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Survival Rate; Taxoids | 2007 |
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids; Vinblastine; Vinorelbine | 2007 |
A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; California; Cisplatin; Comorbidity; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Incidence; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome | 2007 |
Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate; Treatment Outcome; Vomiting | 2008 |
Phase II study of consolidation chemotherapy after concurrent chemoradiation in cervical cancer: preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Comorbidity; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Incidence; Korea; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2007 |
Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Comorbidity; Deoxycytidine; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Incidence; Male; Michigan; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome | 2007 |
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Male; Mesothelioma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Pleural Neoplasms; Pneumonectomy; Radiation Dosage; Radiotherapy, Adjuvant; Survival Analysis; Thrombocytopenia; Time Factors | 2007 |
Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Rituximab; Salvage Therapy; Survival Rate | 2007 |
Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; CD146 Antigen; Cisplatin; Deoxycytidine; Endothelium, Vascular; Female; Gemcitabine; Glycoproteins; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Peptides; Prognosis; Protein Kinase C; Protein Kinase C beta; RNA, Messenger; Survival Rate | 2007 |
Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Kidney Function Tests; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Urinary Bladder Neoplasms | 2007 |
Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis | 2007 |
Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Pain; Rituximab; Survival Analysis; Treatment Outcome | 2008 |
3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2008 |
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Quality of Life; Treatment Outcome | 2008 |
Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-125 Antigen; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Survival Analysis | 2008 |
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Uterine Neoplasms | 2008 |
Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quality of Life; Survival Rate | 2008 |
Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local | 1993 |
Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Immunosuppression Therapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 1997 |
Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bone Marrow Diseases; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Treatment Outcome | 1998 |
A phase I trial of MTA and gemcitabine in patients with locally advanced or metastatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Enzyme Inhibitors; Female; Folic Acid Antagonists; Gallbladder Neoplasms; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Pemetrexed | 1999 |
A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Uterine Cervical Neoplasms | 2000 |
Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Bone Neoplasms; Chondrosarcoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Middle Aged; Neoplasm Recurrence, Local; Osteosarcoma; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 2000 |
Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Pilot Projects; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Deoxycytidine; Female; Gemcitabine; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Steroids | 2000 |
Gemcitabine and vinorelbine in pretreated advanced breast cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Gemcitabine is ineffective in recurrent, preirradiated cervical cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Uterine Cervical Neoplasms | 2000 |
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Weekly cisplatin/low-dose gemcitabine combination for advanced and recurrent cervical carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Uterine Cervical Neoplasms | 2001 |
Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Patient Compliance; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Deoxycytidine; Drug Evaluation; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Ribonucleotide Reductases; Survival Rate | 2001 |
Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms | 2001 |
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Platinum; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2001 |
The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: a Southwest Oncology Group study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local | 2002 |
361 other study(ies) available for gemcitabine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Survival Outcomes of Gemcitabine Plus S-1 Adjuvant Chemotherapy after Surgical Resection for Advanced Biliary Tract Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Klatskin Tumor; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Propensity Score; Survival Rate; Tegafur | 2021 |
Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2021 |
Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle invasive Bladder Cancer: Con.
Topics: BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2022 |
Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.
Topics: Animals; B7-H1 Antigen; Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Mice; Neoplasm Recurrence, Local; Programmed Cell Death 1 Receptor; Transforming Growth Factor beta; Tumor Microenvironment | 2022 |
Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis.
Topics: Carcinoma; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy, Intensity-Modulated; Retrospective Studies; Taxoids; Treatment Outcome | 2022 |
Effectiveness and safety of R-GCD (rituximab, gemcitabine, carboplatin, and dexamethasone) for transplant-ineligible relapse/refractory diffuse large B-cell lymphoma and grade 3a follicular lymphoma: a retrospective analysis comparing with R-GDP (rituxima
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Dexamethasone; Gemcitabine; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab; Salvage Therapy | 2022 |
Durable remission for four pediatric patients with high-risk relapsed classical Hodgkin lymphoma treated with brentuximab vedotin plus gemcitabine but without autologous stem cell transplantation: A report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Child; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous | 2022 |
Molecular classification of patients with NMIBC predicts the efficacy of intravesical chemotherapy with pirarubicin, pharmorubicin and gemcitabine-immunohistochemistry-based classification.
Topics: Administration, Intravesical; Anthracyclines; Antibiotics, Antineoplastic; Deoxycytidine; Doxorubicin; Epirubicin; Gemcitabine; Humans; Immunohistochemistry; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2022 |
Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine Treatment.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Endothelial Cells; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Humans; Mice; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2022 |
Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome | 2022 |
Gemcitabine Combined with Cisplatin Has a Better Effect in the Treatment of Recurrent/Metastatic Advanced Nasopharyngeal Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Quality of Life; Retrospective Studies; Treatment Outcome | 2022 |
Biodegradable gemcitabine-loaded microdevice with sustained local drug delivery and improved tumor recurrence inhibition abilities for postoperative pancreatic tumor treatment.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Lactic Acid; Mice; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Polyethylene Glycols | 2022 |
Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study.
Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Quality of Life; Urinary Bladder Neoplasms | 2022 |
Serum IL-6 level is associated with clinical outcome of intravesical gemcitabine therapy in T1 non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Deoxycytidine; Gemcitabine; Humans; Interleukin-6; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Bacillus; BCG Vaccine; Carcinoma in Situ; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Retrospective Analysis of the Efficacy and Tolerability of Gemcitabine-Based Chemotherapy in Relapsed/Refractory Lymphoma Patients Not Eligible for Stem Cell Transplant.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dexamethasone; Gemcitabine; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab; Stem Cell Transplantation | 2022 |
Gemcitabine, Cisplatin, and Dexamethasone as a Salvage and Mobilization Chemotherapy Before Autologous Stem Cell Transplantation is Effective and Safe Outpatient Regimen in Relapsed and Refractory Hodgkin Lymphoma Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Neoplasm Recurrence, Local; Outpatients; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous | 2022 |
Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Circulating Tumor DNA; Clinical Trials as Topic; Deoxycytidine; Endothelial Growth Factors; Gemcitabine; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Necrosis; Neoplasm Recurrence, Local; Pyridines | 2022 |
Re: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Bacillus; BCG Vaccine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2022 |
The Prognostic Utility of a Geriatric Assessment for Patients with Pancreatic Cancer Receiving Gemcitabine-based Chemotherapy: A Prospective Observational Study.
Topics: Activities of Daily Living; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Gemcitabine; Geriatric Assessment; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Prognosis | 2023 |
Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nivolumab; Prospective Studies; Urinary Bladder; Urinary Bladder Neoplasms | 2023 |
Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous cell carcinoma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Treatment Outcome | 2023 |
Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; BCG Vaccine; Docetaxel; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Non-Muscle Invasive Bladder Neoplasms; Retrospective Studies; Salvage Therapy; Urinary Bladder Neoplasms | 2023 |
Cancer Antigen 125 Expression Enhances the Gemcitabine/Cisplatin-Resistant Tumor Microenvironment in Bladder Cancer.
Topics: Biomarkers, Tumor; CA-125 Antigen; Cisplatin; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mucins; Neoplasm Recurrence, Local; Tumor Microenvironment; Urinary Bladder Neoplasms | 2023 |
Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy Protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
[A Case of an Advanced Intrahepatic Cholangiocarcinoma Effectively Treated by Conversion Surgery after Neoadjuvant Chemotherapy of Gemcitabine, Cisplatin and S-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography | 2022 |
Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T-cell lymphoma: A French retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Dexamethasone; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Methotrexate; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome | 2023 |
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
The application of gemcitabine and pirarubicin in patients with non-muscle invasive bladder cancer.
Topics: Administration, Intravesical; Gemcitabine; Hematuria; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Non-Muscle Invasive Bladder Neoplasms; Urinary Bladder Neoplasms | 2023 |
Combinatorial immunotherapy with gemcitabine and ex vivo-expanded NK cells induces anti-tumor effects in pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Gemcitabine; Humans; Immunotherapy; Killer Cells, Natural; Leukocytes, Mononuclear; Mice; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2023 |
Treatment of primary or recurrent non-resectable pancreatic cancer with proton beam irradiation combined with gemcitabine-based chemotherapy.
Topics: Gastrointestinal Diseases; Gemcitabine; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Proton Therapy; Protons | 2023 |
Comparison of the effectiveness of liposomal doxorubicin and gemcitabine in patients with platinum-sensitive recurrent ovarian cancer receiving third-line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Quality of Life; Reproducibility of Results; Retrospective Studies | 2023 |
Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy.
Topics: Aged; BCG Vaccine; Docetaxel; Gemcitabine; Humans; Neoplasm Recurrence, Local; Non-Muscle Invasive Bladder Neoplasms; Prospective Studies; Retrospective Studies; Urinary Bladder Neoplasms | 2023 |
Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2019 |
[A Case of an Elderly Patient with Multiple Lung Metastases of Postoperative Pancreatic Cancer in Whom Lung Metastases Were Controlled by Biweekly Dose-Down Administration of Gemcitabine].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms | 2019 |
Metabolomic profiling identifies novel biomarkers and mechanisms in human bladder cancer treated with submucosal injection of gemcitabine.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Metabolic Networks and Pathways; Metabolome; Metabolomics; Middle Aged; Neoplasm Recurrence, Local; Principal Component Analysis; Urinary Bladder; Urinary Bladder Neoplasms | 2019 |
Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines | 2019 |
Comparison of gemcitabine and anthracycline antibiotics in prevention of superficial bladder cancer recurrence.
Topics: Aged; Anthracyclines; Antineoplastic Agents; Deoxycytidine; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2019 |
Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2019 |
Gemcitabine, paclitaxel, and oxaliplatin (GEMPOX) in the treatment of relapsed/refractory intracranial nongerminomatous germ cell tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Oxaliplatin; Paclitaxel; Prognosis; Salvage Therapy; Testicular Neoplasms | 2020 |
Pralatrexate Induces Long-Term Remission in Relapsed Subcutaneous Panniculitis-Like T-Cell Lymphoma.
Topics: Adult; Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Cyclophosphamide; Deoxycytidine; Dexamethasone; Doxorubicin; Folic Acid Antagonists; Gemcitabine; Humans; Lymphohistiocytosis, Hemophagocytic; Lymphoma, T-Cell, Peripheral; Male; Neoplasm Recurrence, Local; Panniculitis; Prednisone; Remission Induction; Subcutaneous Fat, Abdominal; Vincristine | 2019 |
Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer - A multi-institutional clinical study in Asia.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Electroporation; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Proportional Hazards Models; Pyridines; Tegafur; Young Adult | 2020 |
Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Infant; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Oxaliplatin; Paclitaxel; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate | 2020 |
Drug-loaded implantable surgical cavity-adaptive hydrogels for prevention of local tumor recurrence.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line; Cell Line, Tumor; Chitosan; Delayed-Action Preparations; Deoxycytidine; Doxorubicin; Drug Implants; Drug Synergism; Female; Gemcitabine; Hyaluronic Acid; Hydrogels; Mice; Mice, Inbred BALB C; Neoplasm Recurrence, Local; Xenograft Model Antitumor Assays | 2020 |
The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Young Adult | 2020 |
Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Drug Resistance, Neoplasm; Evidence-Based Medicine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2020 |
[A Case of Liver Metastases of Ampullary Carcinoma with Clinical Complete Response Treated with Gemcitabine plus Cisplatin].
Topics: Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Treatment Outcome | 2019 |
Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Disease Progression; Drug Monitoring; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Predictive Value of Tests; Prognosis; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor B | 2020 |
Recurrent Bladder Cancer in a Teenage Male.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adolescent; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Cystectomy; Cystoscopy; Deoxycytidine; Gemcitabine; Humans; Male; Monitoring, Physiologic; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
De novo perihilar cholangiocarcinoma arising in the allograft liver 15 years post-transplantation for biliary atresia.
Topics: Adenocarcinoma; Allografts; Bile Duct Neoplasms; Biliary Atresia; Child; Cholangiocarcinoma; Cisplatin; Constriction, Pathologic; Deoxycytidine; Female; Gemcitabine; Humans; Immunosuppressive Agents; Liver; Liver Transplantation; Neoplasm Recurrence, Local; Postoperative Complications; Young Adult | 2020 |
Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Depsipeptides; Gemcitabine; Humans; MAP Kinase Signaling System; Mice; Neoplasm Recurrence, Local; Reactive Oxygen Species; Urinary Bladder Neoplasms; Urothelium; Xenograft Model Antitumor Assays | 2020 |
Editorial Comment.
Topics: BCG Vaccine; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Taxoids; Urinary Bladder | 2020 |
[Neoajuvant Chemotherapy with Gemcitabine and Cisplatin Plus S-1 for Primary Female Urethral Adenocarcinoma].
Topics: Adenocarcinoma; Aged; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Urethra; Urethral Neoplasms; Urinary Bladder Neoplasms | 2020 |
Clinical implications of the serum CA19-9 level in "biological borderline resectability" and "biological downstaging" in the setting of preoperative chemoradiation therapy for pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; CA-19-9 Antigen; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Incidence; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Preoperative Care; Radiation-Sensitizing Agents; Survival Analysis | 2020 |
Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B7-H1 Antigen; Carcinoma, Lewis Lung; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Synergism; Gemcitabine; Immune Checkpoint Inhibitors; Lymphocytes, Tumor-Infiltrating; Mice, Inbred C57BL; Neoplasm Recurrence, Local; Programmed Cell Death 1 Receptor; Tumor Microenvironment; Up-Regulation | 2020 |
Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Confidence Intervals; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Retrospective Studies | 2021 |
Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Topics: Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2020 |
Response rates, long term outcomes and toxicity profile of gemcitabine and vinorelbine based outpatient chemotherapy regimen in primary progressive and relapsed childhood Hodgkin lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Gemcitabine; Hodgkin Disease; Humans; Neoplasm Recurrence, Local; Outpatients; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vinorelbine | 2020 |
Clinical benefits of adjuvant chemotherapy with carboplatin and gemcitabine in patients with non-small cell lung cancer: a single-center retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies | 2020 |
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan | 2020 |
Efficacy and toxicity of pegylated liposomal doxorubicin as therapy for recurrent ovarian cancer in relation to the number of previous chemotherapy regimens: Comparison with gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Retrospective Studies | 2021 |
Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 2021 |
Galactosyltransferase B4GALT1 confers chemoresistance in pancreatic ductal adenocarcinomas by upregulating N-linked glycosylation of CDK11
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Deoxycytidine; Drug Resistance, Neoplasm; Galactosyltransferases; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycosylation; Humans; Neoplasm Recurrence, Local; Organoids; Transcription Factor RelA | 2021 |
Chemotherapy for biliary tract cancer: real-world experience in a single institute.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Practice Patterns, Physicians'; Progression-Free Survival; Retrospective Studies | 2020 |
The age-adjusted Charlson comorbidity index is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuvant chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Comorbidity; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Risk Assessment; Risk Factors; Survival Rate | 2020 |
FDA Approves Pembrolizumab + Chemotherapy Combination for Locally Recurrent Unresectable or Metastatic TNBC.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Double-Blind Method; Drug Approval; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms; United States; United States Food and Drug Administration | 2020 |
[Nab-Paclitaxel plus Gemcitabine for Patients with Recurrence after Resection for Adenocarcinoma of the Pancreas].
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreas; Pancreatic Neoplasms | 2021 |
[A Case of Ipsilateral Breast Tumor Recurrence(IBTR)after Breast-Conserving Surgery Which Successfully Resected after Chemotherapy Using Carboplatin plus Gemcitabine].
Topics: Adult; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Mastectomy; Mastectomy, Segmental; Neoplasm Recurrence, Local | 2020 |
Gemcitabine-Containing Chemotherapy for the Treatment of Metastatic Myxofibrosarcoma Refractory to Doxorubicin: A Case Series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Neoplasm Recurrence, Local; Retrospective Studies | 2021 |
Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Gene Expression Profiling; Humans; Laminin; Male; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2021 |
[Clinical Application of Gemcitabine plus Cisplatin plus Bevacizumab Combination Chemotherapy for Ovarian Clear Cell Carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2021 |
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Retrospective Studies; Tegafur | 2021 |
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Internationality; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Risk Factors; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 2021 |
Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Propensity Score; Retrospective Studies; Treatment Outcome | 2021 |
Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Young Adult | 2021 |
A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Depsipeptides; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Reactive Oxygen Species; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Antineoplastic Agents; BCG Vaccine; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Interferon alpha-2; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Treatment Outcome; Urinary Bladder Neoplasms | 2022 |
Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Middle Aged; Neoplasm Recurrence, Local; Organ Sparing Treatments; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Peripheral Nerves; Retrospective Studies; Survival Rate; Tegafur | 2021 |
[A Rare Case of Non-small Cell Lung Carcinoma Squamous Phenotype with Epstein-Barr Virus Positivity with Prolonged Response to both Chemotherapy and Radiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Antitubercular Agents; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Epstein-Barr Virus Infections; Female; Gemcitabine; Herpesvirus 4, Human; Humans; Lung Neoplasms; Lupus Erythematosus, Systemic; Middle Aged; Neck Dissection; Neoplasm Recurrence, Local; Radiotherapy; Tuberculosis, Pulmonary | 2021 |
Concurrent Chemotherapy Improves the Overall Survival of Patients Irradiated for Locally Recurrent Bladder Cancer.
Topics: Aged; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Demography; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Polyethylene Glycols; Prognosis | 2017 |
Comparison of Efficacy of Adjuvant MEC (Methotrexate, Epirubicin and Cisplatin) and GC (Gemcitabine and Cisplatin) in Advanced Upper Tract Urothelial Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Risk Factors; Survival Rate; Urologic Neoplasms | 2017 |
Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2017 |
Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.
Topics: Aged; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Mutation; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Proto-Oncogene Proteins p21(ras); Translational Research, Biomedical | 2017 |
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Topotecan | 2017 |
Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Kaplan-Meier Estimate; Leukopenia; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Postoperative Period | 2017 |
Exosomes derived from gemcitabine-resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p.
Topics: 3' Untranslated Regions; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Exosomes; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Mice, SCID; MicroRNAs; Middle Aged; Neoplasm Recurrence, Local | 2017 |
Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: Trends and survival outcomes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Retrospective Studies; Taxoids; Uterine Neoplasms | 2017 |
Synergistic effect of a drug loaded electrospun patch and systemic chemotherapy in pancreatic cancer xenograft.
Topics: Administration, Cutaneous; Animals; Antineoplastic Combined Chemotherapy Protocols; Biocompatible Materials; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Liberation; Fluorouracil; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Polyesters; Survival Rate; Transdermal Patch; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Costs; European Union; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic; Survival Rate; Tetrahydroisoquinolines; Trabectedin | 2017 |
Prognostic Factors and Patterns of Locoregional Failure After Surgical Resection in Patients With Cholangiocarcinoma Without Adjuvant Radiation Therapy: Optimal Field Design for Adjuvant Radiation Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Confidence Intervals; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Time Factors | 2017 |
Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Killer Cells, Natural; Lymphocyte Activation; Mice; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Perioperative Care; Prognosis; Survival Rate; Tumor Cells, Cultured | 2018 |
Re-irradiation with 36 Gy (1.5 Gy Twice Daily) Plus Paclitaxel for Advanced Recurrent and Previously Irradiated SCCHN is Feasible.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Re-Irradiation; Squamous Cell Carcinoma of Head and Neck | 2018 |
Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Janus Kinase 1; Mice; Mice, Nude; Neoplasm Recurrence, Local; Pancreatic Neoplasms; STAT Transcription Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Survival Rate | 2018 |
Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Recurrence, Local; Paclitaxel; Poly (ADP-Ribose) Polymerase-1; Xenograft Model Antitumor Assays | 2018 |
Follicular dendritic cell sarcoma of the porta hepatis.
Topics: Abdominal Pain; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Biomarkers, Tumor; Cholangiopancreatography, Endoscopic Retrograde; Dendritic Cell Sarcoma, Follicular; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2018 |
The effects of intra-arterial chemotherapy on bladder preservation in patients with T1 stage bladder cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; China; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Injections, Intra-Arterial; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organ Sparing Treatments; Progression-Free Survival; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2018 |
The Combination of Gemcitabine, Cisplatin, and Paclitaxel as Salvage Chemotherapy for Advanced Urothelial Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Salvage Therapy; Treatment Outcome; Urologic Neoplasms | 2018 |
[Pulmonary Pleomorphic Carcinoma Relapsed after Surgery Surviving Long-term by Chemotherapy and Nivolumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab | 2018 |
The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Precision Medicine; Retrospective Studies; Risk Factors; Survival Rate; Tegafur | 2018 |
Gemcitabine reduces recurrence.
Topics: Administration, Intravesical; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2018 |
Commentary on "A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy-A single-institution experience."
Topics: BCG Vaccine; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2018 |
Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Retreatment; Retrospective Studies; Survival Rate; Topotecan | 2017 |
Hypoxia-Induced PLOD2 is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Male; Neoplasm Recurrence, Local; Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase; Prognosis; Survival Rate | 2018 |
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cystadenocarcinoma, Serous; Deoxycytidine; DNA Repair; DNA Replication; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Culture Techniques; Organoids; Ovarian Neoplasms; Prognosis; Pyrazines; Pyrazoles | 2018 |
Overall survival in patients with relapsed/refractory high grade B-cell lymphomas treated with gemcitabine, oxaliplatin with or without rituximab.
Topics: Deoxycytidine; Gemcitabine; Humans; Lymphoma, B-Cell; Neoplasm Recurrence, Local; Oxaliplatin; Retrospective Studies; Rituximab | 2019 |
Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Platelets; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Inflammation; Liver Neoplasms; Lymphatic Metastasis; Lymphocytes; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neutrophils; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-grade Non-muscle-invasive Bladder Cancer on Tumor Recurrence.
Topics: Administration, Intravesical; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2019 |
[Adjuvant chemotherapy with cisplatin and gemcitabine after radiochemotherapy with curative intent does not improve relapse-free survival in nasopharyngeal cancer patients with persistently detectable EBV DNA].
Topics: Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; DNA; Gemcitabine; Herpesvirus 4, Human; Humans; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local | 2019 |
Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; GTP Phosphohydrolases; Humans; Male; Membrane Proteins; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Radiotherapy; Reoperation; Retrospective Studies; Survival Rate | 2019 |
Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Target Volume Design.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Celiac Artery; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Mesenteric Artery, Superior; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiosurgery; Radiotherapy Dosage; Splenic Artery; Time Factors; Treatment Failure; Tumor Burden | 2019 |
[A Case of Pathological Complete Response Induced by Preoperative Chemotherapy with Gemcitabine plus Nab-Paclitaxel in a Patient with Pancreatic Cancer on Hemodialysis].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Renal Dialysis | 2018 |
[A Case of Long-Term Survival of a Patient with Cholangiocarcinoma and Liver Metastatic Recurrence Who Responded to Gemcitabine plus Cisplatin Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Neoplasm Recurrence, Local | 2018 |
[Treatment Outcomes of Gemcitabine and Cisplatin Combination Therapy for Unresectable and Recurrent Biliary Tract Cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Treatment Outcome | 2018 |
Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: .
Topics: Administration, Intravesical; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2019 |
[Postoperative Recurrence of Pancreatic Cancer Successfully Treated with the Gemcitabine plus Oxaliplatin Regimen Resulting in Long-Term Survival-ACase Report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms | 2019 |
Current Real-Life Results and Future Options of Gemcitabine-Based Salvage Therapy for Relapsed or Refractory Non-Hodgkin Lymphoma.
Topics: Deoxycytidine; Gemcitabine; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Salvage Therapy | 2019 |
Topics: Animals; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Copper Radioisotopes; Deoxycytidine; Disease Models, Animal; ErbB Receptors; Female; Gemcitabine; HCT116 Cells; Humans; Injections, Intraperitoneal; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Pancreatic Neoplasms; Radioimmunotherapy; Radiotherapy, Adjuvant; Treatment Outcome | 2019 |
[A Case of Liver Metastasis of Intrahepatic Cholangiocarcinoma That Achieved Clinical Complete Response after Gemcitabine and Cisplatin Combination Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local | 2019 |
Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Longitudinal Studies; Models, Statistical; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate | 2019 |
Impact of adjuvant chemotherapy on oncologic outcomes following radical nephroureterectomy for patients with pT3NanyM0 upper tract urothelial carcinoma: A retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Nephroureterectomy; Proportional Hazards Models; Retrospective Studies; Urologic Neoplasms | 2019 |
Degree of
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Gene Amplification; Humans; Liposarcoma; Mice; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Proto-Oncogene Proteins c-mdm2; Retrospective Studies; Surgical Procedures, Operative; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Nivolumab with gemcitabine plus cisplatin for biliary cancers: as easy as ABC?
Topics: Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Japan; Neoplasm Recurrence, Local; Nivolumab | 2019 |
[A Case of Boderline Resectable Pancreatic Cancer Curatively Resected after Chemotherapy with Gemcitabine and Nab-Paclitaxel].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms | 2019 |
Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Health Care Costs; Humans; Male; Markov Chains; Multicenter Studies as Topic; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic | 2019 |
The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Heterografts; Humans; Indazoles; Liposarcoma; Male; Mice; Mice, Nude; Neoplasm Recurrence, Local; Pyrimidines; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Chemotherapy, Adjuvant; Circulating Tumor DNA; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liquid Biopsy; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins p21(ras) | 2019 |
Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Topotecan; Treatment Outcome; Young Adult | 2019 |
The efficacy of drug-eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Bronchial Arteries; Carcinoma, Non-Small-Cell Lung; Chemoembolization, Therapeutic; Deoxycytidine; Drug Delivery Systems; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer.
Topics: Animals; Antineoplastic Agents, Immunological; B7-H1 Antigen; Cell Line, Tumor; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Margins of Excision; Mice; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Random Allocation; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Gastropleural fistula in a patient with recurrent ovarian cancer receiving combination therapy with Carboplatin, gemcitabine, and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Female; Gastric Fistula; Gemcitabine; Humans; Intestinal Fistula; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms | 2013 |
A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Receptors, Calcitriol; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Complete remission of recurrent and refractory ovarian cancers using weekly administration of bevacizumab and gemcitabine/oxaliplatin: report of two cases.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin | 2013 |
Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cerebellar Neoplasms; Child; Child, Preschool; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Medulloblastoma; Melphalan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Quality of Life; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Young Adult | 2013 |
Effect of a novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen).
Topics: Adult; Aged; Aged, 80 and over; Balloon Occlusion; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Urinary Bladder; Urinary Bladder Neoplasms | 2013 |
Intraarterial chemotherapy with gemcitabine and cisplatin in locally advanced or recurrent penile squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intra-Arterial; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Penile Neoplasms; Survival Rate | 2013 |
Salvage therapy of gemcitabine plus endostar significantly improves progression-free survival (PFS) with platinum-resistant recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endostatins; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis; Recombinant Proteins; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
Current therapy and future directions in biliary tract malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Retrospective Studies | 2013 |
Adjuvant gemcitabine therapy improves survival in a locally induced, R0-resectable model of metastatic intrahepatic cholangiocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Gemcitabine; Hepatectomy; Mice; Mice, Inbred Strains; Mice, Knockout; Neoplasm Recurrence, Local; Proto-Oncogene Proteins p21(ras); Risk Factors; Survival Rate; Tumor Suppressor Protein p53 | 2013 |
Gemcitabine in patients with intraductal papillary mucinous neoplasm with an associated invasive carcinoma of the pancreas.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Time Factors; Treatment Outcome | 2013 |
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Genital Neoplasms, Female; Humans; Irinotecan; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Exenteration; Prognosis; Retrospective Studies; Survival Rate; Topotecan | 2013 |
NICE guidance on bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Practice Guidelines as Topic; Quality-Adjusted Life Years; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins | 2013 |
Aggressive secondary surgery for local recurrence of pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Reoperation; Tomography, X-Ray Computed | 2013 |
Gemcitabine with paclitaxel therapy against mesocolic leiomyosarcoma: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Leiomyosarcoma; Male; Mesocolon; Neoplasm Recurrence, Local; Paclitaxel; Prognosis | 2013 |
Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analgesics; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiosurgery | 2013 |
Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carboplatin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients?
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Medullary; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate | 2013 |
The safety and efficacy of cisplatin plus gemcitabine in recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms | 2014 |
A great option for elderly patients with locally invasive bladder cancer, BOAI-CDDP-radiation (OMC regimen).
Topics: Age Factors; Aged; Aged, 80 and over; Balloon Occlusion; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Radiotherapy Dosage; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Retrospective Studies; Taxoids; Uterine Neoplasms | 2013 |
Erlotinib-induced thrombocytosis in patients with recurrence of pancreatic cancer after distal pancreatectomy.
Topics: Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Platelet Count; Quinazolines; Splenectomy; Thrombocytosis | 2013 |
USANZ: Time-trends in use and impact on outcomes of perioperative chemotherapy in patients treated with radical cystectomy for urothelial bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Odds Ratio; Perioperative Period; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2013 |
The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies | 2014 |
Bevacizumab-induced transient sixth nerve palsy in ovarian cancer: A case report.
Topics: Abducens Nerve Diseases; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2016 |
Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Sarcoma; Survival Rate; Young Adult | 2013 |
Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer.
Topics: 4-Quinolones; Aniline Compounds; Animals; Antimetabolites, Antineoplastic; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Gemcitabine and Cisplatin followed by chemo-radiation for advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2014 |
Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Prolonged disease-free interval associated with favorable prognosis.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pain Measurement; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage; Tegafur | 2014 |
Salvage chemotherapy with gemcitabine plus oxaliplatin for patients with testicular germ cell cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Testicular Neoplasms | 2014 |
A study of gemcitabine, l-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Deoxycytidine; Dexamethasone; Etoposide; Gemcitabine; Humans; Ifosfamide; Lymphoma, Extranodal NK-T-Cell; Neoplasm Recurrence, Local; Treatment Outcome | 2014 |
The novel bladder preservation therapy BOAI-CDDP-radiation (OMC-regimen): a new treatment option for invasive bladder cancer patients with lymph node metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Balloon Occlusion; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Renal Dialysis; Urinary Bladder Neoplasms | 2014 |
[Outcomes of treatment of 32 cases of advanced or relapsed post-surgery pulmonary sarcomatoid carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Postoperative Period; Survival Rate | 2014 |
Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cisplatin; Cohort Studies; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Polyethylene Glycols; Recurrence; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2014 |
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2015 |
Treatment outcomes of gemcitabine in refractory or recurrent epithelial ovarian cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Treatment Outcome | 2014 |
[Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Leiomyosarcoma; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Sarcoma; Taxoids; Treatment Outcome | 2014 |
Efficacy of permanent iodine-125 seed implants and gemcitabine chemotherapy in patients with platinum- resistant recurrent ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Brachytherapy; Chemoradiotherapy; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Tomography, X-Ray Computed | 2014 |
Poor outcomes after liver transplantation in patients with incidental cholangiocarcinoma irrespective of tumor localization.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Calcineurin Inhibitors; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Incidental Findings; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Prognosis; Sirolimus; Survival Analysis; Treatment Outcome | 2014 |
Long-term complete response in a patient with disseminated pulmonary pleomorphic carcinoma induced by cisplatin and gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction | 2014 |
Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: impact of splenic vessels involvement on operative outcome and pattern of recurrence.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Splenic Artery; Splenic Vein | 2015 |
Differences in the recurrence pattern after neoadjuvant chemotherapy compared to surgery alone in patients with muscle-invasive bladder cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 2015 |
Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Young Adult | 2014 |
Prognostic score for recurrence after Whipple's pancreaticoduodenectomy for ampullary carcinomas; results of an AGEO retrospective multicenter cohort.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Health Status; Humans; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Pancreaticoduodenectomy; Retrospective Studies; Risk Assessment; Survival Rate | 2015 |
Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Outcome of recurrent uterine papillary serous carcinoma treated with platinum-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome; Uterine Neoplasms | 2015 |
Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Failure | 2015 |
Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Differentiation; Cell Growth Processes; Deoxycytidine; Gemcitabine; Humans; Hyaluronan Receptors; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Recurrence; Xenograft Model Antitumor Assays | 2015 |
A retrospective clinical study of bevacizumab combined with gemcibabine or paclitaxel in the treatment of recurrent ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Transitional Cell; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Platinum Compounds; Pleural Neoplasms; Pneumonectomy; Predictive Value of Tests; Proportional Hazards Models; Ribonucleoside Diphosphate Reductase; Risk Factors; Time Factors; Tissue Array Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
Salvage therapy with gemcitabine, vinorelbine, and pegylated liposomal doxorubicin for relapsed or refractory pediatric Hodgkin lymphoma. Results of a retrospective series of four children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Neoplasm Recurrence, Local; Polyethylene Glycols; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate | 2015 |
Recurrence 11 years after complete response to gemcitabine, 5-Fluorouracil, and Cisplatin chemotherapy followed by radiotherapy in a patient with advanced pancreatic cancer: a case report.
Topics: Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2015 |
Analysis on clinical characteristics and influencing factors of patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Risk Factors | 2015 |
Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Radiography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate; Taxoids; Topotecan; Young Adult | 2015 |
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Child; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Prognosis; Retroperitoneal Neoplasms; Salvage Therapy; Survival Rate; Testicular Neoplasms; Transplantation, Autologous; Young Adult | 2015 |
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Time Factors; Topotecan | 2015 |
Application of a patient-derived xenograft model in cytolytic viral activation therapy for nasopharyngeal carcinoma.
Topics: Animals; Anticonvulsants; Antimetabolites, Antineoplastic; Antiviral Agents; Apoptosis; Carcinoma; Cell Proliferation; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Epstein-Barr Virus Infections; Ganciclovir; Gemcitabine; Gene Expression Profiling; Herpesvirus 4, Human; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Inbred NOD; Mice, SCID; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Oncolytic Virotherapy; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Valproic Acid; Viral Load; Virus Activation; Xenograft Model Antitumor Assays | 2015 |
Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Cisplatin; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Membrane Transport Proteins; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins | 2015 |
Resection of metachronous pancreatic cancer 4 years after pancreaticoduodenectomy for stage III pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Second Primary; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis | 2015 |
Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Monitoring; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2015 |
The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cystadenocarcinoma, Serous; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
Gemcitabine and Docetaxel Compared With Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Leiomyosarcoma; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Taxoids; Uterine Neoplasms | 2016 |
Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreas, Exocrine; Pancreatectomy; Pancreatic Neoplasms; Postoperative Care; Propensity Score; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Retrospective Studies | 2016 |
GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Humans; Lymphoma, T-Cell; Male; Middle Aged; Natural Killer T-Cells; Neoplasm Recurrence, Local; Neoplasm Staging; Nose Neoplasms; Retrospective Studies; Treatment Outcome | 2016 |
Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Quality-Adjusted Life Years; Salvage Therapy; Survival Rate; Topotecan | 2016 |
Gemcitabine-Induced Subacute Cutaneous Lupus Erythematosus: A Case Report.
Topics: Administration, Oral; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Lupus Erythematosus, Cutaneous; Lymph Nodes; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Positron Emission Tomography Computed Tomography; Prednisone; Skin; Treatment Outcome | 2016 |
Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Deoxycytidine; Deoxycytidine Kinase; ELAV-Like Protein 1; Female; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nuclear Proteins; Ovarian Neoplasms; Protein Transport; Protein-Tyrosine Kinases; Retrospective Studies | 2016 |
[Effective palliative chemotherapy in a patient with collecting duct carcinoma of a unilateral kidney associated with anuria. Case report].
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Anuria; Carcinoma, Renal Cell; Cisplatin; Creatinine; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hematuria; Humans; Kidney Neoplasms; Kidney Tubules, Collecting; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nephrectomy; Palliative Care; Renal Dialysis; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Prospective Study Delivering Simultaneous Integrated High-dose Tumor Boost (≤70 Gy) With Image Guided Adaptive Radiation Therapy for Radical Treatment of Localized Muscle-Invasive Bladder Cancer.
Topics: Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Feasibility Studies; Follow-Up Studies; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Sparing Treatments; Organs at Risk; Prospective Studies; Radiation Injuries; Radiation-Sensitizing Agents; Radiography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms | 2016 |
Adenocarcinoma of the ampulla of Vater metastasising into the right ventricle.
Topics: Adenocarcinoma; Adult; Albumins; Ampulla of Vater; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Female; Gemcitabine; Heart Neoplasms; Heart Ventricles; Humans; Neoplasm Recurrence, Local; Paclitaxel | 2016 |
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone.
Topics: Adolescent; Adult; Aged; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Osteosarcoma; Recurrence; Sarcoma; Taxoids; Treatment Outcome | 2016 |
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Busulfan; Child; Deoxycytidine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Follow-Up Studies; Gemcitabine; Humans; Hydroxamic Acids; Lymphoma; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Vorinostat; Young Adult | 2016 |
Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells.
Topics: Animals; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Gemcitabine; Killer Cells, Natural; Mice; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt | 2016 |
Gemcitabine-oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum | 2016 |
Primary Poorly Differentiated Squamous Cell Carcinoma of the Extrahepatic Bile Duct.
Topics: Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local | 2016 |
Repeated Hepatectomy for Recurrent Intrahepatic Cholangiolocellular Carcinoma: Report of a Case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Reoperation; Survival; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Killer Cells, Natural; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2016 |
Repeated iodine-125 seed implantations combined with external beam radiotherapy for the treatment of locally recurrent or metastatic stage III/IV non-small cell lung cancer: a retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Radiotherapy; Radiotherapy Dosage; Remission Induction; Retrospective Studies; Treatment Outcome | 2016 |
Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2017 |
Combination of 125I brachytherapy and chemotherapy for unresectable recurrent breast cancer: A retrospective control study.
Topics: Aged; Antimetabolites, Antineoplastic; Brachytherapy; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Iodine Radioisotopes; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies | 2016 |
Response to and toxicity of gemcitabine for recurrent ovarian cancer according to number of previous chemotherapy regimens.
Topics: Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Ovarian Neoplasms | 2017 |
Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Outcome; Young Adult | 2017 |
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Drug Hypersensitivity; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Retrospective Studies | 2017 |
Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Carboplatin; Cyclophosphamide; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Niacinamide; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult | 2017 |
Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Health Surveys; Humans; Japan; Leiomyosarcoma; Lymph Node Excision; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Taxoids; Uterine Neoplasms | 2017 |
Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Tomography, X-Ray Computed | 2008 |
Gemcitabine pulmonary toxicity in ovarian cancer.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Papillary; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Palliative Care; Pneumonia | 2008 |
Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids; Topotecan | 2008 |
Long-term effects of multimodal treatment for patients with resectable carcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Time Factors | 2008 |
Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy.
Topics: Adenocarcinoma; Aged; Annexin A2; Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Adenosquamous; Carcinoma, Pancreatic Ductal; Cell Survival; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survival Rate; Tumor Cells, Cultured | 2008 |
Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Carboplatin; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies | 2008 |
Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiotherapy; Retrospective Studies; Survival Analysis | 2009 |
[Feasibility and response of gemcitabine and carboplatin biweekly combination chemotherapy for patients with postoperative recurrence non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Time Factors | 2009 |
Adjuvant chemoradiotherapy for high-risk pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Membrane Transport Proteins; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2009 |
Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease Progression; Endometrial Neoplasms; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Glucocorticoids; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy | 2009 |
[Local recurrence after surgical resection of pancreatic cancer effectively treated with combined chemoradiotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur; Uracil | 2009 |
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Fluorescent Antibody Technique; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreas; Pancreatic Neoplasms; Prognosis; Ribonucleoside Diphosphate Reductase; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2009 |
Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Survival Rate; Treatment Outcome | 2009 |
Placement of an expandable metallic stent improves the efficacy of chemoradiotherapy for pancreatic cancer with malignant portal vein stenosis or obstruction.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Constriction, Pathologic; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Humans; Hypertension, Portal; Liver Diseases; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage; Stents; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2009 |
Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Contraindications; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Retrospective Studies; Survival Analysis | 2010 |
Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; C-Reactive Protein; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2009 |
Gemcitabine: new indication. Relapsed ovarian cancer: simply more toxic. Increases haematologic toxicity but not overall survival.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Approval; Europe; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Randomized Controlled Trials as Topic; Ribonucleotide Reductases | 2009 |
ABC transporter gene expression in benign and malignant ovarian tissue.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Carboplatin; Cyclophosphamide; Cystadenoma; Deoxycytidine; Female; Gemcitabine; Gene Expression; Humans; Multidrug Resistance-Associated Protein 2; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; ROC Curve; Up-Regulation | 2010 |
Retrospective analysis of the efficacy of gemcitabine for previously treated AIDS-associated Kaposi's sarcoma in western Kenya.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Kenya; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Sarcoma, Kaposi; Treatment Failure; Treatment Outcome; Vinblastine | 2010 |
Efficacy of adjuvant gemcitabine-cisplatin chemotherapy: a comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms | 2010 |
[Gemcitabine combined with cisplatin and methylprednisolone sodium succinate in chemotherapy for relapsed or refractory T cell non-Hodgkin lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, T-Cell; Male; Methylprednisolone Hemisuccinate; Middle Aged; Neoplasm Recurrence, Local; Remission Induction | 2010 |
Adjuvant chemoradiation therapy in gallbladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Injections, Intra-Arterial; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Perioperative Period; Survival Rate; Treatment Outcome | 2011 |
Erlotinib resistance is altered after gemcitabine chemotherapy for recurrent non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines | 2011 |
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
[Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Luminescent Measurements; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Topotecan | 2010 |
Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prospective Studies; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Metachronous multiple adenocarcinomas of the pancreas.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gastrectomy; Gemcitabine; Hepatitis C; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Pancreatic Neoplasms | 2011 |
Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Topotecan; Treatment Outcome | 2011 |
The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinoma.
Topics: Age Factors; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreaticoduodenectomy; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Time Factors | 2011 |
Treatment of borderline cases for curative resection of biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Brachytherapy; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Central Nervous System Neoplasms; Cerebellar Neoplasms; Child; Child, Preschool; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neuroblastoma; Organoplatinum Compounds; Osteosarcoma; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2011 |
Response of recurrent urachal cancer to gemcitabine and cisplatin therapy: a case report and literature review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Pelvic Neoplasms; Urinary Bladder Neoplasms | 2011 |
Feasibility of intravenous gemcitabine and an intraperitoneal platinum agent in the treatment of ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2011 |
Prognostic value of lymph-node dissection in patients undergoing radical cystectomy following previous oncological treatment for bladder cancer.
Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
Bevacizumab-induced laryngeal necrosis.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Laryngeal Diseases; Lung Neoplasms; Middle Aged; Necrosis; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Tubulin Modulators | 2012 |
Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Loss, Surgical; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Dissection; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Proportional Hazards Models; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2012 |
Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Multimodal Imaging; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2013 |
Intensity-modulated radiotherapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate | 2012 |
Carboplatin-gemcitabine combination chemotherapy upregulates AKR1B10 expression in bladder cancer.
Topics: Aged; Aged, 80 and over; Aldehyde Reductase; Aldo-Keto Reductases; Carboplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Urinary Bladder Neoplasms | 2013 |
Gemcitabine with or without docetaxel and resection for recurrent osteosarcoma: the experience at Children's Memorial Hospital.
Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Child; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Neurosurgical Procedures; Osteosarcoma; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Oxonic Acid; Prognosis; Proportional Hazards Models; Tegafur | 2012 |
Adjuvant chemotherapy decreases and postpones distant metastasis in extremity stage IIB/III synovial sarcoma patients.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Extremities; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Mesna; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Remission Induction; Sarcoma, Synovial; Soft Tissue Neoplasms; Taxoids | 2012 |
Gemcitabine and vinorelbine chemotherapy for refractory or relapsing aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2012 |
Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; China; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Osteosarcoma; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Retrospective Studies; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Multienzyme Complexes; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2011 |
Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Antimetabolites, Antineoplastic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2012 |
Malignant fibrous histiocytoma of the ovary: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Gemcitabine; Histiocytoma, Malignant Fibrous; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Ovarian Neoplasms; Taxoids | 2012 |
Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience.
Topics: Adenocarcinoma, Clear Cell; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-125 Antigen; Cystadenocarcinoma, Serous; Deoxycytidine; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2012 |
Gemcitabine-induced pleuropericardial effusion in a patient with pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Pericardial Effusion; Pleural Effusion | 2012 |
Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; HIV-1; Humans; Lymphoma, AIDS-Related; Male; Middle Aged; Myelopoiesis; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Analysis; Virus Replication; Young Adult | 2012 |
First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.
Topics: Adult; Aged; Aluminum Hydroxide; Antineoplastic Combined Chemotherapy Protocols; Bentonite; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lymphoma, Extranodal NK-T-Cell; Magnesium Hydroxide; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Treatment Outcome; Young Adult | 2013 |
Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective analysis of an Anatolian Society of Medical Oncology multicenter study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Medical Oncology; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Survivors | 2012 |
Salvage chemotherapy using gemcitabine for taxane/platinum-resistant recurrent ovarian cancer: a single institutional experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bridged-Ring Compounds; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Taxoids | 2012 |
A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Cisplatin; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Quinazolines; Small Cell Lung Carcinoma; Taxoids | 2012 |
Retrospective study of gemcitabine based chemotherapy for unresectable or recurrent esophagus squamous cell carcinoma refractory to first line chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2012 |
Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nose Neoplasms; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Skin Neoplasms; Survival Rate | 2013 |
Long term survival after trimodal therapy in malignant pleural mesothelioma.
Topics: Adult; Aged; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Length of Stay; Male; Mesothelioma; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Platinum Compounds; Pleural Neoplasms; Pneumonectomy; Postoperative Complications; Retrospective Studies | 2012 |
Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Proportional Hazards Models; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2013 |
[Chemotherapy for recurrent ovarian cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Polyethylene Glycols; Topotecan | 2012 |
[Treatment of recurrent ovarian cancer].
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Reoperation; Topotecan | 2012 |
Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Quality of Life; Retrospective Studies; Survival Rate | 2013 |
Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage; Survival Rate | 2013 |
Salvage chemotherapy for advanced sarcoma patients: a single-institution experience survey.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 2002 |
Intravesical therapy for superficial cancer: need for more options.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials, Phase I as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2002 |
[Ureteroplasty using the appendix: apropos of a case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendix; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Laparotomy; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Nephrostomy, Percutaneous; Paclitaxel; Prostatectomy; Retroperitoneal Space; Transplantation, Autologous; Transplantation, Heterotopic; Ureter; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2002 |
Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Survival Rate; Treatment Outcome | 2002 |
[Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer -- feasible and effective].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pilot Projects; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Time Factors; Tomography, X-Ray Computed | 2003 |
Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Endometrioid; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2003 |
Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neurologic Examination; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 2003 |
A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Rate; Thrombocytopenia; Topotecan; Treatment Failure | 2003 |
Rituximab in combination with vinorelbine/gemcitabine chemotherapy in patients with primary refractory or early relapsed T cell rich B cell lymphoma. A pilot study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Remission Induction; Rituximab; Salvage Therapy; T-Lymphocytes; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Extensive palliative surgery for advanced mesothelioma of the tunica vaginalis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Debridement; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Neoplasm Recurrence, Local; Palliative Care; Penis; Scrotum; Testicular Neoplasms; Urethra | 2003 |
Gemcitabine-induced vasculitis in advanced transitional cell carcinoma of the bladder.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms; Urinary Diversion; Vasculitis | 2004 |
Recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure | 2004 |
Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer.
Topics: Adolescent; Adult; Aged; Deoxycytidine; Drug Costs; Drug Resistance, Neoplasm; Female; Gemcitabine; Health Care Costs; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Topotecan | 2004 |
Long-term disease-free survival effected by gemcitabine in a heavily pretreated patient with recurrent ovarian carcinoma.
Topics: Antimetabolites, Antineoplastic; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Gynecologic Surgical Procedures; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Treatment Outcome | 2005 |
Gemcitabine in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma.
Topics: Adult; Aged; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Registries; Retrospective Studies; Risk Assessment; Salvage Therapy; Survival Analysis; Treatment Outcome | 2004 |
Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2004 |
Gemcitabine and oxaliplatinum: an effective regimen in a patient with progressive refractory mantle cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy | 2004 |
Gemcitabine and haemolytic-uraemic syndrome.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2004 |
Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Cystitis; Deoxycytidine; Gemcitabine; Hematuria; Humans; Incidental Findings; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Orchiectomy; Positron-Emission Tomography; Prostatectomy; Prostatic Neoplasms; Radiation Injuries; Testicular Neoplasms; Transurethral Resection of Prostate; Ultrasonography; Urinary Bladder Neoplasms; Urinary Diversion | 2004 |
[Hypertrophic myopathy due to muscular metastasis of a signet cell adenocarcinoma of the bladder].
Topics: Adrenal Cortex Hormones; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Buttocks; Carcinoma, Signet Ring Cell; Deoxycytidine; Gemcitabine; Humans; Hypertrophy; Male; Muscle Neoplasms; Muscle, Skeletal; Muscular Diseases; Neoplasm Recurrence, Local; Thigh; Treatment Outcome; Urinary Bladder Neoplasms | 2004 |
[Initial results of intra-arterial chemotherapy for poorly differentiated bladder transitional cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Urinary Bladder Neoplasms | 2004 |
Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Survival Analysis | 2004 |
Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Cell Line, Tumor; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Topotecan; Xenograft Model Antitumor Assays | 2005 |
[A patient with recurrent gallbladder cancer responding to chemotherapy with CDDP/CPT-11 and gemcitabine].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Survivors | 2005 |
[A case of recurrence and systemic metastasis of oral cancer successfully treated with combination chemotherapy of cisplatin and gemcitabine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Mouth Neoplasms; Neoplasm Recurrence, Local; Salvage Therapy | 2005 |
[Local recurrence of pancreatic cancer successfully treated with gemcitabine].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Postoperative Period; Quality of Life; Remission Induction; Stomach Neoplasms | 2005 |
Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Area Under Curve; Carboplatin; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Pelvic Exenteration; Pilot Projects; Recurrence; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Uterine Cervical Neoplasms | 2005 |
Induction chemotherapy with cisplatin and gemcitabine followed by reirradiation for locally recurrent nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Survival Rate | 2005 |
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Irinotecan; Male; Mandibular Diseases; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Osteoradionecrosis; Paclitaxel; Prognosis; Radiotherapy Dosage; Treatment Failure; Treatment Outcome | 2006 |
Gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis; Survival Rate; Treatment Outcome | 2005 |
[A study of recurrent pancreatic cancer with metastatic liver tumors after pancreatectomy].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Survival Rate | 2005 |
Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreas; Pancreatic Neoplasms; Radiotherapy, Conformal; Remission Induction; Retrospective Studies; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome | 2006 |
Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Remission Induction; Rituximab; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2006 |
Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Salvage Therapy; Survival Rate | 2006 |
Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Docetaxel; Female; Fibrin Fibrinogen Degradation Products; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Predictive Value of Tests; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2006 |
[A case of recurrent pancreatic cancer responding to TS-1 combined gemcitabine chemotherapy after UFT combined gemcitabine chemotherapy resulting progressive disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Jaundice, Obstructive; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Quality of Life; Remission Induction; Tegafur; Uracil | 2006 |
Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gemcitabine; Humans; Models, Economic; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2006 |
[Interferon-alpha+cisplatin+5-FU therapy for gemcitabine-refractory unresectable and recurrent pancreatic cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Pancreatic Neoplasms; Thrombocytopenia | 2006 |
Strategy for prevention of local recurrence of pancreatic cancer after pancreatectomy: antitumor effect of gemcitabine mixed with fibrin glue in an orthotopic nude mouse model.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Fibrin Tissue Adhesive; Fluorescent Dyes; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Recurrence, Local; Neoplasm Transplantation; Pancreatectomy; Pancreatic Neoplasms; Rhodamines; Transplantation, Heterologous | 2006 |
[Experience with gemcitabine-carboplatin chemotherapy in relapsed ovarian cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Cerebral Ventricle Neoplasms; Combined Modality Therapy; Consciousness Disorders; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Etoposide; Female; Gemcitabine; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Hypophysectomy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pituitary Neoplasms; Temozolomide; Thiotepa; Topotecan | 2008 |
Gemcitabine and cisplatin in a concomitant alternating chemoradiotherapy program for locally advanced head-and-neck cancer: a pharmacology-guided schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Male; Middle Aged; Mouth Neoplasms; Neoplasm Recurrence, Local; Neutropenia; Pharyngeal Neoplasms; Stomatitis | 2006 |
Basal cell carcinoma metastatic to cervical lymph nodes and lungs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Papillary; Deoxycytidine; Diagnostic Errors; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neck Dissection; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Radiotherapy; Seminoma; Skin Neoplasms; Taxoids; Testicular Neoplasms; Thyroid Neoplasms; Thyroidectomy; Unnecessary Procedures | 2006 |
ProteinChip array profiling for identification of disease- and chemotherapy-associated biomarkers of nasopharyngeal carcinoma.
Topics: Adult; Alpha-Globulins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Platelet Factor 4; Protein Array Analysis; Protein Precursors; Salvage Therapy | 2007 |
Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Recombinant Proteins; Salvage Therapy; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine.
Topics: Adenocarcinoma, Clear Cell; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritonitis; Salvage Therapy | 2008 |
Pancreatic cancer: new studies, new treatments. "Periodontal disease,", "gemcitabine" and "adjuvant therapy" are the new buzzwords.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Periodontal Diseases; Radiotherapy, Adjuvant; Smoking | 2007 |
Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |
Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Costs; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Quality of Life | 2007 |
Progression of disease despite good endoscopic local control of upper tract urothelial carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Electrocoagulation; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Nephrectomy; Paclitaxel; Taxoids; Ureteroscopy | 2007 |
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2007 |
[Transarterial chemoperfusion with gemcitabine and mitomycin C in pancreatic carcinoma: results in locally recurrent tumors and advanced tumor stages].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Injections, Intra-Arterial; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Staging; Outpatients; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2007 |
Carbon beam therapy in recurrent ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hysterectomy; Irinotecan; Lymph Node Excision; Neoplasm Recurrence, Local; Omentum; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Radiotherapy, High-Energy; Remission Induction; Salvage Therapy | 2008 |
Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Female; Gemcitabine; Germany; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate; Uveal Neoplasms | 2008 |
A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Failure | 2008 |
Effectiveness of gemcitabine as second-line chemotherapy in non-small cell lung cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome | 2008 |
[Elevation of CA 19.9 in urothelial bladder cancer].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Time Factors; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2008 |
High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlati
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Hodgkin Disease; Humans; Liposomes; Male; Middle Aged; Neoplasm Recurrence, Local; Reed-Sternberg Cells; Survival Rate; Treatment Failure; Vinblastine; Vinorelbine | 2008 |
A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols | 2008 |
[Recurrent gallbladder carcinoma treated with combination chemotherapy with gemcitabine, CPT-11 and S-1--a successful case with metastatic tumors replaced by marked calcification].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Camptothecin; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Liver Neoplasms; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2008 |
Unresectable pancreatic adenocarcinoma treated with palladium-103 implant and chemoradiation.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy, Needle; Brachytherapy; Deoxycytidine; Fatal Outcome; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Palladium; Pancreatic Neoplasms; Radioisotopes; Radiotherapy, Adjuvant; Tomography, X-Ray Computed | 1998 |
Gemcitabine--a major advance?
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; DNA Replication; DNA, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasms; Pancreatic Neoplasms | 1998 |
Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome; United States | 1999 |
Gemcitabine is active in relapsed Hodgkin's disease.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Deoxycytidine; Doxorubicin; Gemcitabine; Hodgkin Disease; Humans; Male; Mechlorethamine; Neoplasm Recurrence, Local; Prednisone; Procarbazine; Tomography, X-Ray Computed; Vinblastine; Vincristine | 1999 |
Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2000 |
The ex vivo effect of high concentrations of doxorubicin on recurrent ovarian carcinoma.
Topics: Adenosine Triphosphate; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Tumor Cells, Cultured | 2000 |
[Refractory non-small-cell lung cancer responding to combination chemotherapy with docetaxel, gemcitabine and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2001 |
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
Topics: Adenocarcinoma; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2001 |
Excellent response to gemcitabine in a massively pre-treated woman with extensive cutaneous involvement after recurrence of breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms | 2001 |
Antimetastatic efficacy of adjuvant gemcitabine in a pancreatic cancer orthotopic model.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Green Fluorescent Proteins; Humans; Luminescent Proteins; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Pancreatic Neoplasms; Tumor Cells, Cultured | 2000 |
A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunocompromised Host; Klebsiella Infections; Klebsiella pneumoniae; Lung Diseases, Fungal; Male; Melphalan; Neoplasm Recurrence, Local; Opportunistic Infections; Pneumonia, Bacterial; Pneumonia, Pneumocystis; Prednisone; Procarbazine; Salvage Therapy; Skin; Transplantation, Homologous; Vinblastine; Vincristine | 2001 |
[Successful outpatient treatment with chemotherapy of weekly gemcitabine and vinorelbine for a patient with recurrent lung cancer].
Topics: Adenocarcinoma; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Quality of Life; Vinblastine; Vinorelbine | 2002 |
Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Treatment Failure | 2002 |